valsartan profile

Valsartan is an angiotensin II receptor blocker (ARB) used to treat high blood pressure and heart failure. It works by blocking the effects of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. Valsartan is synthesized in a multi-step process involving several chemical reactions. It is typically administered orally and is well-absorbed by the body. Valsartan has been shown to reduce blood pressure, improve heart function, and decrease the risk of heart attacks and strokes. Its importance lies in its ability to manage hypertension and heart failure effectively. Valsartan is studied extensively to understand its mechanisms of action, long-term effects, and potential interactions with other medications. Researchers are also investigating its use in other cardiovascular conditions, such as kidney disease and diabetic nephropathy.'

Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	60846
CHEMBL ID	1069
CHEBI ID	9927
SCHEMBL ID	2542
MeSH ID	M0217346

Synonym
BIDD:GT0345
AC-4543
nsc-758927
cgp-48933
CHEMBL1069 ,
bdbm50049186
2-{[2''-(2,3-dihydro-1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanoyl-amino}-3-methyl-butyric acid
3-methyl-2-{pentanoyl-[2''-(1h-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid
(s)-3-methyl-2-{pentanoyl-[2''-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
(s)-3-methyl-2-{pentanoyl-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
3-methyl-2-{((s)-pentanoyl)-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
BRD-K45158365-001-02-3
[3h]valsartan
gtpl593
BSPBIO_003501
SPECTRUM_001796
SPECTRUM5_001582
provas
miten
nisis
kalpress
tareg
vals
MLS001424088
MLS000759423
smr000466318
valsartan
(s)-n-valeryl-n-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
n-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)-n-valeryl-l-valine
DB00177
137862-53-4
valsartan (jp17/usp/inn)
D00400
diovan (tn)
n-valeryl-n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
c24h29n5o3
l-valine, n-(1-oxopentyl)-n-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
cgp 48933
exforge
KBIO2_007423
KBIOGR_001078
KBIO2_004855
KBIOSS_002289
KBIO3_003006
KBIO2_002287
SPECTRUM3_001831
SPECTRUM2_001120
SPECTRUM4_000749
SPBIO_001260
SPECTRUM1505209
diovan
CHEBI:9927 ,
n-pentanoyl-n-{[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-l-valine
HMS2093K22
HMS2051L12
(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
HMS1922L21
varexan
val-489
valpression
n-valeryl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-l-valine
V0112
nsc758927
pharmakon1600-01505209
dtxsid6023735 ,
n-(1-oxopentyl)-n-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-l-valine
HMS2232F05
AKOS015994698
CCG-101028
valsartan [usan:usp:inn:ban]
80m03yxj7i ,
valtan
ezr-104
prexxartan
valzaar
hsdb 7519
unii-80m03yxj7i
nsc 758927
(2s)-3-methyl-2-(pentanoyl-((4-(2-(2h-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid
ec 604-045-2
S1894
AKOS015914315
(s)-2-(n-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid
gtpl3937
valsartan [orange book]
copalia-hct component valsartan
byvalson component of valsartan
valsartan component of entresto
diovan hct component valsartan
exforge component valsartan
valsartan component of exforge hct
valsartan [inn]
valsartan component of immprida
valsartan component of copalia
dafiro component valsartan
valsartan [vandf]
valsartan component of diovan hct
valsartan [usp-rs]
valsartan [usan]
valsartan component of copalia-hct
valsartan [ep monograph]
agsav301 component valsartan
valsartan [hsdb]
exforge hct component valsartan
entresto component valsartan
valsartan [mi]
valsartan component of valturna
copalia component valsartan
valsartan component of imprida-hct
valsartan component of exforge
valsartan [usp monograph]
valsartan component of byvalson
valsartan [ep impurity]
valsartan [jan]
imprida-hct component valsartan
valturna component valsartan
valsartan [mart.]
valsartan [who-dd]
valsartan component of dafiro-hct
dafiro-hct component valsartan
valsartan [ema epar]
imprida component valsartan
CCG-221275
CS-1967
HY-18204
AB00639940-06
l-valine, n-(1-oxopentyl)-n-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
AM90287
NC00278
137863-60-6
SCHEMBL2542
KS-1194
AB00639940-08
n-(1-oxopentyl)-n-[[2'-(1h-tetrazol-5-yl) [1,1'-bi-phenyl]-4-yl]methyl]-l-valine
(s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
(s)-3-methyl-2-{pentanoyl-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
(s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'(1h-tetrazol-5-yl)biphenyl-4-yl-methyl]amine
(2s)-3-methyl-2-{n-pentanoyl-n'-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butanoic acid
(5)-2-{n-[(2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid
(s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine
n-pentanoyl-n-{[2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-l-valine
(s)-3-methyl-2-{pentanoyl-[-2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
n-(1-oxopentyl)-n-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(l)-valine
ACWBQPMHZXGDFX-QFIPXVFZSA-N
(s)-3-methyl-2-[n-({4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
DS-1248
n-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-n-pentanoyl-l-valine
AB00639940_11
AB00639940_09
mfcd00865840
n-(1-oxopentyl)-n-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-l-valine
valsartan (diovan)
(2s)-3-methyl-2-[n-({4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
(2s)-3-methyl-2-{pentanoyl-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid
valsartan, united states pharmacopeia (usp) reference standard
HMS3651E04
(s)-3-methyl-2-[n-({4-[2-(2h-1,2,3,4-tetrazol-5-yl) phenyl]phenyl}methyl)pentanamido]butanoic acid
sr-05000001928
SR-05000001928-1
valsartan for system suitability, european pharmacopoeia (ep) reference standard
valsartan, pharmaceutical secondary standard; certified reference material
valsartan, >=98% (hplc)
valsartan for peak identification, european pharmacopoeia (ep) reference standard
valsartan, european pharmacopoeia (ep) reference standard
J-007068
SBI-0206738.P001
l-valine,n-(1-oxopentyl)-n-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]- (9ci)
HMS3715P12
n-valeryl-n-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-l-valine
SW197658-2
BCP05184
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
valsartan,(s)
(S)-2-(N-((2'-(2H-TETRAZOL-5-YL)-[1,1'-BIPHENYL]-4-YL)METHYL)PENTANAMIDO)-3-METHYLBUTANOIC ACID
Q155472
BRD-K45158365-001-05-6
NCGC00178027-08
(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid.
V-120
NCGC00178027-11
(s)-2-(n-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoicacid
U35 ,
(2~{s})-3-methyl-2-[pentanoyl-[[4-[2-(2~{h}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
l-valine,n-(1-oxopentyl)-n-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]-(9ci)
BV164506
valsartan- bio-x
HB3381
(s)-3-methyl-2-(n-{[2'-(2h-1,2,3,4-tetrazol-5-yl)biphenyl-4-yl]methyl}pentanamido)butanoic acid
valsartana
EN300-6482022
(2s)-3-methyl-2-(n-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}pentanamido)butanoic acid
(s)-n-(1-carboxy-2-methylprop-1-yl)-n-pentanoyl-n-
(2s)-3-methyl-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)butanoic acid
valsartan (mart.)
(s)-n-valeryl-n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)-methyl)-valine
valsartan (ep monograph)
n-pentanoyl-n-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-l-valine
n-(1-oxopentyl)-n-
valsartan (usp-rs)
c09ca03
valsartan (ep impurity)
valsartanum
valsartan (usan:usp:inn:ban)
valsartan (usp monograph)
Z1379303659

Excerpt	Reference	Relevance
"Valsartan (VAL) is a BCS class II drug with low solubility and high permeability and, thus, its formulations often encounter low bioavailability problems. "	( A novel in vitro approach to investigate the effect of food intake on release profile of valsartan in solid dispersion-floating gel in-situ delivery system. Arjuna, A; Djide, NJN; Donnelly, RF; Himawan, A; Mardikasari, SA; Permana, AD; Utami, RN, 2022)	2.39
"Valsartan is an antihypertensive drug that was developed using common marmosets ("	( Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets. Cho, N; Fukasawa, K; Ikeda, H; Kagiyama, K; Kamimura, H; Maeda, S; Matsumoto, S; Miyata, A; Suemizu, H; Uehara, S, 2022)	2.37
"Valsartan (VST) is a common hypertension drug, and nano-carriers can increase its solubility and bioavailability."	( Self-Nanoemulsifying Drug Delivery System-Containing the Poorly Absorbed Drug - Valsartan in Post-Bariatric Surgery. Chen, CH; Chen, CJ; Fang, JY; Huang, TH; Lin, HA, 2023)	1.86
"Valsartan is an angiotensin receptor blocker and sacubitril is a neprilysin inhibitor."	( Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions. Celli, D; Colombo, R; Galo, J, 2021)	1.66
"Valsartan is a novel BDK inhibitor that competes with ATP, via a different mechanism from allosteric inhibitors."	( Antihypertensive drug valsartan as a novel BDK inhibitor. Kitaura, Y; Ogawa, T; Sato, A; Shimomura, Y; Shindo, D, 2021)	1.66
"Valsartan is an antihypertensive drug, recognized to be marketed in an amorphous state, different from that obtained by quenching the liquid state below T"	( Structural description of the marketed form of valsartan: A crystalline mesophase characterized by nanocrystals and conformational disorder. Danède, F; Derollez, P; Guinet, Y; Hédoux, A; Paccou, L, 2017)	2.15
"Valsartan is a synthetic non-peptide angiotensin II type 1 receptor antagonist that dilates blood vessels and reduces blood pressure by blocking the action of angiotensin, and is safe and well tolerated in hypertensive patients. "	( Valsartan reverses depressive/anxiety-like behavior and induces hippocampal neurogenesis and expression of BDNF protein in unpredictable chronic mild stress mice. Ping, G; Qian, W; Song, G; Zhaochun, S, 2014)	3.29
"Valsartan is an antihypertensive drug which selectively inhibits angiotensin receptor type II. "	( Valsartan. Ardiana, F; Indrayanto, G, 2015)	3.3
"Valsartan is a specific angiotensin II antagonist used for the treatment of hypertension. "	( Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats. Abd El-Gawad, NA; Abd El-Halim, SM; Amin, MM; El Gazayerly, ON; El-Awdan, SA, 2016)	2.11
"Valsartan (VAL) is an antihypertensive drug marketed in an amorphous form. "	( Characterization of Two Distinct Amorphous Forms of Valsartan by Solid-State NMR. Aguilar, JA; Apperley, DC; Hodgkinson, P; Milanowski, B; Pyda, M; Skotnicki, M, 2016)	2.13
"Valsartan is an angiotensin receptor blocker which is usually used in hypertension."	( Combined Neprilysin and RAS Inhibition in Cardiovascular Diseases: A Review of Clinical Studies. Bhadra, R; Ghosh, RK; Gupta, A; Tummala, R, 2016)	1.16
"Valsartan is an angiotensin receptor blocker (ARB) with a well-established efficacy and safety profile in hypertensive patients, but with relatively few data in patients on hemodialysis (HD)."	( Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Baier, M; Bambauer, R; Handrock, R; Kirchertz, EJ; Leidig, M; Leinung, D; Schmieder, RE; Szabã, T, 2008)	1.34
"Valsartan is a nonpeptide, orally active angiotensin II type 1 receptor blocker used to treat hypertension alone or in combination with other antihypertensive agents."	( Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Almeida, S; Farré, A; Filipe, A; Neves, R; Spínola, AC; Trabelsi, F, 2009)	2
"Valsartan is a nonpeptide angiotensin receptor antagonist that selectively blocks the binding of angiotensin II to the angiotensin II type 1 receptor. "	( Valsartan: more than a decade of experience. Bailey, J; Black, HR; Samuel, R; Zappe, D, 2009)	3.24
"Valsartan is a selective angiotensin II type 1 receptor blocker indicated for the treatment of hypertension. "	( Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Batolar, LS; Iqbal, M; Khuroo, A; Monif, T; Sharma, PL; Tandon, M, 2010)	2.04
"Valsartan is a marketed drug with high affinity to the type 1 angiotensin (AT1) receptor. "	( Interactions of the AT1 antagonist valsartan with dipalmitoyl-phosphatidylcholine bilayers. Cacho-Nerin, F; Chatzigeorgiou, P; Hodzic, A; Laggner, P; Mavromoustakos, T; Pabst, G; Potamitis, C; Rappolt, M; Siapi, E; Viras, K, 2011)	2.09
"Valsartan is an angiotensin II receptor blocker (ARB) used for treatment of hypertension. "	( Exanthematous drug eruption due to valsartan. Kandiloglu, G; Ozturk, G; Senturk, B; Turk, BG; Turkmen, M, 2012)	2.1
"Valsartan is an effective treatment option for essential hypertension in Taiwanese patients."	( Efficacy and safety of valsartan in hypertensive Taiwanese patients: post-marketing surveillance study. Chang, KC; Chen, IC; Chen, ZC; Hou, CJ; Hsu, KL; Huang, CH; Hung, YJ; Lee, JD; Lei, MH; Liao, PY; Liou, CW; Wang, J; Yeh, TC, 2011)	2.12
"Valsartan is an oral angiotensin II subtype 1 receptor antagonist with well established antihypertensive efficacy in adults. "	( Valsartan: in children and adolescents with hypertension. Croxtall, JD, 2012)	3.26
"Valsartan is a potent, orally active non-peptide tetrazole derivative and selectively inhibits angiotensin II receptor type 1 which causes reduction in blood pressure and is used in treatment of hypertension. "	( Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Babu, PR; Challa, SR; Challa, VR; Johnson, B; Maheswari, C, 2013)	2.08
"Valsartan is a once or twice daily ARB that is FDA-approved for hypertension, LV dysfunction post-myocardial infarction and congestive heart failure as both an adjunct in ACE-inhibitor tolerant, and alternative in ACE-I intolerant patients."	( The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population. Benge, CD; Muldowney, JA, 2012)	1.36
"Valsartan is a safe, well-tolerated and readily titratable ARB. "	( The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population. Benge, CD; Muldowney, JA, 2012)	2.08
"Valsartan (VLT) is a highly selective and orally active antihypertensive drug. "	( Design and development of ethosomal transdermal drug delivery system of valsartan with preclinical assessment in Wistar albino rats. Avachat, AM; Bhosale, SS, 2013)	2.06
"Valsartan is a second class of angiotensin II receptor antagonist, indicated for the treatment of hypertension. "	( The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. Biswas, PN; Shakir, SW; Wilton, LV, 2002)	2.12
"Valsartan (Diovan) is a potent, orally active, specific, and highly selective blocker for the AT1-receptor subtype. "	( [Preclinical and clinical profile of Valsartan, a selective angiotensin II type-1 receptor blocker]. Isomura, Y; Kimura, M; Mitani, H, 2002)	2.03
"Valsartan is a strong angiotensin receptor inhibitor specific for the angiotensin I receptor, which has been proven safe and well-tolerated in clinical trials. "	( High-dose exposure to valsartan with suicidal intention. Atlibatur Akbas, F; Ayer, M; Ergen, K; Ger, E; Kumbasar, B; Serez, K; Uzunoglu, S, 2004)	2.08
"Valsartan (Diovan) is an oral angiotensin II-receptor antagonist with specificity for the angiotensin II type 1 receptor subtype. "	( Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction. Croom, KF; Keating, GM, 2004)	3.21
"Valsartan is a safe and effective alternative for heart failure patients intolerant of ACE inhibitors. "	( Valsartan in chronic heart failure. Ripley, TL, 2005)	3.21
"Valsartan is an angiotensin receptor antagonist that specifically blocks the angiotensin II type 1 receptors. "	( The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Kjeldsen, SE; Mistry, NB; Westheim, AS, 2006)	2.05
"Valsartan is a highly selective angiotensin II AT1-receptor antagonist for the treatment of hypertension. "	( Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Adachi, Y; Hirouchi, M; Hu, Z; Maeda, K; Sugiyama, Y; Yamashiro, W, 2006)	2.01
"Valsartan is a highly selective Ang II receptor blocker that specifically and selectively blocks Ang II at the AT1-receptor."	( New basic science initiatives with the angiotensin II receptor blocker valsartan. de Gasparo, M, 2000)	1.26
"Valsartan is a strong inverse agonist of constitutive inositol phosphate production by the wild-type and N111G mutant receptors."	( Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Fujino, M; Imaizumi, S; Kanazawa, T; Karnik, SS; Kiya, Y; Matsuo, Y; Miura, S; Saku, K, 2008)	1.07
"Valsartan is an oral antagonist of angiotensin II that competes with angiotensin II for the AT1-receptor and is being developed as an antihypertensive agent. "	( The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Hirschhorn, W; Lloyd, P; Morgan, JM; Ortiz, M; Palmisano, M; Piraino, A; Prasad, PP; Spencer, S, 1997)	2.1
"Valsartan, 80 mg, is a potent angiotensin II antagonist with a rapid onset of action and persistent angiotensin II inhibition up to 24 hours. "	( The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Hirschhorn, W; Lloyd, P; Morgan, JM; Ortiz, M; Palmisano, M; Piraino, A; Prasad, PP; Spencer, S, 1997)	2.1
"Valsartan is a specific angiotensin II receptor antagonist with high selectivity for the AT(1) receptor subtype. "	( Clinical advantage of valsartan. McInnes, GT, 1999)	2.06
"Valsartan (Diovan) is an antihypertensive drug belonging to the family of angiotensin II receptor antagonists. "	( Valsartan. Just a second-line antihypertensive drug. , 1999)	3.19
"Valsartan is an angiotensin AT1 receptor antagonist. "	( [Antihypertensive effects of valsartan. National multicentric study]. Prat, H, 2000)	2.04
"Valsartan is a highly selective, orally available antagonist of the angiotensin Type 1 (AT1) receptor. "	( Valsartan: a novel angiotensin type 1 receptor antagonist. Thürmann, PA, 2000)	3.19
"Valsartan is an orally active, selective antagonist of the angiotensin II-1 (AT1) receptor developed for the treatment of hypertension. "	( Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The Valsartan Antihypertensive Long-term Use Evaluation. Brunner, H; Ekman, S; Hansson, L; Henis, M; Julius, S; Kjeldsen, SE; Laragh, J; McInnes, G; Smith, B; Weber, M; Zanchetti, A, 2001)	1.97

Excerpt	Reference	Relevance
"Valsartan has a beneficial effect on LV deformation and function presented in GLS."	( Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography. Khairat, I; Khedr, L; Werida, R, 2020)	2.72
"Valsartan has a protective effect against hypertension and atherosclerosis in humans and experimental animal models. "	( Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice. Chai, M; Dong, Z; Ji, Q; Lin, Y; Liu, Y; Lu, Q; Meng, K; Wu, B; Yu, K; Zeng, Q; Zhang, J; Zhou, Y, 2015)	3.3
"Valsartan has a potential role as a new treatment for high-risk patients in the post-MI setting."	( Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction. Croom, KF; Keating, GM, 2004)	2.49
"Valsartan has an affinity for the AT1 receptor 30,000 times that of the AT2 receptor."	( Angiotensin II antagonism in clinical practice: experience with valsartan. McInnes, GT, 1999)	1.26
"Valsartan has been studied to exert effects on kidney disease. "	( Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway. Dong, J; Huang, D; Jing, L; Wu, M, 2022)	3.61
"Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). "	( Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial. Axelsson Raja, A; Bach, RG; Becker, JR; Benson, L; Bundgaard, H; Canter, C; Cirino, AL; Colan, SD; Day, SM; Ho, CY; Lakdawala, NK; Lever, HM; MacRae, CA; Margossian, R; McMurray, JJV; Mestroni, L; Murphy, AM; Orav, EJ; Owens, AT; Patel, AR; Pereira, AC; Rossano, JW; Russell, MW; Seidman, CE; Solomon, SD; Soslow, JH; Taylor, MRG; Thrush, P; Vissing, CR; Wheeler, MT; Wilmot, I; Zahka, K, 2023)	2.35
"Valsartan has a beneficial effect on LV deformation and function presented in GLS."	( Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography. Khairat, I; Khedr, L; Werida, R, 2020)	2.72
"Valsartan has the potential to attenuate neointimal hyperplasia and to suppress the inflammatory response. "	( Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4-iNOS-ERK-AT1 Receptor Pathway in the Balloon-injured Rat Aorta. Chu, X; Guo, J; Li, Y; Liu, X; Peng, L; Sun, T; Tang, X; Xu, Q; Yang, X; Yu, H; Zhou, J, 2021)	3.51
"Valsartan has been reported to have the function of treating hypertension and improving the prognosis of patients. "	( Valsartan reduces AT1-AA-induced apoptosis through suppression oxidative stress mediated ER stress in endothelial progenitor cells. Li, B; Li, J; Liang, B; Liu, LM; Qi, J; Wang, ZC; Xu, HY, 2017)	3.34
"Valsartan has been reported to reduce brain beta-amyloid protein levels and improve spatial learning in the Tg2576 transgenic mouse model of Alzheimer's disease (AD). "	( The effects of valsartan on cognitive deficits induced by aluminum trichloride and d-galactose in mice. Feng, GF; Han, H; Hu, XD; Liu, Y; Qian, YH; Shi, LL; Yang, WN, 2014)	2.2
"Valsartan has a protective effect against hypertension and atherosclerosis in humans and experimental animal models. "	( Valsartan Attenuates Atherosclerosis via Upregulating the Th2 Immune Response in Prolonged Angiotensin II-Treated ApoE(-/-) Mice. Chai, M; Dong, Z; Ji, Q; Lin, Y; Liu, Y; Lu, Q; Meng, K; Wu, B; Yu, K; Zeng, Q; Zhang, J; Zhou, Y, 2015)	3.3
"Valsartan has been studied extensively and is widely used for the management of hypertension. "	( Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. Ecder, T; Kashihara, N; Locatelli, F; Palmer, BF, 2009)	2.01
"Valsartan has significant blood pressure lowering effect via modulating renin-angiotensin system although its mechanism of action in isoproterenol (ISO)-induced myocardial injury is largely unknown. "	( Valsartan, an angiotensin II receptor blocker, attenuates cardiac dysfunction and oxidative stress in isoproterenol-induced cardiotoxicity. Arya, DS; Bharti, S; Goyal, S; Sahoo, KC; Sharma, AK, 2011)	3.25
"Valsartan has been compared with other antihypertensive agents of proven efficacy, mainly amlodipine, showing a better clinical profile."	( Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan. Sestito, A, 2011)	1.31
"Valsartan maybe has beneficial effect on the liver disease."	( Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Chen, B; Du, G; Guo, J; Li, X; Qiang, G; Shi, L; Xuan, Q; Yang, H; Yang, X; Zhang, H; Zhang, L; Zhou, D; Zu, M, 2012)	1.5
"Valsartan has the more dramatic effect on albuminuria in diabetic patients than non-diabetic patients."	( Efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese patients with essential hypertension: a multicenter prospective open-label observational study. Cao, G; Deng, Y; Ding, X; Li, H; Xu, X; Zhang, X; Zhuang, X, 2012)	1.41
"Valsartan has been investigated in patients with heart failure at dosages ranging from 40 to 160 mg BID."	( Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Angeli, F; Verdecchia, P, 2004)	1.31
"Valsartan has a potential role as a new treatment for high-risk patients in the post-MI setting."	( Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction. Croom, KF; Keating, GM, 2004)	2.49
"Valsartan has not been shown to be safe and effective when used in combination with ACE inhibitors."	( Valsartan in chronic heart failure. Ripley, TL, 2005)	2.49
"Valsartan has beneficial effects on cardiac hemodynamics, and is generally well tolerated in patients with congestive heart failure not taking ACE inhibitors."	( Valsartan in heart failure patients previously untreated with an ACE inhibitor. Bolshakova, TD; Fomina, IG; Kazakov, EN; Lyusov, VA; Mazayev, VP; Olbinskaya, LI; Orlov, VA; Spormann, DO; Sulimov, VA; Sullivan, J; Zvereva, TV, 1998)	3.19
"Valsartan has an affinity for the AT1 receptor 30,000 times that of the AT2 receptor."	( Angiotensin II antagonism in clinical practice: experience with valsartan. McInnes, GT, 1999)	1.26
"Valsartan has additive effects with other antihypertensive drugs and combination therapy is effective in severe hypertension and in hypertension with renal insufficiency, where renal function is well maintained."	( Clinical advantage of valsartan. McInnes, GT, 1999)	1.34
"Valsartan has no demonstrated advantage over losartan, another angiotensin II antagonist."	( Valsartan. Just a second-line antihypertensive drug. , 1999)	2.47
"Valsartan has been recently shown to improve morbimortality in patients with cardiac insufficiency and receiving a conventional treatment including an ACEI."	( [Angiotensin II receptor blockers: current status and future prospects]. Corvol, P; Plouin, PF, 2002)	1.04

Excerpt	Reference	Relevance
"Valsartan could inhibit AT1-AA-induced apoptosis through inhibiting oxidative stress mediated ER stress in EPCs."	( Valsartan reduces AT1-AA-induced apoptosis through suppression oxidative stress mediated ER stress in endothelial progenitor cells. Li, B; Li, J; Liang, B; Liu, LM; Qi, J; Wang, ZC; Xu, HY, 2017)	3.34
"Valsartan is known to inhibit platelet activity in both in vitro and ex vivo clinical setting, whereas aliskiren in vitro modulates antithrombin-III in plasma. "	( Effect of aliskiren and valsartan combination versus aliskiren monotherapy on hemostatic biomarkers in hypertensive diabetics: Aliskiren and Valsartan Impact in Diabetics pilot trial. Aradi, D; Atar, D; Can, M; DiNicolantonio, J; Kipshidze, N; Pokov, AN; Serebruany, VL, )	1.88
"Valsartan may lower EPO and Hb levels in patients with essential hypertension, while benazepril does not have such effects. "	( [Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension]. Guo, LL; Li, M; Wang, AH, 2011)	2.11
"Valsartan could inhibit RAGE expression through downregulation of oxidative stress."	( [The effect of valsartan on the expression of the receptor for advanced glycation end products in human glomerular mesangial cells]. Feng, M; Huang, GL; Zhang, Y; Zhong, LN, 2011)	2.16
"Valsartan reduced the increase of the AT1 receptor, ACE activity and lung injury induced by bleomycin in the early phase."	( Early lung injury contributes to lung fibrosis via AT1 receptor in rats. Cai, Y; Chen, FP; Gong, LK; Li, XH; Liu, LL; Qi, XM; Ren, J; Wang, H; Wu, XF; Xiao, Y; Zhang, L, 2007)	1.06
"Valsartan does not cause cough or adverse metabolic effects; first dose hypotension and rebound hypertension on abrupt withdrawal have not been encountered."	( Clinical advantage of valsartan. McInnes, GT, 1999)	1.34

Excerpt	Reference	Relevance
"Valsartan-centric treatment regimens are associated with significant reductions in BP level and improvement in BP control in both women and men. "	( Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients. Abraham, I; Alkhatib, N; Brié, H; Denhaerynck, K; Hamarneh, D; MacDonald, K; Vancayzeele, S, 2021)	2.06
"Valsartan treatment did not significantly impact the expression of RAS components, including ACE2, in AT and skeletal muscle."	( The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19. Blaak, EE; de Ligt, M; Goossens, GH; Hesselink, MKC; Jocken, JWE; Jorgensen, J, 2021)	2.33
"Valsartan treatment did not affect plasma PTH, although treatment reduced diastolic blood pressure (P = .01) and the aldosterone/renin ratio (P < .001). "	( Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial. Bislev, LS; Bjerregaard Pedersen, E; Langagergaard Rødbro, L; Nørgaard Bech, J; Rejnmark, L; Rolighed, L; Sikjaer, T, 2018)	1.92
"Valsartan treatment in systemic RV patients did not result in improved survival at longer-term follow-up, but was associated with decreased risk of events in symptomatic patients."	( Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: Follow-up of a multicenter randomized controlled trial. Bouma, BJ; Mulder, BJM; Pieper, PG; Roos-Hesselink, JW; Sieswerda, GT; van der Bom, T; van Dijk, APJ; van Dissel, AC; Vliegen, HW; Winter, MM; Zwinderman, AH, 2019)	2.24
"Valsartan pretreatment suppressed MDA content and preserved SOD activity, consistent with reduced NADPH oxidase expression (P<0.01)."	( Valsartan attenuates oxidative stress and NF-κB activation and reduces myocardial apoptosis after ischemia and reperfusion. Chen, C; Dai, R; Hong, M; Lin, R; Wu, B; Wu, H, 2013)	2.55
"Valsartan post-treatment reversed the increase of 3-NT and apoptosis in diabetic cardiomyopathy."	( 3-nitrotyrosine, a biomarker for cardiomyocyte apoptosis induced by diabetic cardiomyopathy in a rat model. Wei, JR; Zhang, YL, 2013)	1.11
"Valsartan treatment was shown to reduce these markers."	( Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation. Cheung, AK; Huang, Y; Liu, X; Zhou, G, 2014)	2.57
"Valsartan treatment reduced microglial number and activation; however, it did not ameliorate neural dysfunction."	( The vasoneuronal effects of AT1 receptor blockade in a rat model of retinopathy of prematurity. Fletcher, EL; Hatzopoulos, KM; Vessey, KA; Wilkinson-Berka, JL, 2014)	1.12
"Valsartan treatment decreased neointimal hyperplasia in balloon-injured rats. "	( Valsartan decreases neointimal hyperplasia in balloon-injured rat aortic arteries by upregulating HO-1 and inhibiting angiotensin II type 1 receptor. Cai, S; Li, Y; Liu, X; Ren, B; Sun, T; Wang, Q; Xu, Q; Yu, H; Zhou, J, 2014)	3.29
"Valsartan treatment had no demonstrable negative effects on growth and development."	( Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Bagga, A; de Paula Meneses, R; Flynn, JT; Gupte, J; Han, G; Mattheyse, L; Meyers, KE; Neto, JP; Shi, V; Solar-Yohay, S; Zurowska, A, 2008)	1.31
"With valsartan treatment, mean +/- SD SBP decreased from 154.4 +/- 15.5 mm Hg to 139.0 +/- 12.0 mm Hg and mean DBP decreased from 91.3 +/- 9.2 mm Hg to 82.6 +/- 7.4 mm Hg. "	( Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study). Abraham, I; Brié, H; Denhaerynck, K; Hermans, C; Lee, C; MacDonald, K; Van der Niepen, P; Vancayzeele, S; Woestenburg, A, 2009)	1.21
"Valsartan treatment for 6 months decreased the diameter and wall thickness of the ascending aorta in patients with T2DM, but may decrease AC of the abdominal aorta."	( Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity. Brennan, AM; Chan, JL; Danias, PG; Khaodhiar, L; Lima, C; Manning, WJ; Mantzoros, CS; Veves, A, 2009)	1.48
"Valsartan add-on treatment to improve blood pressure control prevented more cardiovascular events than conventional non-ARB treatment in high-risk hypertensive patients in Japan. "	( Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Dahlöf, B; Matsubara, H; Sawada, T; Yamada, H, 2009)	2.19
"Valsartan treatment during ROP prevented loss of theme classes and loss of AII amacrine cells."	( Angiotensin type-1 receptor inhibition is neuroprotective to amacrine cells in a rat model of retinopathy of prematurity. Downie, LE; Fletcher, EL; Hatzopoulos, KM; Kalloniatis, M; Pianta, MJ; Vingrys, AJ; Wilkinson-Berka, JL, 2010)	1.08
"Valsartan treatment also blocked Western diet-induced increases in serum levels of the proinflammatory cytokines interferon-gamma and monocyte chemotactic protein 1."	( Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Carter, JD; Cole, BK; Keller, SR; Nadler, JL; Nunemaker, CS; Wu, R, 2010)	2.52
"Valsartan treatment caused a significant reduction in proteinuria from baseline throughout the study in patients with each genotype of the ACE, AGT and TGFB1 genes. "	( Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms. Chae, DW; Do, JY; Huh, W; Jang, HR; Kim, DJ; Kim, SG; Kim, YG; Lee, JE; Lee, YJ; Oh, HY, 2011)	2.11
"Valsartan treatment significantly reduced the blood pressure and urinary protein excretion of patients with chronic non-diabetic proteinuric nephropathies. "	( Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms. Chae, DW; Do, JY; Huh, W; Jang, HR; Kim, DJ; Kim, SG; Kim, YG; Lee, JE; Lee, YJ; Oh, HY, 2011)	2.11
"Valsartan treatment significantly decreased systolic and diastolic blood pressure compared with placebo (P < 0.001)."	( Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Blaak, EE; Diamant, M; Goossens, GH; Hermans, MM; Moors, CC; van der Zijl, NJ, 2011)	2.53
"Valsartan treatment was not superior to non-ARB treatment in reducing the primary endpoint after PCI at 18 months. "	( Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents. Dohi, Y; Fujii, T; Hayashi, Y; Ishibashi, K; Kihara, Y; Kurisu, S; Okada, T; Okimoto, T; Otsuka, M; Tadehara, F; Yamamoto, H, 2011)	2.13
"Valsartan-treated patients (n = 9) showed a significant increase in β-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 ± 0.08 vs."	( 31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients. Bassi, R; Caldara, R; De Cobelli, F; Del Maschio, A; Fiorina, P; Gremizzi, C; Mello, A; Perseghin, G; Secchi, A; Vergani, A, 2012)	1.31
"Valsartan or LAF237 pretreatment significantly increased plasma GLP-1 expression, reduced apoptosis of endothelial cells isolated from diabetic mice aorta. "	( The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice. Cao, F; Li, W; Liu, B; Shen, M; Sun, D; Wang, S; Zhang, Z, 2012)	2.12
"Valsartan treatment reduced systolic blood pressure as assessed by radiotelemetry (135 +/- 3 versus diabetic 153 +/- 6 mmHg) as well as retarding the increase in albumin excretion rate by approximately 50%. "	( Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003)	1.76
"Valsartan treatment preserved renal structure, by preventing the infiltration of inflammatory cells, and lowered renal expression of monocyte chemoattractant protein-1, transforming growth factor-beta1, and interleukin-1beta, compared with vehicle-treated SHRSP."	( Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. Banfi, C; Brioschi, M; Crippa, V; de Gasparo, M; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Sironi, L; Tremoli, E, 2004)	1.04
"Valsartan treatment decreased blood pressure and total peripheral resistance, while cardiac output was restored to normotensive values."	( Systemic hemodynamics in non-anesthetized L-NAME- and DOCA-salt-treated mice. Gross, V; Luft, FC; Obst, M, 2004)	1.04
"Both valsartan and tempol treatment normalized Ren-2 IR index."	( Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Bahtyiar, G; Blendea, MC; Ferrario, CM; Jacobs, D; Kumar, P; McFarlane, SI; Ogrin, C; Sha, Q; Sowers, JR; Stas, S; Stump, CS, 2005)	0.78
"Valsartan-treated animals showed abrogation of weight loss, suppression of release of total and active transforming growth factor beta-1 (TGF-beta1), and diminished connective tissue synthesis. "	( Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Khalil, N; Mancini, GB, 2005)	1.77
"For valsartan-treated patients, savings due to reduced hospitalizations and shorter length of hospital stay were 1,083,938 US dollars and 221,364 US dollars, respectively."	( Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Cerulli, A; Frech, FH; Smith, DG, 2005)	1.26
"Valsartan treatment significantly reduced systolic and diastolic blood pressure and decreased the Alb/Cr ratio."	( Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Fukuoka, T; Gotoh, A; Higaki, J; Irita, J; Kurata, M; Manabe, S; Miyoshi, K; Okura, T; Uchida, K; Watanabe, S, 2006)	2.5
"Valsartan treatment inhibited the local accumulation of DCs and attenuated renal tubulointerstitial damage."	( Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue. Chen, N; Hao, L; Sun, G; Wang, W; Wu, K; Zhang, Y; Zhou, T, 2006)	2.5
"Valsartan treatment decreased BP, ameliorated cardiac hypertrophy and fibrosis, decreased O(2)*(-) production and NAD(P)H oxidase activity in aorta and heart."	( Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan. Chen, S; Huang, H; Li, R; Liu, P; Tang, F; Wang, P; Zhang, H, 2007)	1.27
"Valsartan treatment did not affect the LVM."	( Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. Fujiwara, H; Hukunishi, M; Ito, Y; Kakami, M; Kawasaki, M; Matsuno, Y; Minatoguchi, S; Miyajima, K; Nishigaki, K; Takemura, G, 2007)	1.3
"Valsartan-based treatment reduced the development of new-onset AF, particularly sustained AF in hypertensive patients, compared with amlodipine-based therapy. "	( Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. Hua, TA; Julius, S; Kjeldsen, SE; McInnes, GT; Schmieder, RE; Zanchetti, A, 2008)	1.79
"The valsartan-treated group had 23% less atherosclerotic area, less effective than benazepril treatment."	( Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Arai, Y; Hirose, N; Kawamura, M; Li, J, 1999)	0.99
"Valsartan treatment in GH L-NAME rats caused eutrophic outward remodelling."	( Basilar artery remodelling in the genetically hypertensive rat: effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril. Laverty, R; Ledingham, JM, 2000)	1.23
"Valsartan treatment with a low-Na diet confers extra benefits on blood pressure and MRA structure."	( Effects of nitric oxide synthase inhibition and low-salt diet on blood pressure and mesenteric resistance artery remodelling in genetically hypertensive rats. Laverty, R; Ledingham, JM, 2001)	1.03
"Valsartan-based treatment had a slightly lower incidence of adverse events (1.5 versus 5.5%; P = 0.006)."	( A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. Bertocchi, F; Bonaduce, D; Carretta, R; Condorelli, M; Fogari, R; Malacco, E; Mann, J; Palatini, P, 2001)	1.29
"In valsartan-treated rats, the ratio of collagen to elastin was greater in HSD than in NSD rats."	( Effects of valsartan on mechanical properties of the carotid artery in spontaneously hypertensive rats under high-salt diet. Benetos, A; de Gasparo, M; Labat, C; Lacolley, P; Lajemi, M; Safar, ME, 2001)	1.21
"Valsartan and captopril treatment led to a significant reduction in neointimal thickness and the extent of lumen stenosis compared with untreated animals."	( Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. de Gasparo, M; Feng, TC; Hua, RJ; Ji, YY; Ying, WY, 2001)	1.43
"Treatment of Valsartan attenuated cerebral injury, potentiated the neuroprotective response of iPoCo in normal rats, and also restored the blunted neuroprotective effect of iPoCo in HFD-treated rats along with enhanced Nrf-2 levels."	( Valsartan Protects in High Fat Diet During Ischemic Reperfusion Injury. Jaggi, AS; Kaur, S; Kumar, K; Singh, N, 2023)	2.71
"Treatment with valsartan in the drinking water of db/db mice from 18 to 22 weeks of age, at a dose that was determined previously to maximally reduce proteinuria, prevented the increases in albuminuria and the markers of renal fibrosis seen in untreated db/db mice."	( Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation. Cheung, AK; Huang, Y; Liu, X; Zhou, G, 2014)	2.18
"The treatment with Valsartan combined with Clopidogrel and Leflunomide can reduce the urinary proteins loss and renal function deterioration for IgA nephropathy patients and cause minimal adverse reactions. "	( Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z, 2015)	2.19
"Treatment with valsartan significantly increased the angiotensin-(1-7) levels as well as ACE2 and Mas receptor mRNA/protein expression but decreased the angiotensin II level, ACE and AT1 receptor mRNA/protein expression, as well as the p-ERK protein expression, compared to the injured group (all P < 0.05 or < 0.01)."	( Valsartan attenuates intimal hyperplasia in balloon-injured rat aortic arteries through modulating the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis. Cai, S; Ge, Z; Guan, R; Hou, B; Li, Y; Liu, X; Wang, Q; Yu, H; Zhou, J, 2016)	2.22
"Co-treatment with valsartan and bosentan decreased ET-1 in these mice compared to the single treatments."	( Co-inhibition of Angiotensin II Receptor and Endothelin-1 Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice. Chang, YK; Choi, DE; Choi, H; Jeong, JY; Lee, KW; Na, KR, 2016)	0.76
"Pre-treatment with valsartan significantly alleviated renal dysfunction, pathological injury, and apoptosis along with the inhibition of ER stressrelated biomarkers (P<0.05; n=8 in each group)."	( Valsartan Protects Against Contrast-Induced Acute Kidney Injury in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Apoptosis. Jia, S; Liu, XL; Ma, Y; Peng, PA; Sun, Y; Wu, SJ; Xu, XH; Yu, Y; Zhou, YJ, 2017)	2.22
"Treatment with valsartan for 24 months reduced systolic and diastolic blood pressure significantly."	( Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Enomoto, D; Fukuoka, T; Higaki, J; Irita, J; Jotoku, M; Koresawa, M; Kurata, M; Miyoshi, K; Okura, T; Watanabe, S, 2008)	0.93
"Treatment with valsartan was not associated with a reduction in the incidence of recurrent atrial fibrillation. "	( Valsartan for prevention of recurrent atrial fibrillation. Barlera, S; Di Pasquale, G; Disertori, M; Franzosi, MG; Latini, R; Lucci, D; Maggioni, AP; Staszewsky, L; Tognoni, G, 2009)	2.15
"Treatment with valsartan and fasudil prevented the development of vasoconstriction, improved the carotid blood flow and normalized the hypersensitivity to serotonin."	( Involvement of Rho-kinase in collar-induced vasoconstriction and vascular hypersensitivity to serotonin in rat carotid. Guan, Q; Pang, X; Sun, D; Xie, L; Zeng, D; Zhang, H, 2011)	0.71
"Treatment with valsartan markedly stimulated these EPC functions."	( Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats. Fukuda, N; Maeshima, A; Matsumoto, K; Matsumoto, T; Nojima, Y; Soma, M; Ueno, T; Yamamoto, C; Yoshida, Y, 2011)	1.06
"Treatment with valsartan significantly restored the levels of those oxidative stress relevant molecules."	( Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-β1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels. Cheng, YN; Gao, JJ; Jiao, B; Wang, YS; Zhang, QZ, 2011)	2.15
"Treatment with valsartan or aliskiren and valsartan normalized the elevated arterial pressure and the arterial pressure rhythm, with the combination therapy being more effective in reducing MAP and in restoring the awake/asleep ratio."	( Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats. Ahmad, S; Ferrario, CM; Moniwa, N; Varagic, J; VonCannon, JL, 2012)	0.72
"Treatment with valsartan for up to 52 weeks was well tolerated in children and adolescents with hypertension."	( Valsartan: in children and adolescents with hypertension. Croxtall, JD, 2012)	2.16
"Treatment with valsartan effectively attenuated cardiac hypertrophy and reversed hypertension induced changes on myocardial Calpain I, calcineurin and CaMKIIδ."	( [Role of valsartan on myocardial Calpain I, calcineurin and Ca/calmodulin-dependent protein kinase IIδ expression of renovascular hypertensive rats]. Lu, JY; Qin, XT; Sheng, HZ; Yu, XH; Zhu, JH, 2012)	1.14
"Pre-treatment with valsartan, an AT(1)-receptor blocker, abolished the stretch-mediated PKC epsilon activation."	( Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta. Inagaki, K; Iwanaga, Y; Kihara, Y; Mochly-Rosen, D; Onozawa, Y; Sarai, N; Takenaka, H, 2002)	0.63
"Treatment with valsartan reversed these changes in 67% of overexpressed genes and 83% of underexpressed genes."	( Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction. Bedigian, MP; Falk, SA; Gengaro, PE; Gurevich, AK; Nemenoff, RA; Rizeq, M; Schrier, RW; Summer, SN; Weinberger, HD, 2002)	0.65
"Treatment with valsartan in patients with EH improves small and large AC. "	( Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Gavish, D; Leibovitz, E; Lubimov, L; Shargorodsky, M; Zimlichman, R, 2002)	0.92
"Treatment with Valsartan reduced osteopontin staining by 51%, mRNA by 47%, and mononuclear cell number by 97% in nonclipped kidneys compared to untreated two-kidney, one-clip animals."	( Differential regulation of osteopontin expression in the clipped and nonclipped kidney of two-kidney, one-clip hypertensive rats. Eberhardt, W; Fierlbeck, W; Gauer, S; Geiger, H; Hartner, A; Hauser, IA, 2003)	0.66
"Treatment with valsartan alone or combined with hydrochlorothiazide provides effective blood pressure reduction and is well tolerated. "	( [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives]. Mengden, T; Vetter, H; Weisser, B, 2003)	0.89
"Treatment with valsartan, doxazosin, or N-acetylcysteine did not significantly affect HIF-1alpha and VEGF proteins expression in the banding groups."	( Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart. Chang, H; Fang, WJ; Liou, JY; Shyu, KG; Wang, BW, 2005)	0.67
"Treatment with valsartan 160 mg/HCTZ 25 mg offered a substantial benefit for patients with hypertension not controlled with the combination of candesartan cilexetil 16 mg or telmisartan 80 mg and low dose HCTZ, while maintaining a comparable safety and tolerability profile."	( Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers. Ansari, A; Fuenfstueck, R; Hempel, RD; Klebs, S; Weidinger, G, )	0.69
"Treatment with valsartan in T2DM improved the resting forearm skin blood flow and increased the resting brachial artery diameter but had no effects on arterial blood pressure, large vessel vascular reactivity, or carotid intima-media thickness. "	( Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation. Dudley, K; Ferran, C; Ganda, O; Hubbard, M; Khaodhiar, L; Lima, C; Scali, S; Shrikhande, G; Veves, A, 2006)	2.13
"Treatment with valsartan prevented the cognitive decline in wild-type mice, but this effect was weaker in Agtr2- mice."	( Angiotensin II type-2 receptor stimulation prevents neural damage by transcriptional activation of methyl methanesulfonate sensitive 2. Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Tsukuda, K, 2006)	0.67
"Treatment with valsartan but not benazepril significantly increased intima AT2R expression 2-fold compared with vehicle, which was not reversed by inhibition of AT2R, B1R, and B2R."	( Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade. Barker, TA; Berk, BC; Kennedy, AJ; Korshunov, VA; Massett, MP; Mohan, AM, 2006)	0.67
"Treatment with valsartan but not placebo resulted in a progressive down-regulation of SOD-mRNA expression and a reduction in superoxide dismutase activity, suggesting antioxidant activity and a reduction of reactive oxygen species generation."	( Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients. Chan, P; Chen, TH; Kao, PF; Ko, WC; Tomlinson, B; Yang, HY, 2007)	0.92
"Treatment with valsartan significantly decreased SBP and DBP."	( Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. Fujiwara, H; Hukunishi, M; Ito, Y; Kakami, M; Kawasaki, M; Matsuno, Y; Minatoguchi, S; Miyajima, K; Nishigaki, K; Takemura, G, 2007)	0.92
"Treatment with valsartan significantly reduced mean aortic pressure and LV end-diastolic pressure compared with control."	( Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure. Goldstein, S; Levine, TB; Mishima, T; Sabbah, HN; Sharov, VG; Shimoyama, H; Tanimura, M, 1999)	0.64
"Treatment with valsartan did not produce clinically significant orthostatic changes in diastolic or systolic blood pressure."	( Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. Chiang, YT; Gatlin, M; Glazer, R; Pool, JL, 1999)	0.94
"Treatment with valsartan (3 or 10 mg/kg per day) did not alter plasma cholesterol levels or systolic arterial pressure in any group."	( AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Aragoncillo, P; Cachofeiro, V; de las Heras, N; DeGasparo, M; Lahera, V; Maeso, R; Mann, J; Navarro-Cid, J; Ruilope, LM; Vazquez-Pérez, S, 1999)	0.64
"Treatment with valsartan or combination therapy normalized the total and type I collagen (p < 0.001) as well as TGF-beta 1 mRNA level (p < 0.01) in the septum and was associated with the suppression of macrophages and myofibroblasts in the infarct zone (p < 0.01)."	( Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. Lau, CP; Tipoe, GL; Wing-Hon Lai, K; Yu, CM, 2001)	0.65
"Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P<0.01)."	( A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Cohn, JN; Tognoni, G, 2001)	0.9
"Treatment with valsartan did not alter plasma cholesterol levels or arterial pressure in any group."	( Valsartan improves fibrinolytic balance in atherosclerotic rabbits. Cachofeiro, V; Cediel, E; de Las Heras, N; Lahera, V; Oubiña, MP; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S, 2002)	2.1
"Rats treated with valsartan, alone or in combination with enalapril, showed markedly higher survival rates (67-85%, respectively) than untreated animals (37%) or those treated with enalapril alone (55%)."	( Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. Bruneval, P; Clozel, JP; de Gasparo, M; Hess, P; Nuesslein-Hildesheim, B, 2000)	0.9

Excerpt	Reference	Relevance
" Safety and tolerability variables included data on adverse experiences, rebound hypertension, and clinical laboratory evaluations."	( The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Dyke, S; Fitzsimmons, S; Harris, F; Hester, A; James, D; Kief, J; Oparil, S, )	0.43
" The total number of patients with adverse experiences were 10 (45."	( Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. Aldigier, JC; Botteri, F; Mann, JF; Oddou-Stock, P; Ponticelli, C; Ruilope, LM, 2000)	0.6
"These results indicate that short-term combination of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker is safe and well tolerated in patients with moderate chronic renal failure."	( Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. Aldigier, JC; Botteri, F; Mann, JF; Oddou-Stock, P; Ponticelli, C; Ruilope, LM, 2000)	0.6
" The primary criterion for tolerability was the incidence of adverse experiences."	( Efficacy and safety of valsartan compared with enalapril at different altitudes. Blanco, M; Botero, R; Del Portillo, H; María, E; Matiz, H; Orejarena, H; Velez, JR, 2000)	0.62
" Adverse events irrespective of relationship to trial drug were reported by 12 patients (18."	( Efficacy and safety of valsartan compared with enalapril at different altitudes. Blanco, M; Botero, R; Del Portillo, H; María, E; Matiz, H; Orejarena, H; Velez, JR, 2000)	0.62
" Fewer patients experienced adverse events in the valsartan group (50%) than in the enalapril group (63%), although statistically non-significant."	( Safety and efficacy of valsartan versus enalapril in heart failure patients. Gordon, A; Helmers, C; Löfdahl, P; Pantev, E; Rydberg, E; Willenheimer, R, 2002)	0.88
"We report a case in which the adverse fetal effect of angiotensin II receptor antagonist treatment was reversed."	( Fetal toxicity of valsartan and possible reversible adverse side effects. Berkane, N; Carlier, P; Heim, N; Mathieu, E; Uzan, S; Verstraete, L, 2004)	0.66
" The incidence of adverse events during both phases was comparably low and the results of laboratory tests were unremarkable."	( Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers. Ansari, A; Fuenfstueck, R; Hempel, RD; Klebs, S; Weidinger, G, )	0.35
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Rates of adverse events and laboratory abnormalities were similar in all groups."	( Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Fang, H; Oparil, S; Patel, S; Satlin, A; Yarows, SA; Zhang, J, 2007)	0.59
" Combination therapy was generally well-tolerated; the most commonly reported adverse events were headache (7."	( Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Chrysant, SG; Dattani, D; Hoppe, UC; Hsu, H; Murray, AV; Patel, S; Zhang, J, 2008)	0.57
" However, valsartan/amlodipine offered some advantages in terms of less pronounced BP orthostatic changes and absence of metabolic adverse effects."	( Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, )	0.53
"The addition of an angiotensin II receptor blocker to calcium channel blocker-based antihypertensive therapy may be associated with enhanced efficacy and reduced risk of adverse events."	( Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Ansari, A; Brachmann, J; Handrock, R; Klebs, S; Mahla, G, 2008)	0.57
" Adverse event rates were low in both treatment phases, and most were mild or moderate in severity."	( Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Ansari, A; Brachmann, J; Handrock, R; Klebs, S; Mahla, G, 2008)	0.57
" The aim of this 2 A 5-week, open-label, multicenter, randomized cross-over study was to investigate whether valsartan (Val) 80 mg is as effective, safe and well-tolerated as irbesartan (Irb) 150 mg in patients with arterial hypertension on long-term hemodialysis."	( Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Baier, M; Bambauer, R; Handrock, R; Kirchertz, EJ; Leidig, M; Leinung, D; Schmieder, RE; Szabã, T, 2008)	0.83
" Secondary objectives were predialytic MSupDBP, adverse events (AEs), laboratory abnormalities, hypotension during and after dialysis and quality of life."	( Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Baier, M; Bambauer, R; Handrock, R; Kirchertz, EJ; Leidig, M; Leinung, D; Schmieder, RE; Szabã, T, 2008)	0.62
"Valsartan 80 mg is as effective, safe and well tolerated as irbesartan 150 mg in hypertensive patients on chronic hemodialysis."	( Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Baier, M; Bambauer, R; Handrock, R; Kirchertz, EJ; Leidig, M; Leinung, D; Schmieder, RE; Szabã, T, 2008)	2.06
"To evaluate the evidence for temporal reporting patterns, such as the Weber effect, in spontaneous post-marketing adverse event (AE) reports submitted to the Food and Drug Administration (FDA), for four members of the angiotensin II receptor blockers drug class (ARBs)."	( Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Dal Pan, GJ; Governale, LA; Hammad, TA; McAdams, MA; Swartz, L, 2008)	0.35
" The combination of A 10 + Val 160 was well tolerated, and the observed adverse events (15."	( Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Ansari, A; Braun, N; Handrock, R; Klebs, S; Ulmer, HJ, 2009)	0.58
" Between-group comparisons of adverse events and changes in laboratory parameters did not reach statistical significance, except for uric acid which showed a significant increase in the valsartan/hydrochlorothiazide group compared with the amlodipine group, but was still below the laboratory's upper limit of normal."	( Efficacy and safety of valsartan/hydrochlorothiazide fixed-dose combination compared with amlodipine monotherapy as first-line therapy for mild to moderate hypertension. Chao, CL; Chen, JC; Chiang, FT; Hwang, JJ; Lin, LC; Lin, LY; Lin, YH; Tsai, CT; Wang, YC, )	0.63
" There were no critical adverse effects in the ARB group throughout the study period."	( Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation. Arimura, T; Iwata, A; Kawamura, A; Kiya, Y; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Takamiya, Y; Uehara, Y, 2009)	0.35
" Incidence of adverse events was comparable in monotherapy and combination therapy groups."	( [Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy]. Huang, J; Ke, YN; Zhu, JR, 2009)	0.6
" A new dual RAAS blockade with the direct renin inhibitor aliskiren and the ARB valsartan produces greater BP reductions than monotherapy with the component drugs and is safe and well tolerated."	( The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan. Chrysant, SG, 2010)	0.81
" Safety assessments included monitoring and recording of adverse events (AEs)."	( Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Cardenas, P; Hong, H; Ke, Y; Wang, R; Zhang, Y; Zhu, D; Zhu, J, 2010)	0.6
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
"Early combination therapy is increasingly recommended in hypertension management because of increased risk of adverse effects with high-dose monotherapy."	( Effectiveness and safety of high-dose valsartan monotherapy in hypertension treatment: the ValTop study. Asmar, R; Bilo, G; Di Giovanni, R; Kandra, A; Mengden, T; Parati, G, 2010)	0.63
" Safety was assessed by monitoring and recording adverse events (AEs)."	( Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Chrysant, SG; Dattani, D; Hoppe, UC; Murray, AV; Patel, S; Ritter, S; Zhang, J, 2010)	0.62
"Angiotensin receptor blockers (ARBs) as a class are generally considered safe and better tolerated than other antihypertensive drugs."	( A drug safety evaluation of valsartan. Fogari, R; Zoppi, A, 2011)	0.66
"Valsartan demonstrates to be safe and well tolerated both in monotherapy and in combination therapy of hypertension in a broad range of patients, including the elderly, children, diabetics, obese patients and patients at high cardiovascular risk."	( A drug safety evaluation of valsartan. Fogari, R; Zoppi, A, 2011)	2.11
"Two thousand seven hundred and eighty-five patients with arterial hypertension were enrolled, 52 discontinued (eight due to adverse events), and four patients' data were missing."	( Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. Chazova, IE; Dongre, N; Vigdorchik, AV, 2011)	0.62
"In this multicenter, multicountry study including 7567 Asian patients with hypertension, valsartan/hydrochlorothiazide single pill combination was found efficacious, well tolerated, and devoid of any serious adverse effects."	( Efficacy, safety, and tolerability of valsartan/hydrochlorothiazide in Asian patients with essential hypertension. Dongre, N; Lai, WT; Park, JE; Wang, J, 2011)	0.86
" Valsartan was well tolerated and headache was the most commonly observed adverse event during both the double-blind and 52-week open-label phases."	( Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. Blumer, J; Han, G; Litwin, M; Meneses, R; Meyers, KE; Neto, JP; Shi, V; Solar-Yohay, S; Vande Walle, J; Wells, T, 2011)	1.57
" The most frequent adverse events during the open-label phase were headache and fever."	( The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients. Han, G; Lieberman, K; Meyers, KE; Shi, V; Solar-Yohay, S, 2011)	0.67
" Since these adverse effects did not disappear after the return to Preminent(®) at the end of Stage C, we performed an additional 3-month follow-up (extended stage)."	( Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y, 2011)	0.58
"Single-pill fixed-dose combination therapy using Preminent(®) showed significant 24-h BP-lowering effects and was safe when compared with CodioMD(®)."	( Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). Inoue, A; Kuwano, T; Mitsutake, R; Miura, S; Morii, J; Saku, K; Shiga, Y; Uehara, Y, 2011)	0.58
"Valsartan was well tolerated; most commonly reported adverse events included dizziness, headache, constipation and cough."	( Efficacy and safety of valsartan in hypertensive Taiwanese patients: post-marketing surveillance study. Chang, KC; Chen, IC; Chen, ZC; Hou, CJ; Hsu, KL; Huang, CH; Hung, YJ; Lee, JD; Lei, MH; Liao, PY; Liou, CW; Wang, J; Yeh, TC, 2011)	2.12
" There were no significant differences in adverse effects between groups, with the exception of more respiratory disorders in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group (17 vs 5; P = 0 ."	( Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012)	0.78
" However, respiratory adverse events (particularly coughing) were more frequently reported in the amlodipine/benazepril group."	( Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012)	0.58
" No serious drug-related adverse effects (AEs) were observed."	( Efficacy and safety of valsartan in reducing blood pressure and albuminuria in Chinese patients with essential hypertension: a multicenter prospective open-label observational study. Cao, G; Deng, Y; Ding, X; Li, H; Xu, X; Zhang, X; Zhuang, X, 2012)	0.69
" Adverse events were reported in 202 participants (35."	( Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. Alessi, T; Bakris, GL; Oparil, S; Purkayastha, D; Sowers, JR; Yadao, AM, 2013)	0.62
" Safety was assessed in terms of adverse events and serious adverse events (SAEs)."	( Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. Bagga, A; Coppo, R; Kadwa, M; Schaefer, F; Schlosshauer, R; Senguttuvan, P; Zhang, Y, 2013)	0.7
" Overall, valsartan was well tolerated with no dose-dependent increase in adverse events during the dose-ranging period (Week 0-6) and a comparable incidence of adverse events to placebo during the placebo withdrawal period (Week 7-8)."	( Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. Bagga, A; Coppo, R; Kadwa, M; Schaefer, F; Schlosshauer, R; Senguttuvan, P; Zhang, Y, 2013)	1.1
"7%) patients experienced a total of 174 adverse events (AEs)."	( Efficacy and safety of valsartan and amlodipine single-pill combination in hypertensive patients (PEAK study). Berktaş, M; Boyacı, B; Kızılırmak, P; Yalçın, MR, 2013)	0.7
" Safety assessments included recording all adverse events and serious adverse events."	( Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Baek, SH; Chiang, FT; Gotou, H; Inubushi-Molessa, A; Kario, K; Lefkowitz, M; Sun, N; Supasyndh, O; Zhang, J; Zhang, Y, 2014)	0.4
"Hypothyroidism is a common clinical side effect of lithium treatment, whereas parkinsonism is a very rare adverse event."	( Parkinsonism and severe hypothyroidism in an elderly patient: a case of lithium toxicity due to pharmacological interactions. Basile, G; Epifanio, A; Mandraffino, R; Trifirò, G, 2014)	0.4
" Safety assessments included monitoring of adverse events."	( Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Basile, J; Bharucha, DB; Chen, W; Giles, TD; Gradman, AH; Pattathil, M; Weber, MA, 2014)	0.68
" At least one treatment-emergent adverse event was experienced by 30-36% of participants in each group."	( Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Basile, J; Bharucha, DB; Chen, W; Giles, TD; Gradman, AH; Pattathil, M; Weber, MA, 2014)	0.68
" Safety assessments consisted of recording all adverse events."	( Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW). Ar, I; Ilerigelen, B; Kızılırmak, P, 2014)	0.71
"2%) experienced a total of 12 adverse events; there were no serious adverse events."	( Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW). Ar, I; Ilerigelen, B; Kızılırmak, P, 2014)	0.71
"The standard 60-mg dose of fimasartan, a newly developed selective angiotensin II receptor blocker, is effective and safe for use in patients with mild to moderate hypertension."	( Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study. Bae, JH; Ihm, SH; Jeon, DW; Joo, SJ; Jung, BC; Jung, IH; Kang, SM; Lee, NH; Park, SM; Park, TH; Park, WJ; Pyun, WB; Shin, ES; Shin, JH; Song, JM; Sung, KC; Yoon, YW; Youn, JC, 2014)	0.4
" Most treatment-emergent adverse events (TEAEs) were mild (89 of 95), and there were no serious TEAEs."	( Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study. Bae, JH; Ihm, SH; Jeon, DW; Joo, SJ; Jung, BC; Jung, IH; Kang, SM; Lee, NH; Park, SM; Park, TH; Park, WJ; Pyun, WB; Shin, ES; Shin, JH; Song, JM; Sung, KC; Yoon, YW; Youn, JC, 2014)	0.4
" Safety and tolerability parameters included adverse events."	( Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. Finck, A; Giles, TD; Li, H; Neutel, JM; Punzi, H; Weiss, RJ, 2014)	0.68
" Safety was assessed by monitoring and recording all adverse events (AEs) and change in potassium and creatinine."	( Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction. Akahori, M; Charney, A; Gotou, H; Ito, S; Okino, N; Satoh, M; Tamaki, Y; Zhang, J, 2015)	0.42
" For evaluation of the safety profile, the frequencies of adverse events between groups were also not significantly different."	( Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. Ahn, JC; Ahn, T; Cha, DH; Cho, JH; Cho, SW; Choi, DJ; Hong Baek, S; Hong, S; Hong, TJ; Jeon, ES; Jeon, HK; Jeong, JO; Jeong, MH; John, SH; Juhn, JH; Kang, JH; Kim, BS; Kim, DW; Kim, JJ; Kim, MH; Kim, NH; Kim, SK; Kim, SW; Kim, SY; Kim, YN; Kwan, J; Lee, HY; Lee, NH; Lee, SH; Lee, SY; Lee, YJ; Na, SH; Oh, BH; Park, CG; Park, SH; Park, WJ; Rhee, MY; Ryu, JK; Shin, ES; Shin, JH; Uk Lee, S; Won, KH; Yoo, SY, 2015)	0.66
" There was a low rate of adverse events in all treatment groups."	( Safety of the Up-titration of Nifedipine GITS and Valsartan or Low-dose Combination in Uncontrolled Hypertension: the FOCUS Study. Choi, DJ; Kim, DS; Kim, DW; Kim, JH; Lee, HY; Lee, SY; Park, CG; Park, JB; Park, SW; Rim, SJ; Shim, WJ; Shin, JH; Youn, HJ, 2016)	0.69
"Single oral doses of up to 600 mg of LCZ696 were safe and generally well tolerated in healthy Japanese male subjects."	( Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects. Akahori, M; Ayalasomayajula, S; Langenickel, T; Pal, P; Sunkara, G; Zhou, W, 2017)	0.68
"1%) discontinued the study drug due to adverse events (AEs)."	( Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Hafeez, K; Kario, K; Sun, N; Supasyndh, O; Zhang, J, 2017)	0.7
" Therefore, we have examined dementia-related adverse effects (AEs) in PARADIGM-HF and placed these findings in the context of other recently conducted HFrEF trials."	( Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Cannon, JA; Chen, F; Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shen, L; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR, 2017)	0.46
"Administration of valsartan may lead to attenuation of the nephrotoxic side effect of cyclosporine via enhancing klotho and decreasing oxidative stress levels."	( Effects of Angiotensin II Receptor Blockade on Soluble Klotho and Oxidative Stress in Calcineurin Inhibitor Nephrotoxicity in Rats. Argani, H; Bargahi, N; Dastmalchi, S; Ghasemi, B; Ghazizadeh, T; Ghorbanihaghjo, A; Mesgari Abbasi, M; Mota, A; Nemati, M; Raeisi, S; Rashtchizadeh, N; Vatankhah, AM, 2016)	0.77
" Overall, the incidence of adverse events was 20."	( Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. Hafeez, K; Jia, Y; Sibulo, A; Wang, JG; Yukisada, K; Zhang, J, 2017)	0.73
" The rate of adverse events was comparable between the enalapril and sacubitril-valsartan groups, although the absolute rates are likely underestimated due to the entry criteria and run-in period."	( The safety of sacubitril-valsartan for the treatment of chronic heart failure. Teerlink, JR; Tyler, JM, 2017)	0.99
" Effects were similar in those older and younger than 65 years, and active therapies had adverse event rates similar to placebo."	( Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study. Hafeez, K; Izzo, JL; Jia, Y; Zappe, DH; Zhang, J, 2017)	0.73
" Safety assessments showed that sacubitril/valsartan was safe and well tolerated across all the study groups."	( Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment . Chandra, P; Kulmatycki, KM; Langenickel, T; Lin, TH; Ng, WH; Pal, P; Rajman, I; Sunkara, G; Zhou, W, 2017)	0.98
" We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on adverse events: hospitalizations or emergency room consultations."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
" Rates of adverse events for losartan, valsartan, and candesartan users (N=136 177) aged ≥66 years were calculated monthly, 24 months before and 12 months after generics commercialization."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.72
"Among generic users, immediate or delayed differences in adverse events rates were observed right after generic commercialization for 3 antihypertensive drugs."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
" The overall incidence of adverse events was comparable between the groups."	( Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. Aizenberg, D; Chen, CW; Cheung, DG; Gorbunov, V; Hafeez, K; Zhang, J, 2018)	0.76
"With close monitoring and follow-up, ARNi therapy was a safe alternative to ACEi/ARB therapy for chronic symptomatic HFrEF when initiated within a pharmacist clinic."	( Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic. Davis, LE; Pogge, EK, 2018)	0.73
"We analyzed adverse event cases submitted to the Food and Drug Administration Adverse Event Report System from July 2015 to March 2017."	( Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Hirsh Raccah, B; Matok, I; Muszkat, M; Perlman, A, 2018)	0.72
"During the period evaluated, 9,004 adverse event reports (out of a total of 2,249,479) involved the use of sacubitril-valsartan."	( Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Hirsh Raccah, B; Matok, I; Muszkat, M; Perlman, A, 2018)	0.93
"Sacubitril-valsartan is not associated with a disproportionately high rate of short-term dementia-related adverse effect reports."	( Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Hirsh Raccah, B; Matok, I; Muszkat, M; Perlman, A, 2018)	1.11
" The primary endpoint was long-term safety and tolerability of valsartan and valsartan-based treatments, assessed in terms of adverse events (AEs), serious AEs, laboratory measurements, estimated glomerular filtration rate (eGFR), urinalysis and electrocardiogram."	( Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension. Antonio, ZL; Glazer, RD; Kang, HG; Lou-Meda, R; Stiller, B; Tan, M; Valentin, MA; Wang, L; Yap, HK; Zielinska, E, 2019)	1.03
" The Plasma Micro Sampling Toxicokinetics (PMS-TK) method required ultrasensitive quantitation, was employed to evaluate the relationship between toxic changes and plasma concentrations as well as the effects of frequent blood sampling in individual animals."	( Approaches of validation of a 2-week combined repeated oral dose toxicity study with plasma micro sampling toxicokinetics (PMS-TK) in common marmosets. Inoue, R; Kouhei, Y; Mochizuki, H; Murota, N; Nii, K; Nishime, C; Sato, SI; Taniguchi, M; Tsutsumi, H, 2018)	0.48
" Treatment with sacubitril/valsartan 200 or 400 mg once daily is effective and provided superior BP reduction than olmesartan 20 mg in Asian patients with mild-to-moderate hypertension and is generally safe and well tolerated."	( Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. Guo, W; Huo, Y; Li, W; Wang, Q; Webb, R; Zhao, L, 2019)	1.09
"66) or presented SV-related adverse effects (31 [24."	( Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan. Ayesta, A; Bover-Freire, R; De-Juan, J; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; Iglesias, D; Iniesta, ÁM; Martínez-Sellés, M; Perea-Egido, JA; Rojas-González, A; Vicent, L, )	0.38
"Our finding provides evidence that LCZ 696 was more effective than ARB on blood pressure control and was safe enough in patients with hypertension."	( Effect and safety of LCZ696 in the treatment of hypertension: A meta-analysis of 9 RCT studies. Guo, Y; Jia, J; Li, L; Li, Q; Lin, S; Liu, Y; Wang, F; Zhang, W, 2019)	0.51
"Sacubitril/valsartan is safe when initiated during hospitalization in a clinical trial setting."	( Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort. Bover, R; De-Juan, J; Del Prado, S; Díez-Villanueva, P; Esteban-Fernández, A; Gómez-Bueno, M; López-Azor, JC; Manuel-Iniesta, Á; Martínez-Sellés, M; Pérez, Á; Valero-Masa, MJ; Vicent, L, 2019)	1.22
" The incidence of adverse effects was also similar: hypotension (16 inpatients [16."	( Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort. Bover, R; De-Juan, J; Del Prado, S; Díez-Villanueva, P; Esteban-Fernández, A; Gómez-Bueno, M; López-Azor, JC; Manuel-Iniesta, Á; Martínez-Sellés, M; Pérez, Á; Valero-Masa, MJ; Vicent, L, 2019)	0.83
"It is safe to initiate sacubitril/valsartan during hospitalization in daily clinical practice."	( Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort. Bover, R; De-Juan, J; Del Prado, S; Díez-Villanueva, P; Esteban-Fernández, A; Gómez-Bueno, M; López-Azor, JC; Manuel-Iniesta, Á; Martínez-Sellés, M; Pérez, Á; Valero-Masa, MJ; Vicent, L, 2019)	1.11
"Switching directly from target dose ACE inhibitors or ARBs to maximum-dose sacubitril-valsartan was safe and generally well tolerated."	( Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors. Bergdahl, E; Lindmark, K; Norberg, H, 2019)	0.98
" The changes of clinical, biochemical data and adverse events during observation period were all analyzed."	( Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR. Bo, W; Chen, H; Hongbao, L; Li, L; Peng, Z; XiaoWei, L; Xiong, C, 2020)	0.56
" But the adverse events in TWHF group were higher than those in control group."	( Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR. Bo, W; Chen, H; Hongbao, L; Li, L; Peng, Z; XiaoWei, L; Xiong, C, 2020)	0.56
"TWHF is more effective than valsartan monotherapy in reduction of proteinuria in DN patients with overt proteinuria and normal eGFR, but with more adverse effects."	( Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR. Bo, W; Chen, H; Hongbao, L; Li, L; Peng, Z; XiaoWei, L; Xiong, C, 2020)	0.85
" We compared baseline characteristics, adverse events during follow-up and causes of S/V withdrawal according to age."	( Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Bover, R; De Juan, J; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; Iniesta, ÁM; Martínez-Sellés, M; Vicent, L, )	0.52
"1months S/V was well tolerated, with no age-related differences in adverse events (26."	( Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Bover, R; De Juan, J; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; Iniesta, ÁM; Martínez-Sellés, M; Vicent, L, )	0.52
"Sacubitril/Valsartan is useful and safe in elderly people with HF-rEF in real-life clinical practice, and withdrawal is associated to poor prognosis."	( Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort. Bover, R; De Juan, J; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; Iniesta, ÁM; Martínez-Sellés, M; Vicent, L, )	0.91
"To observe and analyze the clinical effect of nifedipine controlled-release tablets combined with valsartan in the treatment of essential hypertension, and to analyze the adverse reactions of patients."	( Clinical effect and safety of nifedipine controlled-release tablets combined with valsartan in the treatment of primary hypertension. Fu, J; Liu, W; Liu, Y, 2019)	0.96
"Unveiling the mechanism of action of a drug is key to understand the benefits and adverse reactions of a medication in an organism."	( In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan. Aguirre-Plans, J; Fernández-Fuentes, N; Jorba, G; Junet, V; Mas, JM; Oliva, B; Pujol, A; Ruiz, JL; Segú-Vergés, C, 2020)	0.77
" Incidence of adverse drug reactions (ADRs) and discontinuation rate of sacubitril/valsartan were compared between initiation of sacubitril/valsartan in inpatient and outpatient settings."	( Safety and Tolerability of Sacubitril/Valsartan Initiation in Inpatient Versus Outpatient Setting: A Retrospective Real World Study. Chan, H; Chng, BLK; Gao, F; Hon, JS; Sim, KLD; Teo, LYL; Zheng, Y, 2021)	1.12
"9%) and adverse events (78."	( Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study. Aggarwal, RK; Billa, G; Jain, AR; Kumar, S; Rao, NS, )	0.41
" Subsequently, by calculating the theoretical lipophilicity of the molecules (log P), the theoretical toxicity of the DPs was proposed, where the DPs had log P values between 1 and 3, lower values than those of VAL (log P = 4), indicating that DPs could be less toxic than the original compound (VAL)."	( Using computer tools for the evaluation of biodegradability, toxicity, and activity on the AT1 receptor of degradation products identified in the removal of valsartan by using photo-electro-Fenton process. Delgado-Vargas, CA; Espinosa-Barrera, PA; Martínez-Pachón, D; Moncayo-Lasso, A, 2021)	0.82
" The main efficacy endpoint was major adverse cardiac events (MACE) at 30 days and 6 months, defined as a composite of cardiac death, myocardial infarction, and HF hospitalizations."	( Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction. El Nozahi, M; Rezq, A; Saad, M, 2021)	0.87
" Hypotension and hyperkalaemia were the most frequently reported adverse events."	( Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review. Agrawal, R; Corda, S; Jindal, R; Proudfoot, C; Rajput, T; Senni, M; Studer, R, 2021)	0.87
" Sacubitril/valsartan was well tolerated with fewer study drug discontinuations due to adverse events, although the sacubitril/valsartan group had a higher proportion of patients with hypotension."	( Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study. Desai, AS; Guo, W; Iimori, T; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Saito, Y; Sakata, Y; Tsutsui, H; Yamamoto, K, 2021)	1.28
"In Japanese patients with HFrEF, there was no difference in reduction in the risk of CV death or HF hospitalization between sacubitril/valsartan and enalapril, and sacubitril/valsartan was safe and well tolerated."	( Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study. Desai, AS; Guo, W; Iimori, T; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Saito, Y; Sakata, Y; Tsutsui, H; Yamamoto, K, 2021)	1.1
"This review aimed to summarize the adverse events (AEs) reported during the use of sacubitril/valsartan versus angiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor blocker (ARB)."	( Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials. Chen, C; Fang, C; Huang, Y; Ma, L; Zhang, Y; Zhou, H, 2021)	1.13
" We used a random or fixed effects model to calculate the weighted mean difference (WMD) of changes in BP and the risk ratio (RR) for BP control rates and adverse events (AEs)."	( Efficacy and Safety of LCZ696 for Short-term Management of Essential Hypertension Compared With ARBs: A Meta-analysis of Randomized Controlled Trials. Wang, C; Wu, Q; Yang, P; Yang, S; Zhang, H, 2021)	0.62
" This study explores the safety profile of sacubitril/valsartan by comparing adverse events in RCT and real-world use."	( Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Brar, S; D'Albo, N; Dani, SS; Dey, A; Ganatra, S; Kim, YS; Shah, S, 2022)	1.27
" WHO's VigiBase, FAERS, and EMA's EudraVigilance were mined to obtain spontaneously reported real-world adverse events."	( Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Brar, S; D'Albo, N; Dani, SS; Dey, A; Ganatra, S; Kim, YS; Shah, S, 2022)	1.02
" A total of 103,038 adverse events were registered in the spontaneous reporting systems."	( Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Brar, S; D'Albo, N; Dani, SS; Dey, A; Ganatra, S; Kim, YS; Shah, S, 2022)	1.02
"The aim of this study was to characterise clinical priority of adverse events with sacubitril/valsartan for targeting preventive measures."	( Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Antonazzo, IC; De Ponti, F; Diemberger, I; Gatti, M; Raschi, E, 2021)	1.13
"We used the US Food and Drug Administration adverse event reporting system (worldwide pharmacovigilance database) to compare adverse events recording sacubitril/valsartan as suspect with other cardiovascular drugs."	( Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Antonazzo, IC; De Ponti, F; Diemberger, I; Gatti, M; Raschi, E, 2021)	1.1
"Sacubitril/valsartan was recorded in 20,021 reports, with 178 adverse events associated with significant disproportionality: 71."	( Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Antonazzo, IC; De Ponti, F; Diemberger, I; Gatti, M; Raschi, E, 2021)	1.3
"This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart failure, with a focus on important patient outcomes."	( Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis. Bedhomme, S; Bouchant, S; Boussageon, R; Bœuf-Gibot, S; Charuel, E; Menini, T; Pereira, B; Piñol-Domenech, N; Vaillant-Roussel, H, 2021)	1.11
" Case reports from the United States Food and Drug Administration's Adverse Event Reporting System from 1991 to Q4/2020 were used."	( Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan. Ryo, Y; Sunaga, T, 2022)	0.93
" In conclusion, the overwhelming majority of studies show that sacubitril/valsartan is effective and safe in the treatment of HFrEF patients but that it has little benefit in HFpEF patients."	( The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review. He, W; Li, Y; Liu, B; Sun, X; Zhang, A; Zhang, R; Zhu, H, )	0.63
" Adverse events and laboratory test results will be monitored throughout the trial."	( Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022)	0.96
" The total incidence of adverse cardiovascular events in the sacubitril/valsartan group was significantly lower than that in the control group {relative risk (RR) =0."	( Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis. Chen, J; Chen, T; Shou, Y; Yan, K; Zhang, L; Zhao, H, 2022)	1.2
"Sacubitril/valsartan was found to inhibit ventricular remodeling after AMI, improve cardiac function, and reduce the incidence of adverse cardiovascular events after myocardial infarction, the rehospitalization rate, and the mortality rate."	( Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis. Chen, J; Chen, T; Shou, Y; Yan, K; Zhang, L; Zhao, H, 2022)	1.36
" It was also safe and well tolerated."	( Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: A case report. Chen, X; Feng, Y; Li, W; Liu, H, 2022)	1.04
" The potential risk factors for the discontinuation events caused by sac/val-related adverse events (AEs) were explored."	( Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China. Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C, 2022)	0.99
"001), while there was no significant difference in the incidence of adverse events [odds ratio (OR) =1."	( Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials. Jin, JC; Li, BN; Liu, KK; Liu, S; Wu, HX, 2022)	1
"Concomitant use of sacubitril/valsartan for at least 3 months did not alter the efficacy of vericiguat and was similarly safe and tolerated in both study arms."	( Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. Alemayehu, WG; Armstrong, PW; Butler, J; Edelmann, F; Ezekowitz, J; Hernandez, AF; Lam, CSP; McMullan, C; O'Connor, CM; Pieske, B; Ponikowski, P; Roessig, L; Senni, M; Sim, D; Voors, AA; Westerhout, CM, 2022)	1.22
" Demographic summary and event data change in heart conditions after drug intake and adverse effects of drugs under both the SV and control arms were determined."	( The Efficacy and Safety of Sacubitril-Valsartan for the Treatment of Heart Failure in Adults: A Meta-Analysis. Fan, H; Ning, T; Tian, Q; Xiong, Z; Zheng, Z, 2023)	1.18
"The present evidence shows that SV is effective in the treatment of heart failure, reducing hospitalization and cardiovascular mortality, and that the adverse effects are comparable or fewer than those associated with other drugs used for this indication."	( The Efficacy and Safety of Sacubitril-Valsartan for the Treatment of Heart Failure in Adults: A Meta-Analysis. Fan, H; Ning, T; Tian, Q; Xiong, Z; Zheng, Z, 2023)	1.18
" No major adverse events occurred."	( Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study. Fusco, F; Grimaldi, N; Iannuzzi, A; Merola, A; Palma, M; Sarubbi, B; Scognamiglio, G, 2023)	1.19
" The most frequently reported adverse event for sacubitril/valsartan is hypotension and the risk is higher than for ACEI/ARB."	( Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis. Shaikh, AS; Xu, XD; Yang, HR; Zhou, BT, 2023)	1.43
" Hypotension is the most common adverse event with sacubitril/valsartan compared with ACEI/ARB."	( Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis. Shaikh, AS; Xu, XD; Yang, HR; Zhou, BT, 2023)	1.43
"Low-dose sacubitril/valsartan might also be effective and safe in HF patients."	( Efficacy and safety of low-dose sacubitril/valsartan in heart failure patients: A systematic review and meta-analysis. Chen, WW; Dang, HQ; Gao, J; Jiang, J; Li, YM; Liu, YL; Zhang, XZ, 2023)	1.5
"50%) were the most frequent adverse events."	( Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients. Ahmad, A; Alama, MN; Alharthi, TS; Alkreathy, HM; Alluhabi, SI; Alqarni, F; Alrafiah, AR; Damanhouri, ZA, 2023)	1.15
" Key safety endpoints were the incidences of adverse events during hospitalization and during follow-up planned at 1 month, 3-6 months and 12-18 months after discharge."	( Safety and feasibility of angiotensin receptor neprilysin inhibitor in real-world patients with acute decompensated heart failure. Angelini, F; Coppini, L; Ferraro, I; Giordana, F; Musumeci, G; Rossini, R; Ruffino, E; Tizzani, E; Valente, E; Varbella, F, 2023)	0.91
"In-hospital initiation of sacubitril/valsartan treatment in real-world ADHF patients may be a safe and feasible treatment option."	( Safety and feasibility of angiotensin receptor neprilysin inhibitor in real-world patients with acute decompensated heart failure. Angelini, F; Coppini, L; Ferraro, I; Giordana, F; Musumeci, G; Rossini, R; Ruffino, E; Tizzani, E; Valente, E; Varbella, F, 2023)	1.18
"Sacubitril/Valsartan therapy in HFrEF patients is safe and moderately tolerated among the Pakistani population."	( Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction. Ashraf, T; Balouch, IJ; Bashir, S; Bhatti, UH; Karim, M; Khan, MN; Moazzam, A; Naseeb, K; Rauf, R; Soomro, NA, 2023)	1.57
"7%) experienced serious adverse events; however, none were considered related to the study drug."	( Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan Beom, JW; Cho, YH; Jang, JY; Kang, SM; Kim, JS; Kim, WH; Lee, KJ; Ryu, JK; Shin, WY; Yoon, YW, 2023)	1.16
"CIS-induced cardiotoxicity and L-NNA co-administered group showed significant increases in cardiac enzymes, toxic histopathological features, elevated heart weights, angiotensin II (Ang II), neprilysin, malondialdehyde (MDA), inflammatory mediators, blood pressure (BP) and caspase 3 expressions, but there are significant decreases in the antioxidant parameters, vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS)."	( Sacubitril/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFα/IL6 signalling pathways. Ahmed Rifaai, R; Bayoumi, AMA; Mahmoud Refaie, MM; Shehata, S, 2023)	1.3

Excerpt	Reference	Relevance
"The pharmacokinetic and pharmacodynamic properties of nonpeptide angiotensin antagonists in humans are reviewed in this paper."	( Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Biollaz, J; Brunner, HR; Buclin, T; Csajka, C, 1997)	0.3
"Pharmacokinetic and pharmacodynamic interactions between single oral doses of valsartan (160 mg) and furosemide (40 mg) were investigated in an open, randomized, three-period crossover study in twelve healthy male subjects."	( Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Bindschedler, M; de Gasparo, M; Degen, P; Flesch, G; Preiswerk, G, 1997)	0.76
" Pharmacokinetic measurements included plasma concentrations of valsartan and furosemide, and urinary excretion of the latter."	( Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Bindschedler, M; de Gasparo, M; Degen, P; Flesch, G; Preiswerk, G, 1997)	0.77
" Inter- and intra-individual variability of the pharmacokinetic variables was high for both furosemide and valsartan."	( Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Bindschedler, M; de Gasparo, M; Degen, P; Flesch, G; Preiswerk, G, 1997)	0.74
" In addition, to determine the exposure to valsartan when liver function is impaired, a pharmacokinetic study (open, single dose) was performed in patients with mild and moderate impairment of liver function."	( Pharmacokinetics of valsartan in patients with liver disease. Benjamin, IS; Brookman, LJ; Flesch, G; Lloyd, P; Mullins, F; Palmer, KR; Rolan, PE; Sioufi, A; Waldmeier, F; Wyld, PJ, 1997)	0.88
"Pharmacokinetics, pharmacodynamic effects and tolerability of 200 mg valsartan, once-daily for 8 days, were investigated in 16 healthy, normotensive volunteers on a normal sodium diet."	( Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. de Gasparo, M; Flesch, G; Gasparini, M; Howald, H; Müller, P, 1997)	0.76
" Therefore, an interaction trial was performed to evaluate the effects of co-administration of V on the pharmacokinetics of atenolol (A), and vice versa, and to monitor the pharmacodynamic response of plasma angiotensin II (ANG II) concentrations and plasma renin activity (PRA), as well as of heart rate and blood pressure, under resting and exercise conditions."	( Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. Czendlik, CH; Howald, H; Preiswerk, G; Sioufi, A, 1997)	0.53
" On day 7 of each dosing period, serial blood samples were obtained over 12 h for pharmacokinetic assessment."	( Pharmacokinetics of multiple doses of valsartan in patients with heart failure. Glazer, R; Gurrieri, P; McLeod, J; Prasad, PP; Yeh, CM, 2002)	0.59
" The AT(1)R antagonist valsartan (160 mg) was given to all the subjects, and blood samples were taken for pharmacokinetic analysis."	( Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan. Daneshtalab, N; Jamali, F; Lewanczuk, RZ; Russell, A, 2004)	0.87
" Finally, some relevant pharmacokinetics and metabolic properties of the database of 53 compounds are calculated using the VolSurf and MetaSite software to allow the simultaneous characterization of pharmacodynamic and pharmacokinetics properties of the chemical space of angiotensin II receptor antagonists."	( Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. Berellini, G; Cruciani, G; Mannhold, R, 2005)	0.33
" Four open-label studies investigated the pharmacokinetic interactions between aliskiren 300 mg and the antihypertensive drugs amlodipine 10 mg (n = 18), valsartan 320 mg (n = 18), hydrochlorothiazide 25 mg (HCTZ, n = 22) and ramipril 10 mg (n = 17) in healthy subjects."	( Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C, 2006)	0.73
"The potential for a pharmacokinetic drug interaction between valsartan, an antihypertensive drug, and simvastatin, a lipid-lowering agent, was investigated in this study."	( Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Humbert, H; Pommier, F; Prasad, P; Reynolds, CV; Sunkara, G; Yeh, C, 2007)	0.83
" This method was successfully applied to the pharmacokinetic study of fixed dose combination (FDC) of nebivolol and valsartan formulation product after an oral administration to healthy human subjects."	( Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. Gowda, KV; Mandal, U; Pal, TK; Selvan, PS; Solomon, WD, 2007)	0.78
"We conducted 3 open-label, multiple-dose, 3-period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction between vildagliptin, a novel dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, and representatives of 3 commonly prescribed antihypertensive drug classes: (1) the calcium channel blocker, amlodipine; (2) the angiotensin receptor blocker, valsartan; and (3) the angiotensin-converting enzyme inhibitor, ramipril."	( Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C, 2008)	0.71
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Because the body weight of most children in groups 3 and 4 exceeds 40 kg and they received a dose of less than 2 mg/kg, major pharmacokinetic parameters are dose normalized for comparison across the age groups."	( Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. Batisky, DL; Blumer, J; Shi, V; Solar-Yohay, S; Sunkara, G; Wells, T, 2009)	0.68
" This novel method has been applied to human pharmacokinetic study."	( Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: application to a clinical pharmacokinetic study. Mullangi, R; Ramani, AV; Sengupta, P, 2009)	0.55
"The objective of this work was to develop a population pharmacokinetic model to assess the influence of subject covariates on the pharmacokinetics of valsartan in children."	( Population pharmacokinetics of valsartan in pediatrics. Habtemariam, B; Jarugula, V; Kern, S; Pillai, G; Sallas, W; Sunkara, G, 2009)	0.84
" Based on the 90% confidence interval of the individual ratios for Cmax and AUC0-inf, it was concluded that the test formulation is bioequivalent to the reference Hyzaar formulation with respect to the rate and extent of absorption of both LOS and HCTZ."	( Simultaneous determination of losartan and hydrochlorothiazide in human plasma by LC/MS/MS with electrospray ionization and its application to pharmacokinetics. Andraus, MH; Azevedo, CP; Borges, BC; Borges, NC; Moreira, RF; Moreno, RA; Salvadori, MC, 2009)	0.35
"The aim of this study was to evaluate a strategy based on a physiologically based pharmacokinetic (PBPK) model for the prediction of PK profiles in human using in vitro data when elimination of compounds relies on active transport processes."	( Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. Cascais, AC; Funk, C; Lavé, T; Poirier, A, 2009)	0.62
"The aim of this study was to evaluate a physiologically based pharmacokinetic (PBPK) model for predicting PK profiles in humans based on a model refined in rats and humans in vitro uptake-transport data using valsartan as a probe substrate."	( Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Cascais, AC; Funk, C; Lavé, T; Poirier, A, 2009)	0.81
" The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs."	( Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. Habuchi, T; Inoue, T; Kagaya, H; Miura, M; Ohkubo, T; Saito, M; Satoh, S; Suzuki, T, 2009)	0.66
" In the present study, the pharmacokinetic parameters of two oral formulations of valsartan tablets were compared in a randomized, single oral dose, two-treatment crossover design in 24 healthy male volunteers under fasting conditions."	( Pharmacokinetic and bioequivalence study of two brands of valsartan tablets in healthy male volunteers. Islambulchilar, Z; Nemati, M; Valizadeh, H; Zakeri-Milani, P, 2010)	0.83
" Although the bioavailability and pharmacokinetic properties of valsartan have been well characterized, a literature search did not identify any reports concerning the bioavailability of valsartan in the Indian population."	( Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Batolar, LS; Iqbal, M; Khuroo, A; Monif, T; Sharma, PL; Tandon, M, 2010)	0.83
"This study was undertaken to compare the pharmacokinetic properties of 2 branded generic valsartan formulations (tests A and B) with a branded innovator product (reference) in healthy Indian male subjects."	( Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Batolar, LS; Iqbal, M; Khuroo, A; Monif, T; Sharma, PL; Tandon, M, 2010)	0.81
"This single-dose, randomized, open-label, 3-period crossover study compared the pharmacokinetic properties of 3 marketed brands of valsartan 160-mg tablets in healthy Indian male volunteers aged 18 to 45 years under fasting conditions."	( Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Batolar, LS; Iqbal, M; Khuroo, A; Monif, T; Sharma, PL; Tandon, M, 2010)	0.8
"The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study."	( Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. Ayalasomayajula, S; Bhad, P; Jarugula, V; Karan, R; Leon, S; Riviere, GJ; Sunkara, G, 2011)	0.83
"To compare the pharmacokinetic (PK) profiles and evaluate the PK interaction of hydrochlorothiazide (HCTZ) used alone and in combination with benazepril (BENA) or valsartan (VAL) in healthy Chinese volunteers."	( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011)	0.79
" The apparent terminal half-life (t(1/2)) and the time to C(max) (tmax) were unchanged between the two studies."	( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011)	0.59
" The elongated half-life (t(1/2)) and stable blood concentrations for compound 4 due to the hydrolysis of the ester group in the second barrier were demonstrated in pharmacokinetic experiments."	( Synthesis, pharmacokinetics, and pharmacodynamics studies of valsartan peptide derivatives. Chen, J; Cheng, Z; He, L; Hu, G; Hu, Y; Li, Q; Li, Y; Wu, C, 2012)	0.62
" The aim of these studies was to assess the potential for pharmacokinetic interaction between dapagliflozin, a sodium glucose co-transporter-2 inhibitor being developed for the treatment of T2DM, and four medications commonly prescribed in patients with T2DM and cardiovascular disease: simvastatin, valsartan, warfarin, and digoxin."	( Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC, 2012)	0.78
"Potential pharmacokinetic interactions between 20 mg dapagliflozin, 40 mg simvastatin, or 320 mg valsartan were assessed in an open-label, randomized, five-period, five-treatment, unbalanced crossover study in 24 healthy subjects."	( Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Boulton, DW; Chang, M; Griffen, SC; Kasichayanula, S; LaCreta, FP; Liu, X; Shyu, WC, 2012)	0.83
"The aim of this study was to investigate the potential pharmacokinetic interaction between pitavastatin and valsartan in healthy male volunteers in Korea."	( Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers. Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH, 2012)	0.84
" Plasma samples were obtained at steady state for the pharmacokinetic evaluation of pitavastatin and valsartan."	( Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers. Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH, 2012)	0.84
"The pharmacokinetic profiles of pitavastatin and valsartan administered as monotherapy were comparable to combination treatment in these healthy male Korean volunteers, suggesting that individual pharmacokinetic properties are not significantly affected by concurrent administration."	( Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers. Bae, KS; Jin, S; Jung, JA; Kim, MJ; Kim, YH; Lim, HS; Noh, YH, 2012)	0.88
" Quercetin significantly increases the plasma concentration of valsartan and peak concentration (70."	( Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Babu, PR; Challa, SR; Challa, VR; Johnson, B; Maheswari, C, 2013)	0.88
" CYP2C9 variants were associated only with losartan pharmacokinetics: the half-life of losartan was higher in CYP2C9*3 allele carriers (3."	( Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers. Abad-Santos, F; Cabaleiro, T; López-Rodríguez, R; Novalbos, J; Ochoa, D; Prieto-Pérez, R; Román, M; Talegón, M; Wojnicz, A, 2013)	0.39
" The optimized formulation obtained was then tested in rats for an in vivo pharmacokinetic study."	( Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment. Ahad, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y, 2013)	0.39
" The purpose of this study was to investigate the pharmacokinetic properties of typical ARBs in the dog."	( Pharmacokinetics of angiotensin II receptor blockers in the dog following a single oral administration. Baek, IH; Kwon, KI; Lee, BY; Lee, ES, 2013)	0.39
" The pharmacokinetic properties of each drug after co-administration of VAL and HCT were compared with those of each drug administered alone."	( Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers. Hedaya, MA; Helmy, SA, 2013)	0.67
" The interaction of HCT with other angiotensin-receptor blockers should be investigated to determine whether this interaction is limited to VAL or if other angiotensin-receptor blockers have the same pharmacokinetic interactions."	( Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers. Hedaya, MA; Helmy, SA, 2013)	0.67
" The aim of this study is to investigate the potential pharmacokinetic interaction between scutellarin and valsartan in rats."	( Pharmacokinetic interaction between scutellarin and valsartan in rats. Cui, MY; Ju, AX; Li, QH; Tian, CC; Zhang, CT, 2013)	0.85
"The goal of this study was to compare the pharmacokinetic profiles of single administration of a newly developed FDC tablet containing amlodipine orotate 10 mg and valsartan 160 mg (test formulation) with the conventional FDC tablet of amlodipine besylate 10 mg and valsartan 160 mg (reference formulation) in healthy male Korean volunteers."	( Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Bahng, MY; Chae, D; Kim, Y; Lee, D; Park, K; Roh, H; Son, H; Son, M, 2013)	0.81
" Blood samples were collected up to 144 hours after the dose, and pharmacokinetic parameters were determined for amlodipine and valsartan."	( Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Bahng, MY; Chae, D; Kim, Y; Lee, D; Park, K; Roh, H; Son, H; Son, M, 2013)	0.82
"The solubility of valsartan is dependent on pH and thus may cause patient variability in drug absorption and failure in bioequivalence studies; thus, increasing the solubility and release of valsartan at low pH has been suggested for a more favorable pharmacokinetic profile."	( Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. Cho, HJ; Ki, MH; Kim, DD; Kim, JE; Kim, RS; Tae Kim, G; Yoon, IS, 2014)	0.97
" Blood samples were collected up to 24 hours after dosing, and pharmacokinetic parameters were determined after the plasma valsartan concentration was analyzed using UPLC-MS/MS."	( Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. Cho, HJ; Ki, MH; Kim, DD; Kim, JE; Kim, RS; Tae Kim, G; Yoon, IS, 2014)	0.85
"The aim of this study was to develop and optimize a transdermal gel formulation of valsartan using Box-Behnken design and to evaluate it for pharmacokinetic study."	( Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. Ahad, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y, 2014)	0.9
" In vivo pharmacokinetic study of VGF-OPT-transdermal therapeutic system containing iso-eucalyptol showed a significant increase in the bioavailability (2."	( Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. Ahad, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y, 2014)	0.67
" Pharmacodynamic results showed that, oral administration of VAL-NS significantly lowered (p ≤ 0."	( Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. Ali, J; Baboota, S; Gora, S; Mustafa, G; Sahni, JK, 2016)	0.79
" This study compared the pharmacokinetic (PK), pharmacodynamic (PD), and tolerability profiles of cilnidipine and valsartan, both alone and in combination, in healthy male subjects."	( Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Jang, K; Lee, H; Lee, J; Lim, KS; Shin, D; Yu, KS, 2014)	0.83
" The study reported here sought to evaluate the pharmacokinetic and pharmacodynamic interactions between rosuvastatin and valsartan in healthy Korean subjects."	( A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Huh, W; Jang, SB; Jung, JA; Kim, JR; Ko, JW; Lee, SY; Nam, SY, 2015)	0.85
" Lipid profiles and vital signs (systolic and diastolic blood pressure and pulse rate) were measured for the pharmacodynamic assessment."	( A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Huh, W; Jang, SB; Jung, JA; Kim, JR; Ko, JW; Lee, SY; Nam, SY, 2015)	0.64
"The pharmacokinetic profiles of rosuvastatin and valsartan in combination were comparable with those of rosuvastatin and valsartan administered individually, suggesting that their individual pharmacokinetics were not affected by their coadministration."	( A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Huh, W; Jang, SB; Jung, JA; Kim, JR; Ko, JW; Lee, SY; Nam, SY, 2015)	0.9
" The aims of this phase I study were to investigate pharmacokinetic and pharmacodynamic interactions between nebivolol, a vasodilatory β1-selective blocker, and valsartan, an angiotensin II receptor blocker, and to assess safety and tolerability of the combination."	( A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State. Chen, CL; Desai-Krieger, D; Ghahramani, P; Kerolous, M; Ortiz, S; Wright, HM, )	0.53
" The results of the pharmacokinetic study demonstrated that the AUC value of valsartan after transdermal administration was apparently increased."	( The ameliorated longevity and pharmacokinetics of valsartan released from a gel system of ultradeformable vesicles. Ahad, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y, 2016)	0.92
" The Cmax for LBQ657 was similar between age groups."	( Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. Chandra, P; Gan, L; Kode, K; Langenickel, T; Petruck, J; Rajman, I; Rebello, S; Sunkara, G; Zhou, W, 2016)	0.43
" The optimized formulation containing valsartan was tested in rats for bioavailability and pharmacokinetic parameters and compared with that of valsartan pure drug."	( Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan. Chella, N; Daravath, B; Kumar, D; Tadikonda, RR, 2016)	0.93
" In vivo pharmacokinetic studies showed 199 % relative bioavailability with significant improvement (p < 0."	( Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan. Chella, N; Daravath, B; Kumar, D; Tadikonda, RR, 2016)	0.66
" In vivo pharmacokinetic studies were conducted in male Sprague Dawley (SD) rats."	( Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics. Betageri, GV; Nekkanti, V; Venkatesan, N; Wang, Z, 2015)	0.7
"The present study aimed to examine the potential pharmacokinetic drug interaction between valsartan and gemfibrozil."	( Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. Han, HK; Kim, BJ; Mo, L; Yang, SJ, 2016)	0.9
" The validated method can be used as a routine method to support pharmacokinetic studies."	( Development and validation of a reliable and rapid LC-MS/MS method for simultaneous quantification of sacubitril and valsartan in rat plasma and its application to a pharmacokinetic study. Chunduri, RH; Dannana, GS, 2016)	0.64
"The pharmacokinetic profiles of LCZ696 analytes in Chinese subjects are similar to those reported previously in Caucasian subjects."	( Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. Ayalasomayajula, S; Han, Y; Hinder, M; Kalluri, S; Langenickel, T; Pal, P; Pan, W; Sunkara, G; Yang, F; Yuan, Y, 2017)	0.7
" The pharmacokinetic exposure of the LCZ696 analytes in patients with HF observed in this study is comparable to that observed in the pivotal Phase III study."	( Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction. Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I, 2016)	0.68
" Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q."	( Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W, 2016)	0.43
" In 3 separate studies, pharmacokinetic drug-drug interactions (DDIs) potential was assessed when LCZ696 was coadministered with hydrochlorothiazide (HCTZ), amlodipine, or carvedilol."	( Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Greeley, M; Hsiao, HL; Langenickel, TH; Pal, P; Rajman, I; Rebello, S; Roberts, J; Sunkara, G; Zhou, W, 2015)	0.42
"The steady-state Cmax and AUC0-24h of sacubitril and valsartan were unchanged in patients with renal impairment compared with healthy subjects."	( Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. Albrecht, D; Ayalasomayajula, SP; Chandra, P; Jordaan, P; Langenickel, TH; Pal, P; Rajman, I; Sunkara, G; Zhou, W, 2016)	0.92
" The point estimates and the associated 90% confidence intervals for pharmacokinetic parameters were evaluated."	( Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide. Ayalasomayajula, S; Chen, F; Langenickel, TH; Pal, P; Schuehly, U; Sunkara, G; Zhou, W, 2018)	0.72
" Given the potential for co-administration of both drugs in patients with heart failure, this study was designed to investigate the potential for a pharmacodynamic drug interaction affecting blood pressure."	( Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. Ayalasomayajula, S; Buchbjerg, J; Golor, G; Hinder, M; Langenickel, TH; Pal, P; Prescott, MF; Schuehly, U; Sunkara, G, 2018)	0.71
"The results from this study demonstrate no pharmacodynamic drug interaction between nitroglycerin and sacubitril/valsartan in healthy subjects, suggesting that no change of dose selection and escalation recommendations or clinical monitoring during nitroglycerin administration is required."	( Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. Ayalasomayajula, S; Buchbjerg, J; Golor, G; Hinder, M; Langenickel, TH; Pal, P; Prescott, MF; Schuehly, U; Sunkara, G, 2018)	0.92
" The aim of this study was to investigate the possible pharmacokinetic drug-drug interactions between amlodipine, valsartan, and rosuvastatin in healthy Korean male volunteers."	( Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Cho, S; Gwon, MR; Kang, WY; Kim, BK; Lee, HW; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2019)	0.97
"When amlodipine, valsartan, and rosuvastatin were coadministered to healthy volunteers, the pharmacokinetic exposure to valsartan was decreased, but no change in exposure to amlodipine and rosuvastatin occurred."	( Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Cho, S; Gwon, MR; Kang, WY; Kim, BK; Lee, HW; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2019)	1.1
" However, the pharmacokinetic (PK) and pharmacodynamic properties of SAC/VAL in HD patients with HF remain uncertain."	( Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure. Apaer, R; Che, H; Chen, J; Dou, X; Feng, Z; Fu, L; Fu, X; He, C; Huang, R; Ke, G; Kong, Y; Li, S; Li, X; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Mei, L; Shi, W; Su, X; Tang, B; Tao, Y; Wang, X; Wang, Y; Wen, F; Xia, Y; Xiao, J; Xiong, Y; Xu, L; Xue, Z; Ye, Z; Zhang, H; Zhang, L, 2022)	0.97
" Thus, the effects of hypoglycemic drugs on kidney function and pharmacokinetic interactions in combination with antihypertensive and hypoglycemic drugs are of great clinical value."	( Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers. Chen, X; Huang, Y; Jia, Y; Liu, G; Liu, R; Shen, J; Wang, C; Wang, Y, 2022)	0.94
" The pharmacokinetic properties of SHR3824 were evaluated after its administration alone or in combination with valsartan."	( Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers. Chen, X; Huang, Y; Jia, Y; Liu, G; Liu, R; Shen, J; Wang, C; Wang, Y, 2022)	1.16
" Based on these findings, co-administration of SHR3824 and valsartan seemed to have no effect on the pharmacokinetic properties of either drug."	( Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers. Chen, X; Huang, Y; Jia, Y; Liu, G; Liu, R; Shen, J; Wang, C; Wang, Y, 2022)	1.19
"The study was conducted to establish a population pharmacokinetic (PPK) model of valsartan in Chinese healthy subjects and investigate potential covariate impacts on the pharmacokinetics (PK) parameters."	( Population Pharmacokinetic Analysis of Valsartan in Healthy Chinese Subjects. Gao, R; Ji, X; Qiu, W; Wang, Z; Yang, H, 2023)	1.41

Excerpt	Reference	Relevance
"The aim of this study was to compare the time-effect profiles of a once-daily administration of valsartan and amlodipine, each given alone or in combination with hydrochlorothiazide, in terms of ambulatory blood pressure (BP) and heart rate in elderly patients with isolated systolic hypertension."	( Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). Ambrosia, GB; Caiazza, A; Malacco, E; Mugellini, A; Palatini, P; Santonastaso, M; Spagnuolo, V, 2004)	0.78
" The aims of the present study were to investigate, in the New Zealand genetically hypertensive (GH) rat model, the effects of treatment with simvastatin, alone or in combination with valsartan or enalapril, on blood pressure (BP) and structural remodelling of mesenteric resistance arteries (MRA) and of the basilar artery, an artery that plays a major role in the regulation of cerebral resistance."	( Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model. Laverty, R; Ledingham, JM, )	0.57
"To observe the effects of routine doses of benazepril combined with valsartan on congestive heart failure."	( [Effects of benazepril combined with valsartan on congestive heart failure]. Liu, DS; Ye, JF, 2005)	0.84
"To assess whether treatment with insulin-sensitizing agents (ISAs) in combination with ezetimibe and valsartan have greater effect on hepatic fat content and lipid peroxidation compared to monotherapy in the methionine choline-deficient diet (MCDD) rat model of non-alcoholic fatty liver disease (NAFLD)."	( Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S, 2006)	0.78
"To attain recent goals of blood pressure (BP) control, multiple drug therapy combinations are required, including higher doses of thiazide diuretics in combination with other classes of antihypertensive drug therapy."	( Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. Davidai, G; Koval, SE; Murwin, D; Neutel, JM; Punzi, HA; White, WB, 2006)	0.57
" We investigated the blood pressure (BP)-lowering effects of the oral direct renin inhibitor aliskiren, alone or in combination with the angiotensin receptor blocker valsartan."	( Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Aldigier, JC; Azizi, M; Chiang, Y; Januszewicz, A; Pool, JL; Satlin, A; Schmieder, RE; Zidek, W, 2007)	0.75
"In 2004-2005, the antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg combined with hydrochlorothiazide 25 mg were assessed in a large placebo-controlled trial in patients with stages 1 and 2 hypertension and demonstrated that both agents were highly effective in lowering blood pressure (BP) compared with placebo and that telmisartan lowered BP significantly greater than valsartan."	( Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Chrysant, SG; Davidai, G; Guthrie, R; Koval, SE; Murwin, D; White, WB, 2008)	0.82
"We investigated the role of Valsartan (V) alone or in combination with Simvastatin (S) on coronary atherosclerosis and vascular remodeling, and tested the hypothesis that V or V/S attenuate the pro-inflammatory effect of low endothelial shear stress (ESS)."	( Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques. Baker, AB; Beigel, R; Chatzizisis, YS; Coskun, AU; Daley, W; Edelman, ER; Feldman, CL; Gerrity, RG; Jonas, M; Maynard, C; Stone, BV; Stone, PH, 2009)	0.89
"The antihypertensive effects of telmisartan 80 mg versus valsartan 160 mg, both combined with hydrochlorothiazide (HCTZ) 25 mg, were assessed in a pooled analysis from two large trials with identical study designs in patients with stage 1-2 hypertension."	( Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension. Davidai, G; Schumacher, H; White, WB, 2009)	0.6
" This study evaluates irbesartan in relation to commonly used alternative hypertension therapies losartan and valsartan given in combination with hydrochlorothiazide (HCTZ) in the general hypertensive population in Greece."	( Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011)	0.58
"Based on efficacy data from clinical trials and lower attainment costs in various hypertensive patient populations, irbesartan in combination with HCTZ compares favorably with losartan and valsartan in combination with HCTZ in the Greek setting."	( Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Ekman, M; Fragoulakis, V; Maniadakis, N; Papagiannopoulou, V; Yfantopoulos, J, 2011)	0.56
"To compare the pharmacokinetic (PK) profiles and evaluate the PK interaction of hydrochlorothiazide (HCTZ) used alone and in combination with benazepril (BENA) or valsartan (VAL) in healthy Chinese volunteers."	( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011)	0.79
" Overall, HCTZ alone as well as in combination with BENA and VAL was well tolerated within the scope of the current studies in Chinese health volunteers."	( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011)	0.59
" Mean extraction recoveries of three QCs for the triple drug combination were 76."	( Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. Pancholi, SS; Sharma, RN, 2012)	0.61
"To compare the effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation and plasma nitric oxide (NO) and endothelin (ET) in elderly hypertensive patients."	( [Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients]. Sun, CX; Tao, CW; Wu, ZB; Yu, QG; Zhang, Y, 2012)	1.06
"Valsartan in combination with amlodipine or hydrochlorothiazide can both effectively lower BPV in elderly hypertensive patients and improve the vascular endothelial function and the former regimen is more suitable for elderly hypertensive patients."	( [Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients]. Sun, CX; Tao, CW; Wu, ZB; Yu, QG; Zhang, Y, 2012)	2.2
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"We compared the effects of exercise alone and in combination with a calcium channel blocker (amlodipine) or an angiotensin receptor blocker (valsartan) in hypertensive patients."	( Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients. Ikeda, M; Ohta, M; Tajiri, Y; Yamato, H, 2012)	0.58
" PubMed searches were conducted to identify randomized trials (n = 14) comparing the two agents, alone or combined with hydrochlorothiazide."	( Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review. Lacourcière, Y, 2013)	0.74
" We investigated the efficacy and safety of probucol (an anti-oxidant) combined with valsartan (an ARB) on the progression of IgA nephropathy."	( Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study. Feng, Z; Hou, S; Hu, H; Liang, Y; Shi, W; Shi, X; Wang, L; Wang, W; Xia, Y; Xu, L; Yan, H; Ye, Z; Zhang, B; Zhang, L; Zhong, W, 2014)	0.94
" Probucol combined with valsartan led to a more rapid decrease of 24-h urinary protein excretion than valsartan alone."	( Probucol combined with valsartan in immunoglobulin A nephropathy: a multi-centre, open labelled, randomized controlled study. Feng, Z; Hou, S; Hu, H; Liang, Y; Shi, W; Shi, X; Wang, L; Wang, W; Xia, Y; Xu, L; Yan, H; Ye, Z; Zhang, B; Zhang, L; Zhong, W, 2014)	1.02
" We have now compared the effects of the ARB valsartan combined with cilnidipine or amlodipine on cardiac pathophysiology in DS rats."	( Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Harada, E; Hattori, T; Matsuura, N; Murohara, T; Nagasawa, K; Nagata, K; Niinuma, K; Takahashi, K; Takatsu, M; Watanabe, S, 2015)	0.99
"Although cilnidipine and valsartan are widely coadministered to patients with hypertension, their drug-drug interaction potential has not been investigated."	( Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Jang, K; Lee, H; Lee, J; Lim, KS; Shin, D; Yu, KS, 2014)	0.92
"The treatment with Valsartan combined with Clopidogrel and Leflunomide can reduce the urinary proteins loss and renal function deterioration for IgA nephropathy patients and cause minimal adverse reactions."	( Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z, 2015)	2.19
"Thirty healthy male Korean subjects were administered with rosuvastatin (20 mg/day), valsartan (160 mg/day), and both drugs concomitantly for 4 days in a randomized, open-label, multiple-dose, three-treatment, three-period crossover study."	( A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Huh, W; Jang, SB; Jung, JA; Kim, JR; Ko, JW; Lee, SY; Nam, SY, 2015)	0.87
"To study the protective effects of valsartan (Val) and benazepril, (Ben) combined with atorvastatin (Ato), on cardiorenal syndrome (CRS) in rats."	( Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Chen, J; Hu, YJ; Peng, DF; Tang, SY, 2015)	1.01
"Valsartan and benazepril, combined with atorvastatin, can have significant protective effects on cardiorenal functions of rats with CRS, with no significant difference between these two drugs."	( Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Chen, J; Hu, YJ; Peng, DF; Tang, SY, 2015)	2.17
"The aims to investigate the different protective effects of valsartan and benazepril when combined with atorvastatin in the cardio-renal functions of cardio-renal syndrome (CRS) patients."	( Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS). Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY, 2015)	1.02
"When combined with atorvastatin, both valsartan and benazepril effectively improved the cardio-renal functions of early CRS patients."	( Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS). Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY, 2015)	1.05
"To investigate the clinical effect of double dose of valsartan combined with tacrolimus in the treatment of diabetic nephropathy (DN)."	( Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy. Hou, XL; Jin, H; Wu, J; Zhang, B; Zhang, HB; Zhang, HN, 2016)	0.97
" Patients were randomly divided into three groups according to the sequence of admission, group A (conventional dose of valsartan group, n = 28 cases), group B (double dose of valsartan group, n = 29 cases) and group C (double dose of valsartan combined with tacrolimus group, n = 29)."	( Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy. Hou, XL; Jin, H; Wu, J; Zhang, B; Zhang, HB; Zhang, HN, 2016)	0.92
"Double dose of valsartan combined with tacrolimus treatment of DN patients can improve clinical symptoms, reducing inflammation, inhibiting or even reversing the interstitial fibrosis, which will improve the curative effect and reduce the recurrence, as to provide a new theoretical basis for the clinical treatment of the disease."	( Clinical study of double dose of valsartan combined with tacrolimus in treatment of diabetic nephropathy. Hou, XL; Jin, H; Wu, J; Zhang, B; Zhang, HB; Zhang, HN, 2016)	1.07
" Here, we assessed the potential for pharmacokinetic drug-drug interaction of LCZ696 (400 mg, single dose or once daily [q."	( Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Akahori, M; Dahlke, M; Gan, L; Jiang, X; Langenickel, T; Mendonza, A; Neelakantham, S; Nguyen, J; Pal, P; Rajman, I; Rebello, S; Reynolds, C; Sunkara, G; Swan, T; Zhou, W, 2016)	0.43
" In 3 separate studies, pharmacokinetic drug-drug interactions (DDIs) potential was assessed when LCZ696 was coadministered with hydrochlorothiazide (HCTZ), amlodipine, or carvedilol."	( Pharmacokinetic drug-drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Greeley, M; Hsiao, HL; Langenickel, TH; Pal, P; Rajman, I; Rebello, S; Roberts, J; Sunkara, G; Zhou, W, 2015)	0.42
" As several HF patients are likely to use statins as co-medications, the potential for a pharmacokinetic drug-drug interaction between atorvastatin and LCZ696 was evaluated."	( Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects. Ayalasomayajula, S; Han, Y; Langenickel, T; Pal, P; Pan, W; Rajman, I; Sunkara, G; Yang, F; Yuan, Y; Zhou, W, 2017)	0.46
" In this clinical study, 26 healthy subjects received simvastatin 40 mg alone or in combination with LCZ696 or after 1 or 2 h of LCZ696 dosing."	( In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). Alexander, N; Ayalasomayajula, S; Goswami, B; Han, Y; Hanna, I; Hinder, M; Langenickel, T; Malcolm, K; Natrillo, A; Sunkara, G; Zhou, W, 2016)	0.65
" After one week of washout in previously treated patients, 74 subjects were treated with valsartan or valsartan combined with HCTZ for 16 weeks according to the protocol."	( The efficacy and safety of valsartan and a combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension: a subgroup analysis of the effect of valsartan and its combination with…. Accetto, R; Barbic Zagar, B; Sirenko, Y; Vincelj, J; Widimsky, J; Yevgenyevna, IC, 2018)	1
"To observe and analyze the clinical efficacy and ultrasound detection results of treatment of hypertensive patients with heart disease with valsartan combined with hydrochlorothiazide."	( Clinical efficacy and ultrasound inspection of the treatment of hypertensive heart patients with Valsartan combined with hydrochlorothiazide. Dai, M; Qian, D; Tao, H; Zhang, C, 2018)	0.9
" The aim of this study was to investigate the possible pharmacokinetic drug-drug interactions between amlodipine, valsartan, and rosuvastatin in healthy Korean male volunteers."	( Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. Cho, S; Gwon, MR; Kang, WY; Kim, BK; Lee, HW; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2019)	0.97
" Participants were divided into six treatment groups based on the hypertensive drug therapy they were using; lisinopril, losartan or valsartan alone or in combination with hydrochlorothiazide (A, B and C group respectively) or combination of lisinopril, losartan or valsartan with/without hydrochlorothiazide together with amlodipine (D, E and F respectively)."	( Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019)	0.72
"These data suggest that lisinopril/lisinopril + hydrochlorothiazide, losartan/losartan + hydrochlorothiazide and valsartan/valsartan + hydrochlorothiazide alone or in combination with amlodipine are equally effective and well tolerated for the reduction of both systolic and diastolic blood pressure and improve arterial stiffness in patients with essential hypertension."	( Effects of Different Antihypertensive Drug Combinations on Blood Pressure and Arterial Stiffness. Hebibovic, S; Jatic, Z; Rustempasic, E; Skopljak, A; Sukalo, A; Valjevac, A, 2019)	0.72
"The aim of this study was to compare curative effects of valsartan alone or combined with alpha-lipoic acid (ALA) on inflammatory cytokine indices including hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α) and renal function indices including urinary albumin excretion rate (UAER), β2-microglobulin (β2-MG) and cystatin C (Cys C) of patients with early-stage diabetic kidney disease (DKD)."	( Curative Effects of Valsartan Alone or Combined with Alpha-lipoic Acid on Inflammatory Cytokines and Renal Function in Early-stage Diabetic Kidney Disease. Jiang, Z; Li, X; Meng, F; Tan, Z, 2019)	1.08
"To observe and analyze the clinical effect of nifedipine controlled-release tablets combined with valsartan in the treatment of essential hypertension, and to analyze the adverse reactions of patients."	( Clinical effect and safety of nifedipine controlled-release tablets combined with valsartan in the treatment of primary hypertension. Fu, J; Liu, W; Liu, Y, 2019)	0.96
"Self-controlled designs, specifically the case-crossover (CCO) and the self-controlled case series (SCCS), are increasingly utilized to generate real-world evidence (RWE) on drug-drug interactions (DDIs)."	( Drug-Drug Interaction Surveillance Study: Comparing Self-Controlled Designs in Five Empirical Examples in Real-World Data. Bykov, K; Gagne, JJ; Kim, S; Li, H; Lo Re, V; Vine, SM, 2021)	0.62
"To analyze the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI)."	( Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI). Chen, C; Li, Y; Peng, Y; Wu, X, 2021)	1.09
"Patients were divided into a control group (bisoprolol), with 39 cases, and a combination group (bisoprolol combined with sacubitril valsartan sodium tablets), with 42 cases, according to their different medications after surgery."	( Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI). Chen, C; Li, Y; Peng, Y; Wu, X, 2021)	1.06
"Bisoprolol combined with sacubitril valsartan sodium tablets has a good application effect in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after PCI."	( Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI). Chen, C; Li, Y; Peng, Y; Wu, X, 2021)	1.13
" The purpose of this study was to evaluate the efficacy of valsartan combined with α-lipoic acid on renal function in patients with DN."	( Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis. Cai, J; Jiang, D; Sun, F, 2021)	1.25
" Randomized controlled trials (RCTs) evaluating the effects of valsartan combined with α-lipoic acid in DN patients were included."	( Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis. Cai, J; Jiang, D; Sun, F, 2021)	1.25
" The pooled analysis indicated that α-lipoic acid combined with valsartan could remarkably reduce UAER (P < 0."	( Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis. Cai, J; Jiang, D; Sun, F, 2021)	1.25
"α-lipoic acid combined with valsartan could significantly reduce the level of urinary albumin and oxidative stress, increase antioxidant capacity and alleviate renal function damage in patients with DN, and this will provide a reference for the selection of treatment drugs for DN."	( Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis. Cai, J; Jiang, D; Sun, F, 2021)	1.31
" The aim of this study was to evaluate the efficacy and safety of TJT combined with Val/Aml in the treatment of stage 2 hypertension with hyperactivity of liver yang."	( Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022)	0.96
" Eligible patients will be randomly assigned (1:1) into groups receiving either TJT or placebo three times daily for 28 days, both combined with Val/Aml 80/5 mg."	( Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022)	0.96
"This is the first placebo-controlled randomized trial conducted to evaluate the efficacy and safety of a Chinese herbal extract combined with Val/Aml in patients with stage 2 hypertension."	( Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022)	0.96
"To explore the effect of Yiqi Huayu Pinggan Zishen recipe combined with valsartan in the treatment of hypertension and its effect on MMP-9, Ang II, and MCP-1."	( Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1. Li, D; Liu, Q; Xie, Y; Yan, J, 2022)	1.2
" The former group was cured with valsartan, and the latter group was cured with Yiqi Huayu Pinggan Zishen recipe combined with valsartan."	( Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1. Li, D; Liu, Q; Xie, Y; Yan, J, 2022)	1.25
"Yiqi Huayu Pinggan Zishen recipe combined with valsartan in the treatment of hypertension can remarkably reduce the clinical symptoms, enhance the renal function, strengthen the therapeutic effect, promote the ability of independent movement, and reduce the levels of serum MMP-9, MCP-1, and Ang II with high safety, which has the value of clinical application."	( Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1. Li, D; Liu, Q; Xie, Y; Yan, J, 2022)	1.22
"To investigate the effects of metoprolol succinate combined with Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac function and coagulation function in patients with congestive heart failure (CHF)."	( Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure. Ding, Y; Li, J; Wei, Z; Zhu, L, 2022)	0.94
" The control group was cured with metoprolol succinate sustained-release tablets, and the study group was cured with metoprolol succinate sustained-release tablets combined with Entresto."	( Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure. Ding, Y; Li, J; Wei, Z; Zhu, L, 2022)	0.72
"Clinical practice demonstrated that LVESD and LVEDD decreased and LVEF increased after treatment with Entresto combined with metoprolol in CHF patients, which can effectively facilitate cardiac function and vascular endothelial function, reduce oxidative stress reaction, and improve blood coagulation indexes, suggesting that Entresto combined with metoprolol can improve ventricular remodeling with good safety."	( Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure. Ding, Y; Li, J; Wei, Z; Zhu, L, 2022)	0.72
" However, the concrete function of valsartan in combination with tripterygium glycosides in chronic nephritis remained largely unknown."	( Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway. Dong, J; Huang, D; Jing, L; Wu, M, 2022)	2.44
"Valsartan in combination with tripterygium glycosides protects against chronic nephritis via suppressing the Toll-like Receptor 4 pathway."	( Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway. Dong, J; Huang, D; Jing, L; Wu, M, 2022)	3.61
"Adverse drug events due to drug-drug interactions can be prevented by avoiding concomitant use of causative drugs; therefore, it is important to understand drug combinations that cause drug-drug interactions."	( Possibility of Multiple Drug-Drug Interactions in Patients Treated with Statins: Analysis of Data from the Japanese Adverse Drug Event Report (JADER) Database and Verification by Animal Experiments. Horii, N; Inoue, N; Kobayashi, D; Mutoh, M; Negishi, A; Numajiri, S; Ohshima, S; Oshima, S, 2022)	0.72
" Therefore, the results of valsartan and amlodipine tablets combined with alpha-lipoic acid on total antioxidant capacity (T-AOC) need to be investigated."	( Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. Su, F; Xia, Q, 2023)	1.6
"This study aimed to evaluate the efficacy of nifedipine controlled-release tablets combined with sacubitril valsartan in diabetic nephropathy (DN) patients with hypertension."	( Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension. Hu, L; Liu, G; Wei, Y, 2023)	1.34
" The present investigation aims to evaluate the protective function of valsartan, an angiotensin receptor blocker, alone and in combination with angiopoietin-like protein 3 (Angptl3) knockout against renal damage and podocyte injury in streptozotocin (STZ)-induced diabetic mice."	( Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice. Chen, Y; Han, X; Liu, J; Ma, Y; Xie, D; Xu, H, 2023)	1.39

Excerpt	Reference	Relevance
" The diuretic effect of furosemide, as assessed by urinary water and electrolyte excretion, was unchanged after co-administration of valsartan, despite the lower bioavailability of furosemide after the combined treatment."	( Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Bindschedler, M; de Gasparo, M; Degen, P; Flesch, G; Preiswerk, G, 1997)	0.73
" These results suggest that the combination of an ARB and an ACEI exerts an additive inhibitory effect, presumably through an increase in production and bioavailability of NO from the endothelium."	( Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Katayama, S; Morita, T; Yagi, S, 2004)	0.32
"We investigated the acute or chronic effects of angiotensin (Ang) II on the bioavailability of NO in Ang II-infused rabbits using the catheter-type NO sensor."	( Effects of angiotensin II on NO bioavailability evaluated using a catheter-type NO sensor. Akasaka, T; Goto, M; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Yoshida, K, 2006)	0.33
" NO bioavailability and NAD(P)H oxidase activity were evaluated by chemiluminescence."	( Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. Ebrahimian, T; Gratton, JP; He, Y; Savoia, C; Schiffrin, EL; Touyz, RM, 2006)	0.33
" Remarkably, the least permeable 7c showed both permeability and oral bioavailability (80%) higher than losartan, but its terminal half-life was shorter."	( Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems. Anzini, M; Cappelli, A; Caselli, G; Ferrari, F; Gallelli, A; Giordani, A; Giorgi, G; Giuliani, G; Makovec, F; Mennuni, L; Mohr, Gl; Nannicini, C; Peris, W; Valenti, S; Vomero, S, 2008)	0.35
"We investigated whether aliskiren, a direct renin inhibitor, improves NO bioavailability and protects against spontaneous atherosclerotic changes."	( Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kitabata, H; Kuroi, A; Mochizuki, S; Muragaki, Y; Takarada, S; Tanimoto, T; Tsujioka, H; Yoshida, K, 2008)	0.35
"We investigated the effects of co-administration of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and angiotensin II type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor."	( Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, A; Tsujioka, H; Yoshida, K, 2008)	0.35
"The aim of this study was to compare the relative bioavailability of a new valsartan 160-mg formulation (ie, test drug) and that of a reference formulation so that bioequivalence could be assessed, as required by European regulatory authorities for the marketing of a generic product."	( Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions. Almeida, S; Farré, A; Filipe, A; Neves, R; Spínola, AC; Trabelsi, F, 2009)	0.79
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
" Oral bioavailability of two 40 mg valsartan orodispersible tablets was compared to the conventional commercial tablets after administration of a single dose to four healthy volunteers."	( Valsartan orodispersible tablets: formulation, in vitro/in vivo characterization. El-Setouhy, DA; Ibrahim, HK, 2010)	2.08
"A self-microemulsifying drug delivery system (SMEDDS) has been developed to enhance diffusion rate and oral bioavailability of valsartan."	( Preparation and bioavailability assessment of SMEDDS containing valsartan. Dixit, AR; Patel, SG; Rajput, SJ, 2010)	0.81
"To develop a valsartan-loaded gelatin microcapsule using hydroxypropylmethylcellulose (HPMC) as a stabilizer, which could improve the physical stability and bioavailability of valsartan, the gelatin microcapsules were prepared with various ratios of gelatin and HPMC using a spray-drying technique."	( Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer. Choi, HG; Kim, JO; Kim, YI; Li, DX; Oh, DH; Seo, YG; Yan, YD; Yang, KY; Yong, CS, 2010)	1.08
" Although the bioavailability and pharmacokinetic properties of valsartan have been well characterized, a literature search did not identify any reports concerning the bioavailability of valsartan in the Indian population."	( Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Batolar, LS; Iqbal, M; Khuroo, A; Monif, T; Sharma, PL; Tandon, M, 2010)	0.83
" SDs increased C(max) and AUC(0-24) of valsartan by 2-7 folds in rats, implying that SDs should be effective to improve the bioavailability of valsartan."	( Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion. Han, HK; Im, YB; Lee, HK; Lee, W; Park, YJ, 2010)	0.87
"With the aim of developing a novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes, various valsartan-loaded solid dispersions were prepared with water, hydroxypropyl methylcellulose (HPMC) and sodium lauryl sulphate (SLS)."	( Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Choi, HG; Kim, DW; Kim, JO; Kim, KK; Lee, BJ; Sung, JH; Yan, YD; Yong, CS, 2012)	1.14
"BENA decreased the bioavailability of HCTZ in Chinese healthy volunteers while VAL greatly increased the concentration of HCTZ in plasma during coadministration."	( Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction. Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L, 2011)	0.59
" In addition, the in vitro and in vivo mucoadhesion properties as well as the bioavailability of the coated pellets in rats were evaluated by using VAL suspension and core pellets as control preparations."	( Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique. Cao, QR; Cui, JH; Lee, BJ; Liu, Y; Xu, WJ; Yang, M, 2012)	0.61
" Thus, the present studies demonstrated the bioavailability enhancement potential of porous carriers based S-SNEDDS for a BCS class II drug, valsartan."	( Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers. Beg, S; Patra, ChN; Rao, ME; Singh, HP; Swain, S, 2012)	0.8
"5-fold increase in oral bioavailability in the case of SD-VAL-Nano compared with the commercial product while the SD-VAL-Micro provided a much less desirable pharmacokinetic profile."	( Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state. Che, E; Jiang, T; Ma, Q; Sun, C; Sun, H; Wang, S; Zheng, X, 2013)	0.72
" In vivo pharmacokinetic study of nanoethosomal transdermal therapeutic system showed a significant increase in bioavailability (3."	( Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment. Ahad, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y, 2013)	0.39
" Compared with the microsuspensions and commercial preparation, the dissolution of valsartan nanosuspensions was faster and the bioavailability can be enhanced to some extent."	( [Preparation of valsartan nanosuspensions and its in vitro dissolution]. Guo, YX; Li, F; Liu, Y; Pan, WS; Song, SS; Yang, XG, 2013)	0.96
"Peptidomimetic drugs have favorable bioavailability owing to H(+)/peptide transporter 1 (PEPT1) located in the intestine."	( Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats. Huo, X; Liu, K; Liu, Q; Ma, X; Meng, Q; Peng, J; Sun, H; Sun, P; Wang, C, 2014)	0.72
"The aim of this study was to assess the bioavailability and tolerability of a newly developed oral formulation of valsartan 160 mg (wet-granulation tablet) in healthy Korean male volunteers."	( Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. Cho, HJ; Ki, MH; Kim, DD; Kim, JE; Kim, RS; Tae Kim, G; Yoon, IS, 2014)	0.85
"This study aimed to improve the dissolution rate and oral bioavailability of valsartan (VAL), a poorly soluble drug using solid dispersions (SDs)."	( Enhanced dissolution and oral bioavailability of valsartan solid dispersions prepared by a freeze-drying technique using hydrophilic polymers. Cao, QR; Cao, Y; Cui, JH; Shi, LL; Xie, HJ; Xu, WJ; Zhu, XY, 2016)	0.92
" In vivo pharmacokinetic study of VGF-OPT-transdermal therapeutic system containing iso-eucalyptol showed a significant increase in the bioavailability (2."	( Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. Ahad, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y, 2014)	0.67
" The valsartan-loaded redispersible dry emulsion with HPMC/poloxamer 407 showed enhanced pH-independent valsartan release, resulting in a dramatically enhanced oral bioavailability of valsartan compared to the raw material and commercial product."	( Oral absorption of a valsartan-loaded spray-dried emulsion based on hydroxypropylmethyl cellulose. Baek, IH; Cho, W; Choo, GH; Ha, ES; Hwang, SJ; Kim, JS; Kim, MS, 2014)	1.24
"18 mg mL(-1); 23% of oral bioavailability) with the aim of improving the aqueous solubility thus the bioavailability and consequently better anti-hypertensive activity."	( Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. Ali, J; Baboota, S; Gora, S; Mustafa, G; Sahni, JK, 2016)	0.79
"The overall results proved that newly developed VAL-NS increased the plasma bioavailability and pharmacodyanamic potential over the reference formulation containing crude VAL."	( Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study. Ali, J; Baboota, S; Gora, S; Mustafa, G; Sahni, JK, 2016)	0.79
" The pharmacokinetic parameters and relative bioavailability were calculated, while the bioequivalence between test and reference preparations were evaluated."	( [Troubleshooting of bioinequivalence of compound valsartan tablets]. Chen, XY; Shao, D; Zhan, Y; Zhang, YF; Zhong, DF, 2014)	0.66
"4-fold increase in oral bioavailability of VAL in the case of HPCM-based formulation compared with the commercially available VAL preparation (Valzaar(®))."	( Increasing the dissolution rate and oral bioavailability of the poorly water-soluble drug valsartan using novel hierarchical porous carbon monoliths. Che, E; Gao, J; Han, J; Song, Y; Sun, B; Zhang, M; Zhang, Y, 2014)	0.62
"Valsartan (VAL) shows poor oral bioavailability mainly as a result of its low water solubility at low pH."	( In vitro dissolution and physicochemical characterizations of novel PVP-based solid dispersions containing valsartan prepared by a freeze-drying method. Cao, QR; Cui, JH; Liu, Y; Shi, LL; Xu, WJ, 2014)	2.06
" The in vitro dissolution and oral bioavailability of valsartan were dramatically enhanced by the composite nanoparticles."	( Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process. Baek, IH; Kim, MS, 2014)	0.94
" In vivo pharmacokinetic studies corroborated marked enhancement in the oral bioavailability drug from SNEDDS vis-à-vis the marketed formulation."	( QbD-Oriented Development of Self-Nanoemulsifying Drug Delivery Systems (SNEDDS) of Valsartan with Improved Biopharmaceutical Performance. Bandyopadhyay, S; Beg, S; Katare, OP; Sharma, G; Singh, B, 2015)	0.64
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."	( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery. Bharate, SS; Vishwakarma, RA, 2015)	0.42
"The objective of this study was to design and optimize a novel lipid-based delivery system with higher loading, improved pharmacokinetics consequently enhancing the oral bioavailability of drugs with low partition coefficient like valsartan."	( Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. Chella, N; Kumar, D; Narayana, L; Shastri, NR, 2015)	0.6
"68-fold increase in the oral bioavailability and Cmax of valsartan from lipid-based formulation compared to plain drug."	( Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient. Chella, N; Kumar, D; Narayana, L; Shastri, NR, 2015)	0.66
"Soluplus(®) (SP) and D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS)-based solid dispersion (SD) formulations were developed by hot-melt extrusion (HME) to improve oral bioavailability of valsartan (VST)."	( Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan. Cho, HJ; Kang, WS; Kim, DD; Lee, JY; Piao, J; Yoon, IS, 2015)	0.81
" The lower solubility in the upper part of gastrointestinal tract (pH-dependant solubility) where its absorption window exists further contributes to the low oral bioavailability of valsartan."	( Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan. Chella, N; Daravath, B; Kumar, D; Tadikonda, RR, 2016)	0.85
" The optimized formulation containing valsartan was tested in rats for bioavailability and pharmacokinetic parameters and compared with that of valsartan pure drug."	( Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan. Chella, N; Daravath, B; Kumar, D; Tadikonda, RR, 2016)	0.93
" In vivo pharmacokinetic studies showed 199 % relative bioavailability with significant improvement (p < 0."	( Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan. Chella, N; Daravath, B; Kumar, D; Tadikonda, RR, 2016)	0.66
"The objective of our investigational work was to develop a proliposomal formulation to improve the oral bioavailability of valsartan."	( Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics. Betageri, GV; Nekkanti, V; Venkatesan, N; Wang, Z, 2015)	0.91
" The aim of this study was to improve the dissolution and thereby the bioavailability of Valsartan through the development of self nano-emulsifying drug delivery systems."	( Effect of formulation variables on design, in vitro evaluation of valsartan SNEDDS and estimation of its antioxidant effect in adrenaline-induced acute myocardial infarction in rats. Abd El-Gawad, NA; Abd El-Halim, SM; Amin, MM; El Gazayerly, ON; El-Awdan, SA, 2016)	0.89
"The objective of this study was to develop proliposomes and self-nanoemulsifying drug delivery system (SNEDDS) for a poorly bioavailable drug, valsartan, and to compare their in vivo pharmacokinetics."	( Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System. Betageri, GV; Nekkanti, V; Wang, Z, 2016)	0.87
" Consequently, the oral bioavailability of valsartan was significantly higher (p < 0."	( Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. Han, HK; Kim, BJ; Mo, L; Yang, SJ, 2016)	0.94
"The aim of the present study was to develop a novel semi-solid self-microemulsifying drug delivery system (SMEDDS) using Gelucire(®) 44/14 as oil with strong solid character to improve the oral bioavailability of poorly soluble drug valsartan."	( Preparation and evaluation of valsartan by a novel semi-solid self-microemulsifying delivery system using Gelucire 44/14. Bao, Z; Li, P; Li, Y; Wang, H; Yuan, Y; Zhao, K, 2016)	0.91
" The pharmacokinetic study revealed that the bioavailability of optimized formulation (72."	( Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation. Biswas, N; Kuotsu, K, 2017)	0.71
" This study was conducted to evaluate the effect of food on the oral bioavailability of LCZ696 analytes."	( Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects . Albrecht, D; Ayalasomayajula, S; Chandra, P; Langenickel, TH; Pal, P; Rajman, I; Sunkara, G; Wolfson, ED; Zhou, W, 2016)	0.65
" The aim of this study was to improve dissolution rate and oral bioavailability by developing a self-nanoemulsifying drug delivery system."	( Development of self-nanoemulsifying drug delivery system for oral bioavailability enhancement of valsartan in beagle dogs. Gao, Y; He, Z; Hu, M; Li, Z; Liu, X; Liu, Y; Sun, J; Sun, Y; Wang, Y; Xiang, R; Zhang, W; Zhou, M, 2017)	0.67
"The aim was to improve the oral bioavailability and antihypertensive activity of poorly soluble drug valsartan (VAL) by modifying the design and delivery of mesoporous silica nanoparticles (MSNs)."	( Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan. Biswas, N, 2017)	0.88
" Neprilysin (NEP) inhibition, auxiliary to RAS blockage increases the bioavailability of natriuretic peptides and benefits the cardio-renal system."	( Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications? Gaikwad, AB; Malek, V, 2017)	0.46
" Inhibition of neprilysin by inhibiting the breakdown of natriuretic peptides, increases their bioavailability resulting in an increase in diuresis and sodium excretion and, in addition to exerting an inhibition of the renin-angiotensin-aldosterone (RAAS) system."	( [Neprilysin inhibition and chronic kidney disease]. Barbera, V; Bellasi, A; Cozzolino, M; De Pascalis, A; Di Lullo, L; Floccari, F; Mudoni, A; Rivera, R; Ronco, C; Santoro, A; Verdesca, S, 2017)	0.46
" Generic drug equivalence is evaluated through comparative bioavailability studies."	( Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017)	0.46
" Specifically, the effects of sacubitril/valsartan on vascular function and NO bioavailability have not been investigated."	( Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure. Goodchild, TT; Koiwaya, H; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, A; Trivedi, RK; Yoo, D, 2018)	0.75
" Furthermore, myocardial NO bioavailability was significantly enhanced in animals receiving sacubitril/valsartan therapy."	( Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure. Goodchild, TT; Koiwaya, H; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, A; Trivedi, RK; Yoo, D, 2018)	0.7
" Sacubitril/valsartan-mediated improvements in cardiac and vascular function are likely related to increases in NO bioavailability and explain, in part, the benefits beyond angiotensin receptor blockade."	( Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure. Goodchild, TT; Koiwaya, H; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, A; Trivedi, RK; Yoo, D, 2018)	0.86
" The objective of this study was to identify the beagle food taking patterns and demonstrate their effects on bioavailability in valsartan."	( Identification of beagle food taking patterns and protocol for food effects evaluation on bioavailability. Chen, W; He, Y; Hu, X; Ren, X; Shakya, S; Wang, C; Wu, L; Xu, J; Zhang, G; Zhang, J, 2018)	0.69
"This study aimed to improve dissolution rate of valsartan in an acidic environment and consequently its oral bioavailability by solid dispersion formulation."	( Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: In vitro-in silico approach. Cvijić, S; Djuriš, J; Dobričić, V; Ibrić, S; Medarević, D; Mitrić, M, 2018)	0.95
"Drug nanoparticles are a promising solution to the challenging issues of low dissolution rates and erratic bioavailability due to their greater surface/volume ratio."	( Carrier particle mediated stabilization and isolation of valsartan nanoparticles. Davern, P; Hodnett, BK; Hudson, SP; Kumar, A, 2019)	0.76
"To investigate the mechanism of enhancing solubility and bioavailability of water-insoluble drug, valsartan (VAL), with being mega-loaded by cyclodextrin metal organic framework (CD-MOF)."	( MOF Capacitates Cyclodextrin to Mega-Load Mode for High-Efficient Delivery of Valsartan. Chen, Y; Guo, T; He, Y; Li, G; Li, J; Lin, Y; Wang, C; Wu, L; Xu, X; Zhang, J; Zhang, S; Zhang, W; Zhang, X, 2019)	0.96
"Co amorphous systems are supersaturated drug delivery systems which offer a basic platform for delivery of multicomponent adducts (combination of more than one active pharmaceutical ingredient (API)) and/or as a fixed dose combination therapy, in addition to their potential to improve the apparent solubility, dissolution rate and ultimately bioavailability of poorly water soluble APIs."	( Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation. Chavan, RB; Chella, N; Lodagekar, A; Mannava, MKC; Nangia, AK; Shastri, NR; Yadav, B, 2019)	0.88
" Biopharmaceutics Classification System (BCS) is an important tool which uses in vitro results for comparison with bioavailability in vivo (biowaiver)."	( The Evaluation of Valsartan Biopharmaceutics Properties. Barcellos, NMS; Caldeira, TG; de Carvalho Mapa, B; de Castro, LML; de Souza, J; Della Croce, CC; Pegorelli, BG; Soares, AFM, 2020)	0.89
" We then evaluated the bioavailability of two BDDSs in beagle dogs to confirm that there was no discrepancy in vivo with the results obtained in vitro."	( Evaluation of Drug Dissolution Rate in Co-amorphous and Co-crystal Binary Drug Delivery Systems by Thermodynamic and Kinetic Methods. Fan, H; Hu, C; Zhang, F, 2021)	0.62
"Valsartan (VAL) is a BCS class II drug with low solubility and high permeability and, thus, its formulations often encounter low bioavailability problems."	( A novel in vitro approach to investigate the effect of food intake on release profile of valsartan in solid dispersion-floating gel in-situ delivery system. Arjuna, A; Djide, NJN; Donnelly, RF; Himawan, A; Mardikasari, SA; Permana, AD; Utami, RN, 2022)	2.39
"The bioavailability of the antihypertensive drug valsartan can be enhanced by various microencapsulation methods."	( Sustainable Stabilizer-Free Nanoparticle Formulations of Valsartan Using Eudragit Feczkó, T; Fodor-Kardos, A; Hajba-Horváth, E; Shah, N; Wacker, MG, 2021)	1.12
" However, VAL exhibits poor absorption and low bioavailability when administrated orally."	( Improved transdermal delivery of valsartan using combinatorial approach of polymeric transdermal hydrogels and solid microneedles: an Asri, RM; Djide, NJN; Enggi, CK; Nirmayanti, N; Nur, JF; Permana, AD; Satria, MT; Usman, JT, 2023)	1.19
" In the final PPK model, food affected the absorption rate constant, while aspartate aminotransferase, alanine aminotransferase, and creatinine affected the clearance of the central compartment."	( Population Pharmacokinetic Analysis of Valsartan in Healthy Chinese Subjects. Gao, R; Ji, X; Qiu, W; Wang, Z; Yang, H, 2023)	1.18
"Due to the limitations of oral administration of valsartan, in this study, we aimed to develop thermosensitive hydrogel for sustained transdermal delivery and improved bioavailability of valsartan, which was further improved using solid microneedles."	( Combinatorial Approach of Thermosensitive Hydrogels and Solid Microneedles to Improve Transdermal Delivery of Valsartan: an In Vivo Proof of Concept Study. Alhidayah, A; Amir, MN; Nirmayanti, N; Nur, JF; Permana, AD; Usman, JT, 2022)	1.19
" Valsartan is highly selective antihypertensive that is rapidly absorbed after oral administration, but its oral bioavailability is only 25%."	( Preparation and evaluation of a lipid-based drug delivery system to ımprove valsartan oral bioavailability: pharmacokinetic and pharmacodynamic analysis. Gülmezoğlu, E; Karasulu, HY; Yıldız Türkyılmaz, G, 2022)	1.86
"The antihypertensive drug valsartan, has an imperfect bioavailability due to its low solubility, permeability and excessive first pass hepatic metabolism."	( Formulation, in-vitro evaluation and optimization of valsartan nano-lipid complex by Box-Behnken design. Amir I Mohamed, -; Hanaa A Mahmoud, -; Magdy I Mohamed, -; Mohamed A Kasssem, -; Nesrin M Nabil, -; Yousef A Elsherif, -, 2023)	1.46

Excerpt	Relevance	Reference
" A dose-response curve for Ang II was obtained for each subject before and at 2, 4, 6, 8 and 24 h after administration of placebo and of the two doses of valsartan."	( Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Cohen, T; de Gasparo, M; Howald, H; Müller, P; Racine-Poon, A; Sioufi, A, 1994)	0.73
" A dose-response effect was seen, although the incremental reduction in blood pressure with doses of valsartan > 80 mg was relatively small."	( The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Dyke, S; Fitzsimmons, S; Harris, F; Hester, A; James, D; Kief, J; Oparil, S, )	0.64
" The characterisation of their pharmacokinetic-pharmacodynamic relationships deserves further refinement for designing optimal therapeutic regimens and proposing dosage adaptations in specific conditions."	( Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Biollaz, J; Brunner, HR; Buclin, T; Csajka, C, 1997)	0.3
" Peak concentrations of radioactivity and valsartan in plasma measured 1 h after dosing showed rapid onset of absorption."	( Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Bühlmayer, P; De Gasparo, M; Flesch, G; Kriemler, HP; Müller, P; Waldmeier, F; Winkler, T, 1997)	0.79
"5 or 25 mg/day to valsartan 80 mg/day resulted in a greater blood pressure reduction than increasing the valsartan dosage from 80 to 160 mg/day."	( Valsartan/hydrochlorothiazide. Langtry, HD; McClellan, KJ, 1999)	2.08
" However, ACE inhibitors may not suppress Ang II activity over their entire dosing interval and, with long-term therapy, Ang II levels tend to return to normal."	( Cardiac protection: evolving role of angiotensin receptor blockers. Califf, RM; Cohn, JN, 2000)	0.31
" In addition, the numerically larger smoothness index with losartan suggested a more homogeneous antihypertensive effect throughout the 24-hour dosing interval."	( Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Aroca Martinez, GJ; Bunt, AM; Carbajal, ET; Cuevas, JH; Dumortier, T; Garcia, LH; Hitzenberger, G; Lara Teran, J; Leao Neves, P; Middlemost, SJ; Monterroso, VH; Rodriguez Chavez, V; Smith, RD; Vogel, DR, )	0.33
"To compare the antihypertensive efficacy and tolerability of telmisartan 80 mg with valsartan 80 mg throughout a 24 h dosing interval."	( A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Dubiel, RF; Littlejohn, T; Marbury, T; Mroczek, W; VanderMaelen, CP, 2000)	0.76
"Telmisartan 80 mg once daily was superior to valsartan 80 mg once daily in reducing diastolic blood pressure during the last 6 h of the 24 h dosing interval."	( A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Dubiel, RF; Littlejohn, T; Marbury, T; Mroczek, W; VanderMaelen, CP, 2000)	0.8
"First-derivative ultraviolet spectrophotometry and high-performance liquid chromatography (HPLC) were used to determine valsartan and hydrochlorothiazide simultaneously in combined pharmaceutical dosage forms."	( Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. Altinay, S; Göğer, NG; Ozkan, SA; Satana, E; Sentürk, Z, 2001)	0.81
" The ambulatory blood pressure data support a consistent reduction of blood pressure with valsartan over a 24h period and for up to 32 h after dosing in those who missed a dose."	( Canadian valsartan study in patients with mild-to-moderate hypertension. Bonnefis-Boyer, S; Hébert, D; Laplante, A; Lasko, BH, 2001)	0.95
" To investigate blockade of postsynaptic AT1 receptors, we studied the effect of the AT1 antagonists on dose-response curves elicited by exogenous Ang II."	( Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2001)	0.51
" Interestingly, the greatest doses of the AT1 antagonists caused less than maximal reduction in the stimulation-induced increase in DBP, resulting in a U-shaped dose-response relationship."	( Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA, 2001)	0.51
" In conclusion, switching to V/HCTZ combination therapy provides an additional lowering of BP compared to dosage increase of the thiazide in patients with BP insufficiently controlled by HCTZ 12."	( Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Adam, SA; Handrock, R; Kolloch, R; Schmidt, A; Weidinger, G, 2001)	0.6
" In this study we investigated the importance of drug dosing in mediating these differences by comparing the AT(1)-receptor blockade induced by 3 doses of valsartan with that obtained with 3 other antagonists at given doses."	( Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Brunner, HR; Burnier, M; Centeno, C; Maillard, MP; Nussberger, J; Würzner, G, 2002)	0.51
" Angiotensin II (Ang II) antagonistic effects were determined in vivo from rightward shifts in Ang II dose-response curves for diastolic blood pressure (BP) and dose ratios were calculated."	( The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man. Belz, GG; Breithaupt-Grögler, K; Butzer, R; Fuchs, W; Hausdorf, C; Mang, C, 2000)	0.31
" Mean changes in diastolic blood pressure for the last 6 hours before dosing and the nighttime period were significantly greater with telmisartan than with valsartan (p<0."	( Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring. Bakris, G, )	0.62
" Eighteen patients with chronic stable heart failure and left ventricular ejection fractions	( Pharmacokinetics of multiple doses of valsartan in patients with heart failure. Glazer, R; Gurrieri, P; McLeod, J; Prasad, PP; Yeh, CM, 2002)	0.59
" The selected studies were included in a meta-analysis of the dose-response relationship for each drug."	( The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Elmfeldt, D; Meredith, P; Olofsson, B, 2002)	0.31
" The valsartan dosage was 80 mg/day."	( [Tolerance to valsartan in office practice in 3,197 hypertensive patients (the VALSE study)]. Bourdeix, I; Francillon, A; Ghannad, E; Gosse, P; Vaillant, J, 2000)	1.18
" The angioedema subsequently resided after a dosage reduction and observation."	( Valsartan-induced angioedema. Irons, BK; Kumar, A, )	1.57
" Initial dosage prednisolone was given for 1 month, and then tapered gradually in terms of dosage and interval."	( [Quadritherapy with cyclosporine for membranous lupus nephropathy]. Iwasawa, H; Matsumoto, H; Nagaoka, Y; Nakao, T; Okada, T; Tomaru, R; Wada, T, 2003)	0.32
" The primary study end point was reduction in the BP in the early morning period (last 6 h of the dosing period)."	( Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Davidai, G; Lacourciere, Y; White, WB, 2004)	0.56
"After the active dose, telmisartan reduced the BP during the last 6 h of the dosing period by -11/-7."	( Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Davidai, G; Lacourciere, Y; White, WB, 2004)	0.56
"On a day of active therapy, telmisartan lowered both systolic and diastolic BP to a greater extent than valsartan for the last 6 h of the dosing interval."	( Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Davidai, G; Lacourciere, Y; White, WB, 2004)	0.77
" Dosage was doubled at week 4 and hydrochlorothiazide was added at week 12 if blood pressure response was inadequate."	( Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Stumpe, KO, 2004)	0.32
" Antihypertensive agents should sustain BP control, particularly in the last 6 h of the dosing interval or if dosing is missed."	( Sustained antihypertensive activity of telmisartan compared with valsartan. Davidai, G; Krzesinski, JM; Lacourcière, Y; Schumacher, H; White, WB, 2004)	0.56
"Due to its longer half-life, telmisartan offers more sustained BP control, especially at the end of the dosing period and provides sustained efficacy in poorly compliant patients in the event of a missed dose with a statistical superiority compared with valsartan."	( Sustained antihypertensive activity of telmisartan compared with valsartan. Davidai, G; Krzesinski, JM; Lacourcière, Y; Schumacher, H; White, WB, 2004)	0.74
" At the end of this crossover sequence, patients received combined ramipril at 5 mg/d, valsartan at 80 mg/d, and an increased furosemide dosage for an additional 4-wk period."	( Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. Delcroix, C; Ekhlas, A; Esnault, VL; Moutel, MG; Nguyen, JM, 2005)	0.55
" Twenty-four-hour ambulatory blood pressure monitoring (ABPM) allows accurate assessment of a patient's hypertension and risk for cardiovascular events, and provides the most accurate measure of an antihypertensive agent's efficacy throughout a 24-hour dosing interval."	( Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Dubiel, R; Jones, M; Smith, DH, 2005)	0.53
"Both candesartan and valsartan similarly alter taste sensitivity after the repeated dosing of the drug."	( Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan. Ando, H; Fujimura, A; Ioka, T; Sugimoto, K; Tsuruoka, S; Wakaumi, M; Yamamoto, H, 2005)	0.87
" The reduction was slightly larger with bed-time dosing (15."	( Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Ayala, DE; Calvo, C; Chayán, L; Fernández, JR; Fontao, MJ; Hermida, RC; López, JE; Mojón, A; Rodríguez, M; Soler, R, 2005)	0.59
"In non-dipper hypertensive patients, dosing time with valsartan should be chosen at bedtime, for improved efficacy during the nocturnal resting hours, as well as the potential associated reduction in cardiovascular risk."	( Treatment of non-dipper hypertension with bedtime administration of valsartan. Ayala, DE; Calvo, C; Covelo, M; Fernández, JR; Hermida, RC; López, JE; Mojón, A, 2005)	0.81
" In each study, subjects received multiple once-daily doses of aliskiren and the test antihypertensive drug alone or in combination in two dosing periods separated by a drug-free washout period."	( Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C, 2006)	0.53
" Changes in DBP and SBP were fitted to a first-order dose-response surface (lack-of-fit test, P = ."	( Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Aldigier, JC; Azizi, M; Chiang, Y; Januszewicz, A; Pool, JL; Satlin, A; Schmieder, RE; Zidek, W, 2007)	0.55
" However, during the first 7 h after dosing, ABP was lower on VAL, whereas AML exerted a significantly stronger effect during the last 4 h of the dosing interval--possibly influencing the differences in office BP found in the main study."	( Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. Høegholm, A; Julius, S; Kjeldsen, SE; Mancia, G; Nielsen, ES; Pedersen, OL; Pickering, T; Refsgaard, J; Weber, M, 2007)	0.59
" Ambulatory blood pressure monitoring (ABPM) allows the automatic recording of the circadian variation in blood pressure and evaluation of the efficacy of antihypertensive medication throughout the dosing interval."	( A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours. Gosse, P, 2006)	0.33
" The steady-state pharmacokinetics of valsartan, simvastatin beta-hydroxy acid (active metabolite of simvastatin) and simvastatin (pro-drug) were determined on day 7 of each dosing period."	( Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Humbert, H; Pommier, F; Prasad, P; Reynolds, CV; Sunkara, G; Yeh, C, 2007)	0.86
"Based on the wide therapeutic dosage ranges of valsartan and simvastatin, and the highly variable pharmacokinetics of three analytes, the observed differences in the exposure and C(max) of valsartan, simvastatin beta-hydroxy acid and simvastatin in the combination treatment are unlikely to be of clinical relevance."	( Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects. Humbert, H; Pommier, F; Prasad, P; Reynolds, CV; Sunkara, G; Yeh, C, 2007)	0.85
" Models were adjusted for demographic, clinical, physician, and hospital characteristics; models were also adjusted for dosage categories, which were represented by time-dependent variables."	( Angiotensin II receptor blockers for the treatment of heart failure: a class effect? Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV, 2007)	0.34
"In 12 normotensive male individuals who were on a high-sodium diet, a double-blind, placebo-controlled, randomized, crossover design was used to study the hormonal and BP effects of single oral administrations of 300 mg of the renin inhibitor aliskiren, 320 mg of valsartan, and a combination of these two drugs, each at half dosage (150 mg of aliskiren and 160 mg of valsartan)."	( Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Azizi, M; Bissery, A; Bura-Rivière, A; Guyene, TT; Ménard, J, 2007)	0.77
" The primary endpoint was change from baseline in mean ambulatory systolic and diastolic blood pressure (SBP; DBP) during the last 6 hours of the 24-hour dosing interval."	( Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Davidson, J; Koval, S; Lacourcière, Y; Sharma, AM, 2007)	0.61
"In high-risk, overweight/obese patients with hypertension and type 2 diabetes, T/HCTZ provides significantly greater BP lowering versus V/HCTZ throughout the 24-hour dosing interval, particularly during the hazardous early morning hours."	( Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Davidson, J; Koval, S; Lacourcière, Y; Sharma, AM, 2007)	0.61
" No adjustment in dosage based on pharmacokinetic considerations is required should vildagliptin be coadministered with amlodipine, valsartan, or ramipril in patients with type 2 diabetes and hypertension."	( Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C, 2008)	0.75
" Amlodipine/valsartan, at approved dosage regimens, achieved significantly greater reductions in mean sitting diastolic and systolic blood pressure (BP) than amlodipine or valsartan monotherapy, or placebo in two randomized, double-blind, factorial trials in patients with mild to moderate hypertension."	( Amlodipine/Valsartan: fixed-dose combination in hypertension. Plosker, GL; Robinson, DM, 2008)	1.11
" However, the restenosis rate in patients with stable angina was relatively high (27%) with this dosage and no different from patients taking ACE inhibitors."	( Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Peters, S, 2008)	0.58
" Buffer-acetonitrile (55 + 45, v/v) was used for reversed-phase liquid chromatography to determine the contents of nebivolol and valsartan in the combination-capsule dosage form."	( Determination of nebivolol and valsartan in a fixed-dose combination by liquid chromatography. Bhagwan, SS; Doshi, AS; Gupta, VK; Mehta, TN; Subaaiah, G, )	0.62
" Systolic and diastolic blood pressure decreased dependent on dosage used."	( [Valsartan improves symptoms and quality of life in patients with chronic heart failure]. Baumhäkel, M; Böhm, M; Müller, U, 2008)	1.26
" After this, subjects were enrolled into a 52-week, open-label phase during which valsartan was dosed to achieve SBP <95th percentile."	( Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Bagga, A; de Paula Meneses, R; Flynn, JT; Gupte, J; Han, G; Mattheyse, L; Meyers, KE; Neto, JP; Shi, V; Solar-Yohay, S; Zurowska, A, 2008)	0.82
" In addition, a dose-response was observed with increasing dose of HCTZ with respect to MSSBP."	( Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. Baumgart, P; Ferber, P; Le Breton, S; Reimund, B; Tuomilehto, J; Tykarski, A, 2008)	0.65
" Additionally, we employed a dosage of valsartan (1 mg/ kg/day) that does not affect blood pressure, to avoid the effect of blood pressure lowering."	( Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Aoki, M; Fujiwara, Y; Makino, H; Miyake, T; Morishita, R; Nishimura, M; Shiraya, S; Yamakawa, S, 2008)	0.83
" Blood samples are collected before and for 24 hours after dosing to quantitate valsartan."	( Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. Batisky, DL; Blumer, J; Shi, V; Solar-Yohay, S; Sunkara, G; Wells, T, 2009)	0.9
"The purpose of the study was to develop pulsatile capsule dosage form of valsartan for controlled delivery."	( Chronotherapeutic drug delivery for early morning surge in blood pressure: a programmable delivery system. Averinen, RK; Gupta, PD; Mutalik, S; Nayak, UY; Nayak, Y; Reddy, SM; Shavi, GV; Udupa, N, 2009)	0.58
" Dosing regimens are either not executed as prescribed (noncompliance) or patients stop taking the medication (nonpersistence)."	( Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. Düsing, R; Handrock, R; Klebs, S; Tousset, E; Vrijens, B, 2009)	0.57
" In parallel, execution of the dosing regimen (compliance) was also improved in the intervention group during the early months of treatment but this effect also disappeared by the end of the observation period."	( Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE. Düsing, R; Handrock, R; Klebs, S; Tousset, E; Vrijens, B, 2009)	0.57
"5 mg (V/HCTZ), and electively titrated after weeks 2 and 4 to the next dosage level (maximum dose valsartan/HCTZ 160/25 mg) if BP remained >140/90 mm Hg."	( Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. Calhoun, DA; Jamerson, KA; Palmer, BF; Purkayastha, D; Samuel, R; Zappe, DH, 2010)	0.84
" Eighteen patients with stable proteinuria over 1 g/day with combined ramipril at 5 mg/day and valsartan at 80 mg/day in addition to conventional antihypertensive treatments were randomized to receive combined ramipril at 5 mg/day and valsartan at 80 mg/day, or combined ramipril at 10 mg/day and valsartan at 160 mg/day, or combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage in random order."	( Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration. Ekhlas, A; Esnault, VL; Moranne, O; Nguyen, JM, 2010)	0.58
"The geometric mean urinary protein/creatinine ratio was lower with combined ramipril at 5 mg/day, valsartan at 80 mg/day and increased furosemide dosage compared to combined ramipril at 5 mg/day and valsartan at 80 mg/day, but also to combined ramipril at 10 mg/day and valsartan at 160 mg/day."	( Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration. Ekhlas, A; Esnault, VL; Moranne, O; Nguyen, JM, 2010)	0.58
"A cautious uptitration of loop diuretic dosage in addition to combined half doses of ACEI and ARB better decrease proteinuria in patients with CKD and high residual proteinuria than uptitration to full dose of combined ACEI and ARB."	( Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration. Ekhlas, A; Esnault, VL; Moranne, O; Nguyen, JM, 2010)	0.36
" The morning dosage was titrated if the goal blood pressure was not achieved."	( [Impact of antihypertensive medication timing on degree and stability of blood pressure lowering in patients with essential hypertension]. Bai, B; Cui, TQ; Hou, JN; Jiang, LS; Mu, CL; Zhao, CP, 2009)	0.35
" They were successfully applied to the determination of AML and VAL in synthetic mixtures and in a pharmaceutical dosage form."	( High-performance liquid chromatographic and first derivative of the ratio spectrophotometric determination of amlodipine and valsartan in their binary mixtures. Dogan-Topal, B; Kul, D; Kutucu, T; Ozkan, SA; Uslu, B, )	0.34
"A simple, precise, accurate stability-indicating gradient reverse phase ultra-performance liquid chromatographic (RP-UPLC) method was developed for the quantitative determination of purity of Valsartan drug substance and drug products in bulk samples and pharmaceutical dosage forms in the presence of its impurities and degradation products."	( Stability-indicating UPLC method for determination of Valsartan and their degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. Krishnaiah, Ch; Kumar, R; Mukkanti, K; Reddy, AR, 2010)	0.8
" Amlodipine, however, has been shown to be effective in reducing BP throughout the day and night, independent of dosing time."	( Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2010)	0.69
"The safety of once-daily (qd) dosing of valsartan in heart failure (HF) patients is not known."	( Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH, 2010)	0.88
" Similar proportions of patients tolerated qd vs bid dosing (bid 67% vs qd 68%)."	( Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH, 2010)	0.61
"Valsartan administered qd has a similar safety and tolerability profile with comparable 24-hour RAAS blockade, as assessed by increases in PRA, as bid dosing in patients with moderate to severe (NYHA class II-III) heart failure."	( Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH, 2010)	2.05
" Once-daily treatment with amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg) reduces ABP to a significantly greater extent than component-based dual therapy and maintains its effectiveness over the entire 24-h dosing period."	( 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. Calhoun, DA; Crikelair, N; Glazer, RD; Lacourcière, Y; Yen, J, 2011)	0.87
"In this ABPM substudy (n=108), initiation of treatment with valsartan/hydrochlorothiazide lowered ABP more effectively than either monotherapy throughout the daytime, night-time, and 24-h monitoring periods, as well as during the last 4 and 6-h dosing periods."	( Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Cushman, WC; Duprez, DA; Izzo, JL; Purkayastha, D; Samuel, R; Weintraub, HS; Zappe, D, 2011)	1.01
"Administration of angiotensin receptor blockers at bedtime results in greater reduction of nighttime blood pressure than dosing upon awakening, independent of the terminal half-life of each individual medication."	( Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2011)	0.7
" The results of the study provide information about optimal dosing of the drug in the management of patients after MI."	( The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial. Baek, H; Cho, YR; Choi, SY; Hong, TJ; Hur, SH; Hwang, JY; Kim, KS; Kim, YD; Lee, SG; Park, JS; Park, K; Park, TH; Yang, TH, 2011)	0.62
"6H(2)O) in a dose-response manner, was higher in the UMR106 osteoblastic cell line than that of the MC3T3E1 normal line at concentrations ≥100 μM."	( Dinuclear copper(II) complexes with valsartan. Synthesis, characterization and cytotoxicity. Di Virgilio, AL; Etcheverry, SB; Nascimento, OR; Williams, PA, 2012)	0.65
"6 mmHg), ABP in the last 4 hours of the dosing period (-21."	( Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. Duprez, D; Ferdinand, K; Purkayastha, D; Samuel, R; Wright, R, 2011)	0.37
" Following 2 further weeks of treatment, the reduction in msSBP was maintained in patients who were re-randomized to continue receiving the same dosage of valsartan but not in those re-randomized to placebo."	( Valsartan: in children and adolescents with hypertension. Croxtall, JD, 2012)	2.02
" Home BP monitoring, if done with proper technique, provides a reliable indicator of BP control in elderly patients and may help guide drug dosing and titration."	( Home and clinic blood pressure responses in elderly individuals with systolic hypertension. Cushman, WC; Duprez, DA; Izzo, JL; Purkayastha, D; Samuel, R; Weintraub, HS; Zappe, D, )	0.13
" The observed effect may be beneficial to develop oral valsartan dosage forms using safe P-gp inhibitor (quercetin) to improve its oral bioavailability."	( Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Babu, PR; Challa, SR; Challa, VR; Johnson, B; Maheswari, C, 2013)	0.88
" Surprisingly, the increasing dosage of valsartan in the Val-Val50 group showed non-significant tendencies to attenuate the albuminuria compared with vehicle infusion."	( Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan. Fan, YY; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Mori, H; Nakano, D; Nishiyama, A, 2012)	0.89
" Thus, the physicochemical differences of raw materials should be carefully considered in early dosage formulation approaches."	( Effects of solvents and crystallization conditions on the polymorphic behaviors and dissolution rates of valsartan. Lee, BJ; Park, JB; Tran, PH; Tran, TT, 2012)	0.59
" Valsartan with bedtime dosing in CKD patients with the nondipping BP pattern have better renal and cardiovascular protection."	( Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern. Chen, Z; Li, CC; Liu, X; Lou, T; Peng, H; Wang, C; Ye, ZC; Zhang, J, 2013)	1.7
"Accurate, sensitive and reproducible reversed-phase high-performance liquid chromatography (RP-HPLC), high-performance thin-layer chromatography (HPTLC) and ultraviolet (UV) spectrophopometric methods were developed for the concurrent estimation of amlodipine besylate (AMLO), hydrochlorothiazide (HCTZ) and valsartan (VALS) in bulk and combined tablet dosage forms."	( Concurrent estimation of amlodipine besylate, hydrochlorothiazide and valsartan by RP-HPLC, HPTLC and UV-spectrophotometry. Kothari, C; Mehta, P; Sharma, M; Sherikar, O, 2014)	0.81
" The primary endpoint was the slope analysis of the dose-response curve for mean sitting SBP (MSSBP) derived through MSSBP reduction over the first 6 weeks."	( Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. Bagga, A; Coppo, R; Kadwa, M; Schaefer, F; Schlosshauer, R; Senguttuvan, P; Zhang, Y, 2013)	0.7
" Greater reductions were observed with the medium and high doses, although the dose-response trend was not statistically significant (P = 0."	( Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. Bagga, A; Coppo, R; Kadwa, M; Schaefer, F; Schlosshauer, R; Senguttuvan, P; Zhang, Y, 2013)	0.7
"Although a dose-response trend was observed, statistical significance was not achieved during the dose ranging (primary endpoint) or the placebo-withdrawal periods of the study."	( Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. Bagga, A; Coppo, R; Kadwa, M; Schaefer, F; Schlosshauer, R; Senguttuvan, P; Zhang, Y, 2013)	0.7
" A fixed-dose combination (FDC) drug is a formulation including fixed amounts of active drug ingredients combined in a single dosage form that is expected to improve medication compliance."	( Pharmacokinetic comparison of 2 fixed-dose combination tablets of amlodipine and valsartan in healthy male Korean volunteers: a randomized, open-label, 2-period, single-dose, crossover study. Bahng, MY; Chae, D; Kim, Y; Lee, D; Park, K; Roh, H; Son, H; Son, M, 2013)	0.62
"Once-daily fimasartan effectively maintained a BP-reduction profile over the full 24-hour dosing interval; this profile was comparable to or slightly better than that of once-daily valsartan."	( Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension. Chae, SC; Jeong, MH; Kim, DS; Kim, KS; Lee, H; Oh, BH, 2013)	0.58
" However, side effects as well as the narrow therapeutic dosing range often complicate its use."	( Temporal association as a prerequisite factor of valsartan-induced lithium toxicity. Giannakopoulos, P; Lazarczyk, MJ, 2014)	0.66
"In contrast to previous reports, the toxicity in our patient occurred not upon introduction or titration of lithium or valsartan but after subtle modifications in daily dosing schedule for lithium."	( Temporal association as a prerequisite factor of valsartan-induced lithium toxicity. Giannakopoulos, P; Lazarczyk, MJ, 2014)	0.87
" The methods were used for the quantitative analysis of the drugs in raw materials and pharmaceutical dosage form via handling the UV spectral data."	( Different approaches in Partial Least Squares and Artificial Neural Network models applied for the analysis of a ternary mixture of Amlodipine, Valsartan and Hydrochlorothiazide. Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY, 2014)	0.6
" Follow-up visits were performed every 4 weeks, and the dosage was doubled in subjects with insufficient blood pressure reduction."	( Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension. Aydoğdu, A; Azal, Ö; Baysan, O; Deniz, F; Meriç, C; Sağlam, K; Serdar, M; Taşçı, İ, 2014)	0.79
"It was concluded that the developed transdermal gel accentuates the flux of valsartan and could be used as an antihypertensive dosage form for effective transdermal delivery of valsartan."	( Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats. Ahad, A; Aqil, M; Kohli, K; Mujeeb, M; Sultana, Y, 2014)	0.9
" Therefore, a formulation strategy using the redispersible dry emulsion with HPMC/poloxamer 407 is very effective for the development of a new dosage form containing valsartan."	( Oral absorption of a valsartan-loaded spray-dried emulsion based on hydroxypropylmethyl cellulose. Baek, IH; Cho, W; Choo, GH; Ha, ES; Hwang, SJ; Kim, JS; Kim, MS, 2014)	0.92
" It is possible for the pharmacist to crush valsartan 80-mg tablets and prepare a suspension which has dosage flexibility that can be calculated according to body-surface area, kidney, and liver functions, without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost-effective dosage form."	( Preparation and stability evaluation of extemporaneous oral suspension of valsartan using commercially available tablets. Assali, M; Ghanem, M; Qaddomi, A; Zaaror, YA; Zaid, AN, )	0.62
" Individual-level linkage of nationwide registries of hospitalization and drug dispensing in Denmark was used to describe patterns of ARB prescriptions and estimate dosage before and after November 2010."	( Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies. Gislason, GH; Kristensen, SL; Køber, L; Lamberts, M; Selmer, C; Torp-Pedersen, C; von Kappelgaard, LM, 2014)	0.4
"Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction."	( Time of administration important? Morning versus evening dosing of valsartan. Crikelair, N; Kandra, A; Palatini, P; Zappe, DH, 2015)	0.65
" Evening dosing also did not improve BP lowering in patients requiring add-on HCTZ or in nondippers at baseline."	( Time of administration important? Morning versus evening dosing of valsartan. Crikelair, N; Kandra, A; Palatini, P; Zappe, DH, 2015)	0.65
"Once-daily dosing of valsartan 320 mg results in equally effective 24-h BP efficacy, regardless of dosing time."	( Time of administration important? Morning versus evening dosing of valsartan. Crikelair, N; Kandra, A; Palatini, P; Zappe, DH, 2015)	0.97
" We investigated the relevant impact of different dosing times of antihypertensive drugs beyond CPAP application."	( Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study. Andrikou, I; Aragiannis, D; Bilo, G; Dimitriadis, K; Filis, K; Kasiakogias, A; Parati, G; Sideris, S; Stefanadis, C; Thomopoulos, C; Tsiachris, D; Tsioufis, C, 2015)	0.42
"Evening dosing of antihypertensive drugs improves night-time BP and dipping status in nonsleepy patients with OSA, irrespective of CPAP application."	( Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study. Andrikou, I; Aragiannis, D; Bilo, G; Dimitriadis, K; Filis, K; Kasiakogias, A; Parati, G; Sideris, S; Stefanadis, C; Thomopoulos, C; Tsiachris, D; Tsioufis, C, 2015)	0.42
" Therefore, the preparation of composite nanoparticles with valsartan-hydroxypropyl methylcellulose and poloxamer 407 by using the SAS process could be an effective formulation strategy for the development of a new dosage form of valsartan with high oral bioavailability."	( Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process. Baek, IH; Kim, MS, 2014)	0.93
" Initial dosage (Neb/Val 5/160 mg/d) was titrated up to 20/320 mg/d to achieve blood pressure (BP) goal (JNC7 criteria), with the addition of hydrochlorothiazide (up to 25 mg/d) if needed."	( Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. Finck, A; Giles, TD; Li, H; Neutel, JM; Punzi, H; Weiss, RJ, 2014)	0.68
"A new rapid stability-indicating UPLC method for separation and determination of impurities in amlodipine besylate, valsartan and hydrochlorothiazide in their combined tablet dosage form was developed."	( A new, rapid, stability-indicating UPLC method for separation and determination of impurities in amlodipine besylate, valsartan and hydrochlorothiazide in their combined tablet dosage form. Coufal, P; Janečková, L; Jedlička, A; Vojta, J, 2015)	0.84
"9701) for area under the concentration-time curve (AUC) over a dosing interval at steady state."	( A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Huh, W; Jang, SB; Jung, JA; Kim, JR; Ko, JW; Lee, SY; Nam, SY, 2015)	0.64
" The methods of analysis of valsartan in pharmaceutical dosage forms and in biological fluids using spectrophotometer, CE, TLC, and HPLC methods are discussed in details."	( Valsartan. Ardiana, F; Indrayanto, G, 2015)	2.15
"To ensure safe oral administration, pediatric patients require an appropriate dosage form to be swallowed without relevant difficulties."	( Choice of excipients for gelly-like pulp prepared ex tempore "on a spoon"- "placebo" and with sartans. Boniecka, M; Kluk, A; Sznitowska, M; Wolska, E; Zarazińska, M, 2016)	0.43
" Bedtime dosing will more efficiently control the circadian spikes of hypertension in the morning."	( Chronotherapeutically Modulated Pulsatile System of Valsartan Nanocrystals-an In Vitro and In Vivo Evaluation. Biswas, N; Kuotsu, K, 2017)	0.71
"The PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial was a double-blind trial that randomized 8442 patients with heart failure (HF) with reduced ejection fraction (HFrEF) to receive twice daily dosing of either 200 mg of LCZ696 or 10 mg of enalapril in addition to standard medical therapy for HF."	( Limitations of Sacubitril/Valsartan in the Management of Heart Failure. Aronow, WS; Chabbott, DR; Mondal, P; Yandrapalli, S, )	0.43
" The initial dosage of valsartan 80 mg/day was titrated up to 320 mg/day to achieve the BP goal, with the addition of hydrochlorothiazide (HCTZ) in a fixed-dose combination (FDC), if needed."	( The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial. Accetto, R; Barbič-Žagar, B; Chazova, IY; Sirenko, Y; Vincelj, J; Widimsky, J, 2017)	1.06
" Despite morning dosing of both drugs, ambulatory blood pressure reductions were more pronounced at nighttime than at daytime or the 24-hour average."	( Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. Hinder, M; Hirschhorn, E; Ihm, SH; Langenickel, TH; Lee, HY; Pal, P; Prescott, MF; Rhee, MY; Tan, RS; Tomlinson, B; Wang, TD; Yang, F, 2017)	0.77
" Blood pressure monitoring in rats showed that the morning dosing of Diovan tablet efficiently controlled BP for just over 360min whereas the effect of M-MSN lasted for >840min."	( Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan. Biswas, N, 2017)	0.66
" To ensure tolerability, initiating the lower dosage form of sacubitril/valsartan is warranted in patients with severe renal impairment, moderate hepatic impairment, and low blood pressure, and close monitoring is warranted in such patients."	( Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure. Rodgers, JE, 2017)	1.08
" We conclude that crystalline valsartan/sacubitril 400 mg daily (1) is superior to valsartan 320 mg daily for lowering SBP, (2) has similar efficacy to the combination of free valsartan 320 mg plus free sacubitril 200 mg, (3) represents the optimal dosage for systolic hypertension in patients of any age, and (4) is safe and well tolerated."	( Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study. Hafeez, K; Izzo, JL; Jia, Y; Zappe, DH; Zhang, J, 2017)	1.02
" Here, we hypothesized different efficacy of morning versus evening dosing of VA in spontaneously hypertensive rats (SHR) and the involvement of circadian clock genes Bmal1 and Per2."	( mRNA levels of circadian clock components Bmal1 and Per2 alter independently from dosing time-dependent efficacy of combination treatment with valsartan and amlodipine in spontaneously hypertensive rats. Doka, G; Klimas, J; Kralova, E; Krenek, P; Potucek, P; Radik, M, 2017)	0.66
"Although clinical guidelines advocate the use of the highest tolerated dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after acute myocardial infarction (MI), the optimal dosing or the risk-benefit profile of different doses have not been fully identified."	( The impact of a dose of the angiotensin receptor blocker valsartan on post-myocardial infarction ventricular remodelling. Bae, WH; Hong, TJ; Hur, SH; Hwang, JY; Jeong, B; Kim, BS; Kim, KS; Kim, YD; Lee, SG; Lee, SH; Oh, JH; Park, JS; Park, K; Park, TH; Yang, TH, 2018)	0.73
"In heart failure with reduced left ventricular ejection fraction (HFREF) patients, the dosage of sacubitril/valsartan is modulated according to a gradual increase regimen."	( In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization : A retrospective cohort study. Ariano, C; De Vecchis, R; Di Biase, G; Noutsias, M, 2019)	1.02
"290), indicating individual optimal dosing of sacubitril/valsartan."	( The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Beliën, H; Dupont, M; Martens, P; Mullens, W; Vandervoort, P, 2018)	0.98
" Furthermore, achieving an optimal iron status (the limit to start a substitution is significantly higher than in patients without heart failure), decreasing the heart frequency with Ivabradine (if heart rate persists above 70 / min despite fully dosed betablocker) and «lifestyle changes» can add to the success of the medical treatment."	( [Pharmacological therapy of heart failure with reduced ejection fraction]. Bösch, C; Dobner, S; Hunziker, L; Martinelli, M; Rhyner, D; Schnegg, B; Suter, T; Wieser, M; Wigger, O, 2018)	0.48
"41), with no evidence of a dose-response relation (P=0."	( Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. Ernst, MT; Hallas, J; Johansen, NB; Kristensen, KB; Pottegård, A; Quartarolo, P, 2018)	0.73
" It was confirmed that the degradation product was formed by the reaction of amlodipine with formaldehyde originating from the excipients present in the dosage form."	( Identification and structure elucidation of a new degradation impurity in the multi-component tablets of amlodipine besylate. Břicháč, J; Douša, M; Gibala, P; Kalášek, S; Kalužíková, A; Štefko, M; Tkadlecová, M, 2019)	0.51
"Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto, Quebec, Canada) in a nonclinical trial population."	( Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice. Du, AX; Ezekowitz, JA; Hanninen, M; McAlister, FA; Oudit, GY; Paterson, DI; Shanks, M; Thomas, J; Westerhout, CM, 2019)	1.02
"8% of participants were taking any diuretics (n = 6290 for loop diuretics, n = 496 for other diuretics); of those, recorded dosage data for loop diuretics were available on 5487 participants."	( Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Claggett, B; Desai, AS; Kachadourian, J; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR, 2019)	0.76
" After multivariate analysis, recovery of LV dysfunction was associated with non-ischemic etiology of HF, smaller baseline LV end-diastolic diameter (LVEDD), and higher initial dosage of sacubitril/valsartan."	( Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management. Chang, HY; Chen, KC; Chong, E; Feng, AN; Fong, MC; Fu, HN; Huang, KC; Yin, WH, 2020)	0.99
"Non-ischemic etiology of HF, smaller baseline LVEDD, and higher initial dosage of sacubitril/valsartan could predict better recovery of LV function."	( Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management. Chang, HY; Chen, KC; Chong, E; Feng, AN; Fong, MC; Fu, HN; Huang, KC; Yin, WH, 2020)	1.02
"Five simple, sensitive, accurate and precise spectrophotometric methods were developed for the simultaneous determination of Nebivolol hydrochloride (NEB) and Valsartan (VAL) in their binary mixtures and in pharmaceutical dosage form."	( Simultaneous determination of Nebivolol hydrochloride and Valsartan in their binary mixture using different validated spectrophotometric methods. Aboul Kheir, AA; El Henawee, MM; Elmasry, MS; Meselhy, EM, 2020)	1
"This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor (ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial population characteristics and the mortality benefit observed in the Prospective Comparison of ARNI with angiotensin-converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF; NCT01035255) trial."	( Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan. Raina, A; Sokos, GG, 2020)	0.76
" During the follow-up, up-titration, down-titration, and maintenance of SV dosing were observed in 7 (30%), 5 (21."	( Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. Chun, KH; Ha, J; Kang, SM; Kim, H; Lee, CJ; Lee, S; Lee, SH; Oh, J; Park, S, 2020)	0.95
" Secondary outcomes included dosing regimens, healthcare utilization in the 6 months prior to sac/val initiation and during the study, patient well-being, safety, and tolerability."	( Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS). Ackermann, G; Ahmed, K; Dieterle, T; Hullin, R; Meyer, I; Schaefer, S, 2020)	0.86
" Mean sacubitril-valsartan dosage at baseline was 101 ± 62 mg/day and 126 ± 59 mg/day at end."	( Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS). Campillejo, RD; de Vinuesa, EG; Gervasini, G; Robles, NR; Valladares, J; Villa, J, 2021)	1.35
" The active-treatment arm will receive valsartan in a dosage titrated to blood pressure up to a maximum of 160 mg bid, and the placebo arm will receive matching placebo."	( Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease. Aarts, GWA; Bresser, P; Cornel, JH; Cortenbach, K; de Jager, CPC; de Leeuw, PW; Gommans, DHF; Hassing, RJ; Konijnenberg, LSF; Konst, RE; Koop, Y; Mensink, F; Mol, JQ; Nas, J; Pinto, YM; Pinto-Sietsma, SJ; Rooijakkers, MJP; Thannhauser, J; Tijssen, JGP; van Agtmael, MA; van den Heuvel, MM; van der Hoeven, HG; van Gilst, WH; van Kimmenade, RRJ; van Royen, N; van Rumund, A; Vart, P; Verbon, A; Verhaert, DVM; Vonk-Noordergraaf, A; Vos, JL, 2020)	1.04
" New data are grouped in categories such as real-world data, randomised controlled trials, surrogate end-points, cost-effectiveness, use of sacubitril/valsartan as an anti-hypertensive treatment, effect on diuretic dosing and implementation of this novel compound in other populations."	( Angiotensin Receptor Neprilysin Inhibitors-2019 Update. Chalikias, G; Tziakas, D, 2020)	0.76
" Blinded study medication was administered for 8 weeks, with initial dosing selected based on the systolic blood pressure at randomization and titrated toward a target of sacubitril/valsartan 97/103 mg twice daily, or enalapril 10 mg twice daily, with an algorithm based on systolic blood pressure and the investigator's assessment of tolerability."	( Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. Berg, DD; Braunwald, E; DeVore, AD; Duffy, CI; Gurmu, Y; Lala, A; Morrow, DA; Pinney, SP; Velazquez, EJ, 2020)	1.03
" We have developed three sensitive, selective, fast, simple, green, accurate, precise, and robust isocratic high-performance liquid chromatography methods for simultaneous determination of valsartan and atenolol in dosage forms."	( New liquid chromatography assays for simultaneous quantification of antihypertensives atenolol and valsartan in their dosage forms. Abdel-Megied, A; Ahmed, H; Ezike, OF; Kovalenko, S; Logoyda, L; Peleshok, K; Piponski, M, 2021)	1.03
" The purpose of this study is to investigate real-world outpatient experience of prescribing sacubitril/valsartan therapy based on appropriate patient selection, dosing conversion, and tolerability."	( Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients. Elston, C; Gengler, B; Kester, J; Montepara, C; Rerick, L, 2021)	1.14
" The method was successfully used for quality control laboratories and the determination of these drugs combinations in pharmaceutical dosage forms."	( Development and Validation of a UPLC-DAD Method for the Simultaneous Quantification of Eight Antihypertensive Drugs in the Pharmaceutical Matrix. Abousalih, FZ; Azougagh, M; Benchekroun, YH; Bennani, I; Bouatia, M; El Karbane, M; Saffaj, T, 2021)	0.62
" This developed method was used for the quantitative determination of Sacubitril calcium and Valsartan in both pure and pharmaceutical dosage form."	( Synchronized determination of the novel heart failure combination therapy containing sacubitril calcium and valsartan by a validated spectrofluorimetric method. Alphonse Mahrouse, M; Hashem, HMA; Mahmoud, ST; Moussa, BA, 2021)	1.05
" Whether initiation of sacubitril/valsartan limits the use and dosing of other elements of guideline-directed medical therapy for HFrEF is unknown."	( Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Bhatt, AS; Claggett, BL; Desai, AS; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Vaduganathan, M; Vardeny, O; Zile, MR, 2021)	1.22
"3 %) and New York Heart Association (NYHA) class II-III symptoms were assigned to receive ARNIs twice daily, according to the recommended dosage of 24/26, 49/51, 97/103 mg."	( The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings. Camerotto, A; Cuppini, S; Mazza, A; Minuz, P; Rigatelli, G; Rubello, D; Schiavon, L; Torin, G; Townsend, DM, 2020)	0.87
" The aim of the study was to characterize sacubitril/valsartan use and dosage patterns nationally."	( National Trends in the Use of Sacubitril/Valsartan. Jackevicius, CA; Krumholz, HM; Mody, FV; Ozaki, AF, 2021)	1.14
" Further exploration of barriers to the use of sacubitril/valsartan and dosing uptitration and their clinical implications warrant further evaluation."	( National Trends in the Use of Sacubitril/Valsartan. Jackevicius, CA; Krumholz, HM; Mody, FV; Ozaki, AF, 2021)	1.13
" Our objective was to describe the sacubitril/valsartan initiation rate, associated characteristics, and 6-month follow-up dosing among veterans with HFrEF who are renin-angiotensin-aldosterone system inhibitor (RAASi) naïve."	( Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction. Alba, PR; Bress, AP; Choi, ME; Cook, J; Dodson, JA; Fang, JC; He, T; Herrick, JS; King, JB; Levitan, EB; Mohanty, AF; Obi, EN; Patterson, OV; Russo, PA; Vardeny, O, 2021)	1.27
" These issues have been linked to significant gaps in the usage and dosing of guideline-directed medical therapy with ARNI in patients with HFrEF."	( Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor. Jang, HN; Kang, MG; Kim, MJ; Lee, JS; Song, HN, 2022)	0.72
" During follow-up, 27% of patients increased their dosage to 49/50 mg twice daily, 68% of patients were taking 24/26 mg twice daily, and 5% of the patients were still taking 12/13 mg twice daily."	( Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study. Fu, G; Lu, J; Shen, C; Xiong, C; Yang, Y, 2022)	1.11
" Participants were initially instructed to take SV 50 mg twice daily, and the dosage was gradually increased up to 100 mg twice daily."	( Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients. Ding, XX; Liu, BC; Tang, HX; Wang, B; Wang, GH; Zhang, XL; Zheng, J, 2022)	1.04
"This study aims to investigate the dosage pattern, efficacy, and safety of sacubitril/valsartan (Sac/Val) in Chinese heart failure with reduced ejection fraction (HFrEF) patients regarding real-world settings."	( Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients. Cheang, I; Dai, C; Li, X; Liao, S; Lu, Q; Lu, X; Shi, S; Su, X; Wang, J; Xu, D; Yuan, F; Yuan, J; Zhang, M; Zhao, Y; Zhou, J; Zhu, X, 2022)	1.21
"Spontaneously hypertensive rats (SHR) were pretreated by daily angiotensin receptor blocker (ARB; 30 mg/kg intraperitoneally), Sacubitril/Valsartan (ARNI; 60 mg/kg intraperitoneally) or the same dosage of physiological saline for 1 week."	( The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats. Chen, S; Kang, L; Liu, Y; Si, J; Xu, B; Zhong, C, 2022)	1.23
" Mytilus galloprovincialis were exposed to environmental levels of CBZ and VAL dosed alone or in combination: measurement of drug bioaccumulation was integrated with changes in the whole transcriptome and responsiveness of various biochemical and cellular biomarkers."	( Mixtures of environmental pharmaceuticals in marine organisms: Mechanistic evidence of carbamazepine and valsartan effects on Mytilus galloprovincialis. d'Errico, G; Gorbi, S; Mezzelani, M; Milan, M; Peruzza, L; Regoli, F, 2023)	1.12
" Up-titration was defined as an increase in dosage above 24/26 mg BID beyond 12 weeks after the initiation of sacubitril/valsartan."	( Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction. Ijichi, T; Matsumura, K; Miho, M; Morimoto, J; Nakazawa, G; Takabayashi, K; Takase, T; Ueno, K; Ueno, M; Yagi, E, )	0.64
" The mean dosage of azilsartan was 30 ± 10 mg/day at baseline and that of sacubitril/valsartan after 3 months of treatment was 204 ± 64 mg/day."	( Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension. Fukushima, H; Horio, T; Ishimitsu, T; Iwashima, Y; Rai, T, 2023)	1.41
" Sacubitril/valsartan was started at a dosage of 12/13 mg in 52 (43%) patients, 24/26 mg in 61 (50%) patients and 49/51 mg in 8 (7%) patients."	( Safety and feasibility of angiotensin receptor neprilysin inhibitor in real-world patients with acute decompensated heart failure. Angelini, F; Coppini, L; Ferraro, I; Giordana, F; Musumeci, G; Rossini, R; Ruffino, E; Tizzani, E; Valente, E; Varbella, F, 2023)	1.29
"All methods were applied successfully for the analysis of the studied drugs in their bulk powder, pharmaceutical dosage form Byvalson®, and in vitro release at intestinal pH (7."	( A Novel, Sustainable, and Eco-Friendly Spectrophotometric and Chemometric Approach for Determination of Severely Overlapped Spectrum via Unified Regression Equation: Greenness and Whiteness Assessment. Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2023)	0.91
" Results were agreeable, encouraging their applicability in quality control laboratories for dosage form and making these methods an eco-friendly substitute for the analysis of this combined dosage form and for evaluating the dissolution profile."	( A Novel, Sustainable, and Eco-Friendly Spectrophotometric and Chemometric Approach for Determination of Severely Overlapped Spectrum via Unified Regression Equation: Greenness and Whiteness Assessment. Fares, NV; Farouk, M; Hemdan, A; Magdy, R, 2023)	0.91
" Therefore, clinical and computational studies have proposed optimizing antihypertensive medications' dosing time (Ta)."	( Understanding the dosing-time-dependent antihypertensive effect of valsartan and aspirin through mathematical modeling. Cortés-Ríos, J; Rodriguez-Fernandez, M, 2023)	1.15
" The purpose of this study was to investigate the efficacy of different initial timing and dosage of sacubitril/valsartan in AMI patients."	( The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Gu, J; Wang, CQ; Wang, Y; Zhang, JF, 2023)	1.37
" After a median follow-up of 38 months, early use or high dosage of sacubitril/valsartan was associated with an improvement in primary endpoint as well as the incidence of new-onset HF."	( The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Gu, J; Wang, CQ; Wang, Y; Zhang, JF, 2023)	1.39
"Early use or high dosage of sacubitril/valsartan medication is associated with an improvement in clinical outcome."	( The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Gu, J; Wang, CQ; Wang, Y; Zhang, JF, 2023)	1.43
"5 mg/day and the mean dosage was increased to 84."	( The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension. Ako, J; Eda, Y; Fujita, T; Iida, Y; Ikeda, Y; Ishii, S; Koitabashi, T; Nabeta, T; Oikawa, J; Takigami, Y; Yazaki, M, 2023)	1.18

Role	Description
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
angiotensin receptor antagonist	A hormone antagonist that blocks angiotensin receptors.
xenobiotic	A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminant	Any minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
biphenylyltetrazole	A member of the class of biphenyls that consists of a biphenyl ring system substituted by a tetrazole ring at an unspecified position.
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
monocarboxylic acid	An oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Valsartan Action Pathway	7	4

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Luciferase	Photinus pyralis (common eastern firefly)	Potency	9.5283	0.0072	15.7588	89.3584	AID588342
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	7.0795	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	82.0350	0.1100	7.1903	10.0000	AID1449628; AID1473738
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0027	0.0004	0.1555	3.8000	AID37838
Type-1B angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.0023	0.0004	0.1334	3.8000	AID37687; AID37838
Type-1 angiotensin II receptor	Homo sapiens (human)	IC50 (µMol)	0.0074	0.0002	0.0932	3.6000	AID1810191
Type-1 angiotensin II receptor	Homo sapiens (human)	Ki	2.3515	0.0002	0.1837	4.7000	AID1352010; AID39790
Type-1 angiotensin II receptor	Oryctolagus cuniculus (rabbit)	Ki	4.7000	0.0002	1.1828	4.7000	AID39790
Type-2 angiotensin II receptor	Homo sapiens (human)	Ki	10.0000	0.0002	0.5650	7.7790	AID1515582
Squalene synthase	Rattus norvegicus (Norway rat)	Ki	10.0000	0.0050	0.6558	2.6000	AID1515582
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	10.0000	0.0013	0.0339	0.2040	AID1634589
Type-1 angiotensin II receptor	Homo sapiens (human)	EC50 (µMol)	10.0000	0.0005	0.0135	0.0676	AID1634585; AID1634587
Platelet glycoprotein VI	Homo sapiens (human)	Kd	100.0000	0.0411	0.0411	0.0411	AID1692279
Leukotriene B4 receptor 2	Homo sapiens (human)	EC50 (µMol)	16.0000	0.0700	1.9375	6.8000	AID1779666
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Thromboxane A2 receptor	Homo sapiens (human)	MEC	50.0000	0.5000	2.0000	5.0000	AID1692291
Type-1 angiotensin II receptor	Homo sapiens (human)	Affinity	0.0017	0.0005	0.0315	0.2300	AID243379
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
smooth muscle contraction	Thromboxane A2 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Thromboxane A2 receptor	Homo sapiens (human)
response to nutrient	Thromboxane A2 receptor	Homo sapiens (human)
response to xenobiotic stimulus	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of blood coagulation	Thromboxane A2 receptor	Homo sapiens (human)
response to testosterone	Thromboxane A2 receptor	Homo sapiens (human)
thromboxane A2 signaling pathway	Thromboxane A2 receptor	Homo sapiens (human)
response to ethanol	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of angiogenesis	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Thromboxane A2 receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Thromboxane A2 receptor	Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesis	Thromboxane A2 receptor	Homo sapiens (human)
inflammatory response	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of blood pressure	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Thromboxane A2 receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Thromboxane A2 receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Thromboxane A2 receptor	Homo sapiens (human)
regulation of cell growth	Type-1 angiotensin II receptor	Homo sapiens (human)
kidney development	Type-1 angiotensin II receptor	Homo sapiens (human)
renin-angiotensin regulation of aldosterone production	Type-1 angiotensin II receptor	Homo sapiens (human)
maintenance of blood vessel diameter homeostasis by renin-angiotensin	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Type-1 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Type-1 angiotensin II receptor	Homo sapiens (human)
Rho protein signal transduction	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of vasoconstriction	Type-1 angiotensin II receptor	Homo sapiens (human)
calcium-mediated signaling	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of phospholipase A2 activity	Type-1 angiotensin II receptor	Homo sapiens (human)
low-density lipoprotein particle remodeling	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of renal sodium excretion	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin-activated signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of cell population proliferation	Type-1 angiotensin II receptor	Homo sapiens (human)
symbiont entry into host cell	Type-1 angiotensin II receptor	Homo sapiens (human)
regulation of inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of protein metabolic process	Type-1 angiotensin II receptor	Homo sapiens (human)
cell chemotaxis	Type-1 angiotensin II receptor	Homo sapiens (human)
phospholipase C-activating angiotensin-activated signaling pathway	Type-1 angiotensin II receptor	Homo sapiens (human)
blood vessel diameter maintenance	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of CoA-transferase activity	Type-1 angiotensin II receptor	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Type-1 angiotensin II receptor	Homo sapiens (human)
inflammatory response	Type-1 angiotensin II receptor	Homo sapiens (human)
blood vessel remodeling	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure by circulatory renin-angiotensin	Type-2 angiotensin II receptor	Homo sapiens (human)
angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressure	Type-2 angiotensin II receptor	Homo sapiens (human)
brain renin-angiotensin system	Type-2 angiotensin II receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger	Type-2 angiotensin II receptor	Homo sapiens (human)
brain development	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of blood pressure	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of heart rate	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of cell growth	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of phosphoprotein phosphatase activity	Type-2 angiotensin II receptor	Homo sapiens (human)
regulation of metanephros size	Type-2 angiotensin II receptor	Homo sapiens (human)
exploration behavior	Type-2 angiotensin II receptor	Homo sapiens (human)
nitric oxide-cGMP-mediated signaling	Type-2 angiotensin II receptor	Homo sapiens (human)
angiotensin-activated signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
vasodilation	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of blood vessel endothelial cell migration	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Type-2 angiotensin II receptor	Homo sapiens (human)
negative regulation of neurotrophin TRK receptor signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
neuron apoptotic process	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of metanephric glomerulus development	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of branching involved in ureteric bud morphogenesis	Type-2 angiotensin II receptor	Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway	Type-2 angiotensin II receptor	Homo sapiens (human)
inflammatory response	Type-2 angiotensin II receptor	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
positive regulation of platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet activation	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
immune response-regulating signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
chemotaxis	Leukotriene B4 receptor 2	Homo sapiens (human)
negative regulation of adenylate cyclase activity	Leukotriene B4 receptor 2	Homo sapiens (human)
keratinocyte migration	Leukotriene B4 receptor 2	Homo sapiens (human)
leukotriene signaling pathway	Leukotriene B4 receptor 2	Homo sapiens (human)
neuropeptide signaling pathway	Leukotriene B4 receptor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
thromboxane A2 receptor activity	Thromboxane A2 receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Thromboxane A2 receptor	Homo sapiens (human)
protein binding	Thromboxane A2 receptor	Homo sapiens (human)
angiotensin type I receptor activity	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin type II receptor activity	Type-1 angiotensin II receptor	Homo sapiens (human)
protein binding	Type-1 angiotensin II receptor	Homo sapiens (human)
bradykinin receptor binding	Type-1 angiotensin II receptor	Homo sapiens (human)
protein heterodimerization activity	Type-1 angiotensin II receptor	Homo sapiens (human)
angiotensin type II receptor activity	Type-2 angiotensin II receptor	Homo sapiens (human)
protein binding	Type-2 angiotensin II receptor	Homo sapiens (human)
receptor antagonist activity	Type-2 angiotensin II receptor	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein binding	Platelet glycoprotein VI	Homo sapiens (human)
collagen binding	Platelet glycoprotein VI	Homo sapiens (human)
signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
collagen receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein tyrosine kinase binding	Platelet glycoprotein VI	Homo sapiens (human)
leukotriene receptor activity	Leukotriene B4 receptor 2	Homo sapiens (human)
leukotriene B4 receptor activity	Leukotriene B4 receptor 2	Homo sapiens (human)
G protein-coupled peptide receptor activity	Leukotriene B4 receptor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
acrosomal vesicle	Thromboxane A2 receptor	Homo sapiens (human)
plasma membrane	Thromboxane A2 receptor	Homo sapiens (human)
nuclear speck	Thromboxane A2 receptor	Homo sapiens (human)
plasma membrane	Thromboxane A2 receptor	Homo sapiens (human)
plasma membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-1 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-2 angiotensin II receptor	Homo sapiens (human)
plasma membrane	Type-2 angiotensin II receptor	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
membrane raft	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
cell surface	Platelet glycoprotein VI	Homo sapiens (human)
extracellular exosome	Platelet glycoprotein VI	Homo sapiens (human)
tetraspanin-enriched microdomain	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
nucleoplasm	Leukotriene B4 receptor 2	Homo sapiens (human)
plasma membrane	Leukotriene B4 receptor 2	Homo sapiens (human)
membrane	Leukotriene B4 receptor 2	Homo sapiens (human)
plasma membrane	Leukotriene B4 receptor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID237099	Time required for elimination of 50% of the compound	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID656169	Toxicity in rat spontaneous hypertensive model assessed as effect on heart rate at 30 mg/kg, po	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID39790	Inhibition constant against Angiotensin II receptor, type 1 was determined	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1221960	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID656162	Displacement of [I125]angiotensin2 from AT1 receptor in Sprague-Dawley rat VSMC after 2.5 hrs by gamma spectrophotometry	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID717876	Cardiotoxicity in SHR rat assessed as effect on heart rate at 10 mg/kg, po	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1214092	Clearance in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1221961	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1352018	Antimigratory activity against human A549 cells at 10 uM after 72 hrs by wound-healing assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cel
AID1214072	Tmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1193492	Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1698003	Fraction unbound in rat plasma
AID1692279	Binding affinity to recombinant GP6 (unknown origin) at protein to compound ratio of 1 : 1 to 1 : 10 by 2D 15N-1H TROSY-HSQC NMR spectroscopy	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1217711	Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1214040	Tmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1217707	Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1214074	AUC in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID717894	Displacement of [125I]Angiotensin-2 from angiotensin AT1 receptor in Sprague-Dawley rat VSMC after 60 mins by gamma counting	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID28679	Partition coefficient (logD6.8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID588963	Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1B3	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID1211805	Drug excretion in Sprague-Dawley rat assessed as compound excreted into bile at 8 uCi, iv	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1692291	Modulation of TxA2 receptor in human platelet suspension assessed as lowest concentration that reduced U46619-induced platelet aggregation preincubated for 5 min followed by U46619 stimulation by light transmission aggregometry	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1217708	Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1214039	Half life in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1211549	Unbound fraction in Sprague-Dawley rat plasma at 100 uM by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1214136	Half life in human plasma expressing CYP2C81/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1352017	Antimigratory activity against mouse NIH/3T3 cells at 10 uM after 72 hrs by wound-healing assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cel
AID656170	Toxicity in rat spontaneous hypertensive model assessed as effect on heart rate at 15 mg/kg, po	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1211551	Drug uptake in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID717888	Antihypertensive activity in SHR rat assessed as decrease in mean arterial pressure at 10 mg/kg, po	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID1221963	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1214082	Clearance in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1697999	Dissociation constant, acidic pKa of compound measured up to 18 mins by capillary electrophoresis
AID1221978	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1214138	Clearance in human plasma expressing CYP2C81/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1221965	Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1214140	Cmax in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1214083	AUC in human plasma expressing CYP2C91/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1698001	Lipophilicity, log D of the compound at pH 7.4 by by shake flask method
AID1214137	Tmax in human plasma expressing CYP2C81/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214159	AUC in women plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID37838	Inhibitory activity against Angiotensin II receptor, type 1 in rat aortic membrane	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID1193494	Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1217712	Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID247113	Maximal effect produced by the drug in human	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1211838	Total biliary clearance in human at 20 mg, iv after 24 hrs by T-tube method	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1214162	Half life in men plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1217727	Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1193497	Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID717882	Antihypertensive activity in Sprague-Dawley rat renal hypertensive model assessed as decrease in mean arterial pressure at 10 mg/kg, po	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID1211550	In vivo intrinsic biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID656177	Acute toxicity in intragastrically dosed ICR rat	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
AID1214067	Tmax in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1193499	Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1810191	Displacement of [125-I]-[Sar1, AngII from AT1R (unknown origin) expressed in Escherichia coli BL 21 (DE3) incubated for 2 hrs by radioimmunoassay	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Selective Discovery of GPCR Ligands within DNA-Encoded Chemical Libraries Derived from Natural Products: A Case Study on Antagonists of Angiotensin II Type I Receptor.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID39652	Inhibition against Angiotensin II receptor, type 1	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1221979	Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1214089	Cmax in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1193500	Thermodynamic equilibrium solubility, log S of the compound	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1698006	Ratio of drug level in cynomolgus monkey blood to plasma administered through iv dosing by LC-MS/MS analysis
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214166	Clearance in men plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1221972	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221971	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1810202	Antihypertensive activity against two-kidney two clip renovascular hypertensive Sprague-Dawley rat model assessed as decrease in systolic blood pressure at 8.3 mg/kg, po measured after 4 days of treatment by noninvasive sphygmomanometry	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Selective Discovery of GPCR Ligands within DNA-Encoded Chemical Libraries Derived from Natural Products: A Case Study on Antagonists of Angiotensin II Type I Receptor.
AID1214038	Cmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214090	Half life in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID239885	pKa value against human Angiotensin II receptor type 1	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1214160	Cmax in men plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214071	Half life in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1698007	Ratio of drug level in human blood to plasma administered through iv dosing by LC-MS/MS analysis
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1515586	Antihypertensive activity in spontaneously hypertensive rat assessed as reduction in mean arterial pressure administered via oral gavage in ascending cumulative doses every 60 mins measured up to 24 hrs by telemetry method
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1214087	Clearance in human plasma expressing CYP2C91/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID330796	Displacement of [125I]Sar1,Ile8-Ang2 from AT1 receptor in Wistar rat hepatic membrane	2008	Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7	Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
AID1515584	Inhibition of APP (unknown origin)
AID29138	Acid dissociation value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID588977	Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP2	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID237981	Percentage modification of drug adsorbed after administration to human	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1214158	AUC in men plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1698016	Dissociation constant, basic pKa of compound measured up to 18 mins by capillary electrophoresis
AID1217706	Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID28925	Highest effective permeability across hexadecane membrane (pH 4-8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID243379	Binding affinity for AT1 receptor	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1211553	Drug uptake in iv dosed Sprague-Dawley rat liver after 5 hrs by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1221980	Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1214135	Cmax in human plasma expressing CYP2C81/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214037	AUC in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1698009	Hepatic clearance in cynomolgus monkey at < 1 mg/kg, iv administered as cassette dosing
AID1217709	Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID37687	Binding affinity for rat angiotensin II receptor, type 1	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
AID1211873	Total biliary clearance in Sprague-Dawley rat at 8 uCi, iv	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1217705	Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1221957	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221962	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1214069	AUC in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1352010	Displacement of [125I-Sar1-Ile8]-Ang2 from human angiotensin 2 receptor type 1 receptor expressed in HEK293 cells after 1 hr by gamma counting analysis	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cel
AID27037	Half life of compound was determined	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1214164	Tmax in men plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID28234	% absorbed in human GI-tract	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID1214066	Half life in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214161	Cmax in women plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID167354	Compound was tested for its antagonistic activity against angiotensin II-induced contractions in rabbit aorta	1996	Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3	Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1214070	Cmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID237841	Oral bioavailability	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID23918	Renal clearance value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID656163	Antihypertensive activity in rat spontaneous hypertensive model assessed as reduction in systolic blood pressure at 15 mg/kg, po up to 10 hrs	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
AID1214165	Tmax in women plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID717884	Antihypertensive activity in SHR rat assessed as decrease in mean arterial pressure at 10 mg/kg, po measured for 9 hrs after dosing	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Synthesis and biological evaluation of new fluorine substituted derivatives as angiotensin II receptor antagonists with anti-hypertension and anti-tumor effects.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1217704	Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID568932	Antagonist activity at angiotensin AT1 receptor in rat aorta	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1698000	Apparent permeability in dog MDCKII-LE cells at pH 7.4
AID1217729	Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1692293	Inhibition of ADP-stimulated human platelet aggregation assessed as ADP light transmission at 50 uM preincubated for 5 min followed by ADP stimulation by light transmission aggregometry (Rvb = 62 +/- 3%)	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID1216814	Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID1221982	Fraction absorbed in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1211819	Drug excretion in human assessed as compound excreted into bile at 20 mg, iv after 24 hrs by T-tube method	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1211555	In vitro apparent biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1221973	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1217728	Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1214075	Cmax in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211548	In vivo apparent biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1214068	Clearance in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1352011	Cytotoxicity against mouse NIH/3T3 cells up to 30 uM after 48 hrs by WST-1 assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cel
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1352019	Antimigratory activity against human NCI-H358 cells at 10 uM after 48 hrs by wound-healing assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cel
AID1698010	Hepatic clearance in human administered through iv dosing
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588962	Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1B1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1515585	Inhibition of recombinant human ECE1
AID1698011	Fraction unbound in human plasma
AID1214084	Cmax in human plasma expressing CYP2C91/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1698005	Ratio of drug level in Wistar Hannover rat blood to plasma administered through iv dosing by LC-MS/MS analysis
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1214081	Tmax in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214073	Clearance in human plasma expressing CYP2C8*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID28924	Effective permeability (Pe) across a hexadecane membrane (pH 6.8)	2001	Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6	High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID27862	Total clearance value was evaluated	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
AID1214139	AUC in human plasma expressing CYP2C8*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1193496	Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1515582	Displacement of Europium-labeled angiotensin-2 from human AT2 receptor expressed in CHOK1 cell membranes after 120 mins by DELFIA
AID1193498	Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1214085	Half life in human plasma expressing CYP2C91/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1193493	Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1214091	Tmax in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211552	In vitro intrinsic biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1214080	Half life in human plasma expressing CYP2C8*4 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1214088	AUC in human plasma expressing CYP2C9*2 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214167	Clearance in women plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1698004	Fraction unbound in cynomolgus monkey plasma
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID656166	Antihypertensive activity in rat spontaneous hypertensive model assessed as reduction in diastolic blood pressure at 15 mg/kg, po up to 10 hrs	2012	Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8	Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
AID1352013	Cytotoxicity against human A549 cells up to 30 uM after 48 hrs by WST-1 assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cel
AID1217710	Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1211881	Unbound biliary clearance in Sprague-Dawley rat at 8 uCi, iv	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID236277	Volume distribution was determined	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
AID1211554	Biliary excretion index in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1214134	AUC in human plasma expressing CYP2C81/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1221964	Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1211858	Unbound biliary clearance in human at 20 mg, iv after 24 hrs by T-tube method	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID1193495	Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method	2015	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7	Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1221958	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1214041	Clearance in human plasma expressing CYP2C9*3 allele carrier polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1221956	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1515587	Antihypertensive activity in spontaneously hypertensive rat assessed as reduction in mean arterial pressure administered via oral gavage in ascending cumulative doses every 60 mins measured up to 24 hrs in presence of NEP inhibitor candoxatril by telemetr
AID1515583	Inhibition of recombinant human ACE using Mca-BK2 as substrate preincubated for 10 mins followed by fluorogenic substrate addition and measured after 20 mins by fluorescence assay
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1352014	Cytotoxicity against human NCI-H358 cells up to 30 uM after 48 hrs by WST-1 assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Integration of multi-scale molecular modeling approaches with experiments for the in silico guided design and discovery of novel hERG-Neutral antihypertensive oxazalone and imidazolone derivatives and analysis of their potential restrictive effects on cel
AID1698002	Intrinsic clearance in cryopreserved human hepatocytes at 1 uM measured up to 120 mins by LC-MS/MS analysis
AID1214163	Half life in women plasma at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID1779666	Agonist activity at human BLT2 overexpressed in CHO-K1 cells assessed as accumulation of inositol monophosphate measured after 90 mins by HTRF assay	2021	ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8	Discovery of Irbesartan Derivatives as BLT2 Agonists by Virtual Screening.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1698008	Hepatic clearance in Wistar Hannover rat at 1 mg/kg, iv
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1214086	Tmax in human plasma expressing CYP2C91/1 polymorphism at 25 to 320 mg by LC/MS/MS analysis	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346995	Human AT1 receptor (Angiotensin receptors)	1995	Regulatory peptides, Nov-10, Volume: 59, Issue:3	Binding of valsartan to mammalian angiotensin AT1 receptors.
AID1346995	Human AT1 receptor (Angiotensin receptors)
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	13 (0.38)	18.7374
1990's	113 (3.31)	18.2507
2000's	1021 (29.86)	29.6817
2010's	1404 (41.06)	24.3611
2020's	868 (25.39)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	871 (24.35%)	5.53%
Reviews	426 (11.91%)	6.00%
Case Studies	130 (3.63%)	4.05%
Observational	58 (1.62%)	0.25%
Other	2,092 (58.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (393)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT01340326]	Phase 4	800 participants (Actual)	Interventional	2007-11-30	Completed
A Multicenter, Open-label Study to Collect the Safety Information of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study [NCT06149104]	Phase 3	8 participants (Anticipated)	Interventional	2023-12-04	Recruiting
Effects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport Syndrome [NCT00309257]	Phase 2	9 participants (Actual)	Interventional	2004-01-31	Completed
ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Valsartan - [NCT01115972]	Phase 1	24 participants (Actual)	Interventional	2010-03-31	Completed
Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke [NCT01198496]	Phase 4	5,000 participants (Anticipated)	Interventional	2010-10-31	Recruiting
A Randomized Evaluation of the Effects of Valsartan and Aliskiren in Combination Versus Tekturna Alone on Hemostatic Biomarkers in Patients With Newly Diagnosed Mild to Moderate Hypertension and Type 2 Diabetes Mellitus [NCT01095822]	Phase 4	50 participants (Anticipated)	Interventional	2010-03-31	Active, not recruiting
BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension W [NCT00546754]	Phase 3	808 participants (Actual)	Interventional	2007-05-01	Completed
A Multicenter, Randomized, Open-label, Parallel Group, Pilot Study to Evaluate the Use of Sacubitril/Valsartan in HeartMate 3 LVAD Recipients [NCT04103554]	Phase 4	60 participants (Anticipated)	Interventional	2021-02-05	Recruiting
Sacubitril-valsartan (Entresto) Versus Standard Anti-hypertensive Therapy in LVAD Patients - A Feasibility Pilot Study [NCT03279861]	Phase 4	0 participants (Actual)	Interventional	2017-11-30	Withdrawn(stopped due to protocol change)
The Effect of Neprilysin on Plasma Concentrations of Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes [NCT03893526]	Phase 4	12 participants (Actual)	Interventional	2019-01-25	Completed
A Double-blind, Randomized, Multi-center Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of CJ-30061 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Atorvastatin Combination Therapy in Hypertensive Patients With Hyperlipide [NCT03639480]	Phase 3	180 participants (Anticipated)	Interventional	2017-10-13	Enrolling by invitation
Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction: A Double-blind Randomized Controlled Phase IV Trial (VASCEND) [NCT03168568]	Phase 4	79 participants (Actual)	Interventional	2017-05-04	Completed
Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97 mg Sacubitril / 103 mg Valsartan Bid in Patients With HFrEF [NCT02690974]	Phase 4	302 participants (Actual)	Interventional	2016-03-08	Completed
A Randomized, Double-blind, Controlled, Crossover Study to Evaluate the Sodium Excretion of LCZ696 in Patients With Stable Heart Failure, in Patients With Hypertension, and in Healthy Volunteers [NCT01353508]	Phase 2	32 participants (Actual)	Interventional	2011-03-31	Completed
A Multicenter Study to Evaluate Long-term Safety and Tolerability of Open Label Sacubitril/Valsartan in Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed Study CLCZ696B2319 [NCT03785405]	Phase 3	216 participants (Actual)	Interventional	2019-05-02	Active, not recruiting
A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy [NCT00171002]	Phase 3	936 participants (Actual)	Interventional	2004-11-30	Completed
A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Vol [NCT02343250]	Phase 1	54 participants (Actual)	Interventional	2015-03-31	Completed
A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction [NCT03066804]	Phase 3	2,572 participants (Actual)	Interventional	2017-08-22	Completed
A Multi-center, Prospective, Randomized, Double-blind Study to Assess the Impact of Sacubitril/Valsartan vs. Enalapril on Daily Physical Activity Using a Wrist Worn Actigraphy Device in Adult Chronic Heart Failure Patients [NCT02900378]	Phase 3	621 participants (Actual)	Interventional	2016-12-20	Completed
A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction. [NCT02887183]	Phase 4	794 participants (Actual)	Interventional	2016-10-25	Completed
Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure [NCT03771729]	Early Phase 1	30 participants (Anticipated)	Interventional	2018-12-30	Not yet recruiting
An Open-label, Postmarketing Study of Amlodipine/Valsartan Single-Pill Combination for the Treatment of Hypertension [NCT02058446]	Phase 4	36 participants (Actual)	Interventional	2013-10-31	Completed
A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Vol [NCT02088008]	Phase 1	54 participants (Anticipated)	Interventional	2014-05-31	Not yet recruiting
Comparison of the Efficacy and Safety of Cilnidipine 10mg/Valsartan 160mg Combination Therapy, Cilnidipine 5mg/Valsartan 160mg Combination Therapy and Valsartan 160mg Monotherapy in Hypertensive Patients Inadequately Controlled With Valsartan 160mg Monoth [NCT02145104]	Phase 3	286 participants (Actual)	Interventional	2014-06-17	Completed
Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts. [NCT03502031]	Phase 4	72 participants (Anticipated)	Interventional	2018-10-01	Recruiting
A Prospective Randomized Open-Label Blinded End Point (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Valsartan (80 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. [NCT02177396]	Phase 3	426 participants (Actual)	Interventional	1998-04-30	Completed
Effects of the New Angiotensin II Receptor Blocker Azilsartan Versus Valsartan on Blood Pressure in Japanese Patients With Hypertension [NCT01609959]	Phase 4	70 participants (Actual)	Interventional	2012-06-30	Completed
ReaL wOrld, pharmaCy-assessed Adherence to New onseT Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure - a Prospective Cohort Study (LOCATE-HF) [NCT05870709]		0 participants (Actual)	Observational	2023-05-15	Withdrawn(stopped due to Terminated due to business decision)
A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension [NCT02495324]	Phase 4	369 participants (Actual)	Interventional	2015-06-30	Completed
Use of Determination of Drug Levels to Optimize Pharmacotherapy of Heart Failure [NCT06035978]	Phase 4	100 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) [NCT02816736]	Phase 4	365 participants (Actual)	Interventional	2017-03-02	Completed
HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial [NCT03476616]	Phase 4	330 participants (Anticipated)	Interventional	2018-09-01	Not yet recruiting
Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure [NCT04971720]	Phase 2/Phase 3	160 participants (Anticipated)	Interventional	2022-02-18	Recruiting
A Multi-center, Randomized, Double-blind, Double-Dummy, Positive Parallel Controlled Study to Evaluate the Efficacy and Safety in Treatment of Mild-moderate Essential Hypertension [NCT05359068]	Phase 3	900 participants (Anticipated)	Interventional	2021-06-10	Recruiting
A Multi-center, Randomized, Open-label, Active-controlled, 12-week Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure [NCT04458285]		118 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction [NCT05387967]	Phase 4	121 participants (Actual)	Interventional	2021-01-01	Completed
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension [NCT02480764]	Phase 3	612 participants (Actual)	Interventional	2015-08-27	Completed
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction [NCT05168787]		352 participants (Anticipated)	Observational	2020-08-13	Enrolling by invitation
An Open Label, Balanced, Randomized, Two-treatment, Four-period, Two-sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of Two Formulations of Valsartan 320 mg Tablet in Healthy, Adult, Human Subjects Under Fasting Condition [NCT02197442]		36 participants (Actual)	Interventional	2014-01-31	Completed
An 8 Week, Double-blind, Randomized, Parallel-group Study to Compare the Effect of Aliskiren 300mg + Valsartan 320mg vs. Telmisartan 80mg + Ramipril 10mg on Biomarkers of the Renin-angiotensin-aldosterone System in Moderate Hypertension [NCT00939588]	Phase 2	88 participants (Actual)	Interventional	2009-07-31	Completed
Multicenter, Randomized, Open-label Trial to Assess the Efficacy of Sacubitril/Valsartan vs. Amlodipine/Losartan on Left Ventricular Remodeling in Patients With Chronic Severe Aortic Regurgitation [NCT05212597]	Phase 2	100 participants (Anticipated)	Interventional	2022-01-12	Recruiting
PARENT Trial Pilot Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan) [NCT02788656]	Phase 4	4 participants (Actual)	Interventional	2016-09-30	Terminated(stopped due to Inadequate Recruitment)
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health- [NCT02970669]	Phase 4	140 participants (Actual)	Interventional	2016-12-16	Completed
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects [NCT03648333]	Phase 1	27 participants (Actual)	Interventional	2013-12-31	Completed
Effect of Sacubitril/Valsartan Versus Valsartan on Left Ventricular Ejection Fraction and Biomarker in Heart Failure [NCT05881720]	Phase 4	80 participants (Actual)	Interventional	2022-01-01	Completed
Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease [NCT02299310]	Phase 4	60 participants (Anticipated)	Interventional	2014-11-30	Not yet recruiting
The Effect of Continuing or Discontinuing ACE-I/ARBs Therapy on the Incidence of Contrast-induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Coronary Angiography; a Randomized Controlled Trial [NCT05271448]		600 participants (Anticipated)	Interventional	2021-06-01	Recruiting
Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis [NCT03594825]	Phase 4	68 participants (Anticipated)	Interventional	2018-11-30	Not yet recruiting
A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Evaluate the Safety and Efficacy of CJ-30060 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Rosuvastatin Combination Therapy in Hypertensive Patients With Hyperlipi [NCT03536598]	Phase 3	203 participants (Actual)	Interventional	2016-10-14	Completed
An Open Label, Balanced, Randomized, Two-treatment, Two Period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Two Formulations of Valsartan 320mg Tablet in Healthy, Adult, Human Subjects Under Fed Condition. [NCT02197494]		40 participants (Actual)	Interventional	2014-01-31	Completed
A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Drug-drug Interaction Between LGEV1801 and LGEV1802 in Healthy Korean Male Volunteers [NCT03532854]	Phase 1	42 participants (Actual)	Interventional	2018-05-28	Completed
Bariatric Surgery and Pharmacokinetics of Valsartan: BAR-MEDS Valsartan [NCT03535376]		12 participants (Anticipated)	Observational	2016-11-02	Recruiting
A Four-part, Single-center, Open-label, Phase I Clinical Study to Evaluate the Drug-Drug Pharmacokinetic Interaction Between DBPR108 at Steady-state and Metformin Hydrochloride/Glibenclamide/Valsartan/ Simvastatin in Healthy Subjects [NCT04859452]	Phase 1	56 participants (Actual)	Interventional	2021-05-26	Completed
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: Randomized Trial ANSWER-HF [NCT04853758]	Phase 3	200 participants (Anticipated)	Interventional	2021-05-06	Recruiting
National Registry of Adult Heart Failure Patients With Complex Congenital Heart Disease: Systemic Right Ventricle and Single Ventricle Treated With Sacubitril/Valsartan [NCT06149806]		50 participants (Anticipated)	Observational	2021-07-01	Recruiting
Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition [NCT03508739]	Phase 3	25 participants (Anticipated)	Interventional	2018-06-01	Suspended(stopped due to We do not have active funding at this time.)
A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed Dose Combination in Patients With Stage 1 or 2 Essential Hypertension [NCT01508026]	Phase 3	4,161 participants (Actual)	Interventional	2012-01-31	Completed
A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients [NCT00439738]	Phase 4	412 participants (Actual)	Interventional	2006-12-31	Completed
Effect of Sacubitril/Valsartan on Cardiac Function Assessed by Cardiac Magnetic Resonance (CMR) in Hypertensive Patients Stratified by Body Mass Index (BMI): A Real World Study [NCT05498675]		180 participants (Anticipated)	Observational	2021-09-01	Recruiting
A Multi-center, Randomized, Placebo-controlled Patient and Investigator-blinded Study to Explore the Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy (nHCM) [NCT04164732]	Phase 2	45 participants (Actual)	Interventional	2020-01-08	Completed
Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis: A Multicentre Prospective, Randomized, Double-blind and Imitation, Positive-drug Parallel Controlled Clinical Trail [NCT04263922]	Phase 4	466 participants (Anticipated)	Interventional	2020-06-30	Recruiting
Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria [NCT01375322]	Phase 4	226 participants (Actual)	Interventional	2007-06-30	Completed
A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active-controlled, Forced-titration, 12-week Comparison of Combined Angiotensin-neprilysin Inhibition With Sacubitril and Valsartan Versus Enalapril on Changes in Central Aortic Stiffn [NCT02874794]	Phase 4	465 participants (Actual)	Interventional	2016-08-17	Completed
An Eight-week, Randomized, Double-blind, Parallel-group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose [NCT00819767]	Phase 2	68 participants (Actual)	Interventional	2009-02-28	Completed
A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on CKD Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia [NCT05056727]	Phase 3	1,500 participants (Anticipated)	Interventional	2021-09-30	Recruiting
A Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy Phase II Trial to Evaluate the Efficacy and Safety of the Combinations of Lercanidipine and Valsartan in Comparison to Each Component Administered Alone and to Determine the Optimal Dos [NCT01122251]	Phase 2	441 participants (Anticipated)	Interventional	2009-12-31	Completed
Influences of Angiotensin-neprilysin Inhibition With Sacubitril/Valsartan (ENTRESTO®) on Centrally Generated Sympathetic Activity in Heart Failure Patients [NCT03415906]	Phase 2	0 participants (Actual)	Interventional	2017-12-14	Withdrawn(stopped due to Difficulties in recruiting patients)
Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India [NCT04735354]		268 participants (Actual)	Observational	2020-10-27	Completed
Efficacy and Safety of ARNI in Reversing Cardiac Remodeling After Catheter Ablation for Patient With Persistent Atrial Fibrillation and Enlarged Left Atrial [NCT03791723]		90 participants (Anticipated)	Interventional	2019-06-01	Not yet recruiting
Sacubitril/Valsartan (LCZ696) in Patients With Advanced Hypertensive Left Ventricular Hypertrophy and Heart Failure With Preserved Ejection Fraction: Clinical, Haemodynamic and Neurohumoral Effects (a Phase 2, Randomized, Single-center, Parallel Group Stu [NCT03928158]	Phase 2	60 participants (Anticipated)	Interventional	2019-05-31	Recruiting
[NCT00599885]	Phase 4	72 participants (Actual)	Interventional	2007-09-30	Completed
The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Effects on Cerebral Blood Flow. [NCT00627991]		0 participants (Actual)	Interventional	2007-08-31	Withdrawn
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg After 8 Week Treatment in Patients With Mild-to-moderate Systolic Hypertension [NCT01281306]	Phase 2	910 participants (Actual)	Interventional	2011-01-31	Completed
A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With V [NCT01001572]	Phase 3	932 participants (Actual)	Interventional	2009-09-30	Completed
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg [NCT00687973]	Phase 4	393 participants (Actual)	Interventional	2008-01-31	Completed
Hemodynamic Effects of Angiotensin Receptor Neprilysin Inhibition on Noninvasive Pressure-volume Analysis in Patients With Heart Failure With Reduced Ejection Fraction [NCT04498780]		117 participants (Actual)	Observational [Patient Registry]	2020-07-21	Active, not recruiting
Valsartan for SUPpression of Plaque Volume and Restenosis After Drug-Eluting Stent (The VAL-SUPPRESS TRial) [NCT00589732]	Phase 4	220 participants (Actual)	Interventional	2006-09-30	Completed
PRospectIve Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in PatiEnts With Heart Failure and Preserved Ejection Fraction [NCT04128891]	Phase 3	0 participants (Actual)	Interventional	2020-02-01	Withdrawn(stopped due to Funding not approved)
Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects [NCT00839683]	Phase 1	24 participants (Actual)	Interventional	2009-02-28	Completed
Evaluation of the Effect of Double Inhibition of Angiotensin II AT1 Receptor and Neprilysin Activity on Sympathic Nervous System Activity in Patient With Heart Failure [NCT02787798]	Phase 4	4 participants (Actual)	Interventional	2016-10-31	Terminated(stopped due to Today Entresto treatment has marketing authorization and is available for all patients, that is the reason why study was halted prematurely.)
A Randomized, Open-label, Single Dose Crossover Study to Compare the Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg in Health [NCT01918358]	Phase 1	60 participants (Actual)	Interventional	2012-12-31	Completed
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease [NCT04394117]	Phase 4	787 participants (Actual)	Interventional	2020-06-19	Completed
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent [NCT05465031]	Phase 4	600 participants (Anticipated)	Interventional	2023-02-28	Not yet recruiting
Cardiovascular and Metabolic Physiological Adaptations to Intermittent Hypoxia. Physiological Aspects and Expression of Receptors and Cellular Mediators [NCT02058823]	Phase 4	12 participants (Actual)	Interventional	2013-08-07	Terminated(stopped due to budget constraints)
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 [NCT03738878]	Phase 4	32 participants (Anticipated)	Interventional	2018-11-15	Active, not recruiting
The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure [NCT04688294]	Phase 4	60 participants (Actual)	Interventional	2020-01-01	Completed
Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study [NCT04153136]	Phase 2	50 participants (Anticipated)	Interventional	2020-09-11	Recruiting
A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomy [NCT04023227]	Phase 4	919 participants (Actual)	Interventional	2019-12-10	Active, not recruiting
The Effect of Sacubitril/Valsartan Versus Valsartan on the Short-term Prognosis of Hypertensive Patients With Acute Myocardial Infarction [NCT05060588]	Phase 4	200 participants (Anticipated)	Interventional	2021-10-31	Not yet recruiting
Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin. A Ringerike Heart Failure Cohort Phase IV Study of Angiotensin Receptor Neprilysin Inhibiton [NCT03553303]	Phase 4	40 participants (Anticipated)	Interventional	2018-10-16	Recruiting
Valutazione Della capacità d'Esercizio, Della funzionalità Respiratoria e Del Rimodellamento Ventricolare Sinistro in Pazienti Affetti da Scompenso Cardiaco a Frazione d'Eiezione Ridotta Trattati Con Sacubitril/Valsartan [NCT04434170]		100 participants (Anticipated)	Observational	2018-10-15	Active, not recruiting
The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals (NAUTICAL) [NCT04055428]	Phase 2	200 participants (Anticipated)	Interventional	2020-08-15	Recruiting
A Pre-post Analysis of Healthcare Resource Utilization and Costs of Care in a New User Cohort of Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure [NCT05613140]		9,230 participants (Actual)	Observational	2021-08-02	Completed
A Multicenter, Double-blind, Controlled, Randomized Trial to Evaluate the Association Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension [NCT05920005]	Phase 3	698 participants (Anticipated)	Interventional	2023-08-22	Recruiting
A Randomized, Double Blind, Parallel Group Study to Evaluate the Effects of Valsartan Versus Placebo in Patients With Early Stage Heart Failure Due to Diastolic Dysfunction Already Evidenced by an Elevated B-type Natriuretic Peptide Level: the VALIDATE St [NCT00241098]	Phase 4	37 participants (Actual)	Interventional	2003-05-31	Completed
An Open,Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Valsartan/Hydrochlorothiazide 160/25 (Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg) in Patients Not Adequately Responding to a 4 Week Monotherapy With Olm [NCT00171015]	Phase 3	212 participants (Actual)	Interventional	2004-12-31	Completed
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With E [NCT00549770]	Phase 2	1,334 participants (Actual)	Interventional	2007-09-30	Completed
Project to Promote the Evaluation of the Cardiovascular Risk in the Clinical Practice and to Evaluate Its Evolution Following the Implementation of a Preventive Multifactorial Strategy Aimed to Reduce the Total Risk Level (SCORE Algorithm), in Subjects Su [NCT00821574]	Phase 4	144 participants (Actual)	Interventional	2005-07-31	Completed
A 16-weeks, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Anti-inflammatory Actions of 320 mg Diovan in Patients With Type 2 Diabetes With and Without Coronary Artery Disease [NCT00982358]	Phase 4	121 participants	Interventional	2004-07-31	Completed
A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Sy [NCT00391846]	Phase 4	252 participants (Actual)	Interventional	2006-10-31	Completed
An Extension to Study Protocol CVAL489K2302 to Evaluate the Long Term Safety, Tolerability and Efficacy of Valsartan in Children 6 to 17 Years of Age With Hypertension, Versus Enalapril Treatment for 14 Weeks, or Combined With Enalapril Versus Enalapril f [NCT00446511]	Phase 3	250 participants (Actual)	Interventional	2007-06-30	Completed
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive [NCT00425373]	Phase 2/Phase 3	1,474 participants (Actual)	Interventional	2006-11-30	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
A Prospective, Open-label, Active-controlled, Randomized Study Comparing Nifedipine GITS Versus Valsartan Versus a Combination of Both on Central Blood Pressure in Inadequately Controlled Essential Hypertension. [NCT01071122]	Phase 4	365 participants (Actual)	Interventional	2010-01-31	Completed
A Double-blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of Treatment With the Combination of Valsartan/Amlodipine 160/5 mg Compared to Amlodipine 10 mg in Patients With Essential Hypertension Not Ad [NCT00437645]	Phase 3	1,183 participants (Actual)	Interventional	2007-01-31	Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
A 36-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fra [NCT00887588]	Phase 2	307 participants (Actual)	Interventional	2009-11-30	Completed
A Phase I Study to Evaluate the Drug-Drug Interaction of Chiglitazar With Empagliflozin，Atorvastatin and Valsartan in Healthy Subjects. [NCT05681273]	Phase 1	48 participants (Actual)	Interventional	2023-02-17	Completed
Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure [NCT04107220]		300 participants (Anticipated)	Interventional	2016-06-30	Active, not recruiting
A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease [NCT01365481]	Phase 3	150 participants (Actual)	Interventional	2011-08-31	Completed
Effect of Sacubitril/Valsartan on Right Ventricular Dysfunctioning Patients With Connective Tissue Disease [NCT04197050]	Phase 4	60 participants (Anticipated)	Interventional	2020-02-20	Not yet recruiting
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study [NCT02765594]	Phase 4	98 participants (Anticipated)	Interventional	2016-06-30	Recruiting
Enhancing the Natriuretic Peptide System in HFpEF: A Randomized Double-Blind Placebo-Controlled Triple Crossover Study [NCT05279742]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2022-11-04	Enrolling by invitation
Initiation of Angiotensin Receptor-neprilysin Inhibitor (ARNi) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): the INITIATE-HFrEF Randomized Open-label Trial [NCT05989503]	Phase 4	172 participants (Anticipated)	Interventional	2023-08-04	Recruiting
A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of LCZ696 Treatment in Japanese Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction After CLCZ696D2301 (PARAGON-HF) [NCT03909295]	Phase 3	52 participants (Actual)	Interventional	2019-05-07	Terminated(stopped due to This study was terminated early because the primary endpoint of PARAGON-HF was not met.)
Evaluation of Antihypertensive Activity of Valsartan and Amlodipine Compared to Losartan and Amlodipine Through Ambulatory Blood Pressure Monitoring in Moderate Hypertensive Patients in a Randomized, Controlled, Double-Blind Study [NCT00716950]	Phase 4	187 participants (Anticipated)	Interventional	2008-07-31	Recruiting
Physiologic Interactions Between the Adrenal- and the Parathyroid Glands [NCT02572960]	Phase 4	81 participants (Actual)	Interventional	2015-10-31	Completed
The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Chronic Kidney Diseases Patients With Persistent Proteinuria [NCT00858299]	Phase 4	500 participants (Anticipated)	Interventional	2009-03-31	Not yet recruiting
Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke [NCT00874601]	Phase 4	578 participants (Anticipated)	Interventional	2008-10-31	Recruiting
A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria [NCT00171561]	Phase 4	144 participants (Actual)	Interventional	2003-03-31	Completed
A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Amlodipine 5 mg Alone Once Daily in Patients With Mild to Moderate Essential Hype [NCT00413049]	Phase 3	698 participants (Actual)	Interventional	2007-01-31	Completed
A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg /Valsartan 320 mg in Patients With Essential Hypertension Followed by a 26 Week Open-label Extension to Assess the Long-term Sa [NCT00386607]	Phase 3	601 participants (Actual)	Interventional	2006-10-31	Completed
An Open Label Extension Study to Evaluate Safety, Tolerability, and Efficacy of 18 Weeks of Valsartan Treatment in Children 6 Months-5 Years Old With Hypertension [NCT00457626]	Phase 3	66 participants (Actual)	Interventional	2007-04-09	Completed
A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension [NCT00696436]	Phase 3	1,291 participants (Actual)	Interventional	2008-04-30	Completed
Efficacy and Safety of Valsartan 160 mg Plus Hydrochlorothiazide 25 mg Once a Day in Patients With Slight Hypertension and Target Organ Damage [NCT00687206]	Phase 4	20 participants (Anticipated)	Interventional	2008-03-31	Completed
Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study [NCT04587947]		63 participants (Actual)	Interventional	2020-04-01	Completed
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Left Atrial and Left Ventricular Performance, as Assessed With 3D Echocardiography, in Patients After Bone Marrow Transplantation. [NCT04092309]		90 participants (Anticipated)	Interventional	2019-09-20	Recruiting
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3 [NCT00878969]	Phase 3	78 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to insufficient enrollment and retention)
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 2 [NCT00732069]	Phase 2	19 participants (Actual)	Interventional	2008-08-31	Completed
An 8-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combination Based Therapy Versus Amlodipine Monotherapy in Patients With Stage II Hypertension [NCT00350168]	Phase 3	647 participants (Actual)	Interventional	2006-06-30	Completed
A Relative Bioavailability Study of Three LY900020 Tablet Formulations in Healthy Chinese Subjects [NCT04047940]	Phase 1	32 participants (Actual)	Interventional	2019-11-29	Completed
PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada [NCT02957409]		1,009 participants (Actual)	Observational [Patient Registry]	2016-05-20	Completed
Effects of Benazepril,Valsartan or Combination of Both on Residual Renal Function in Peritoneal Dialysis Patients [NCT00721773]		200 participants (Actual)	Interventional	2008-09-30	Completed
An Open-label, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Amlodipine in Combination With Valsartan Compared to Losartan in Combination With Hydrochlorothiazide Given for 52 Weeks on the Regression of Left Ventricular Hypertrophy [NCT00446563]	Phase 3	90 participants (Actual)	Interventional	2007-03-31	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Subjects With Essential Hypertension [NCT00591578]	Phase 3	984 participants (Actual)	Interventional	2007-12-31	Completed
Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan [NCT04185103]		20 participants (Anticipated)	Observational	2019-10-15	Recruiting
An 8 Week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Antihypertensive Efficacy and Safety of Aliskiren Administered in Combination With Valsartan Versus Valsartan Alone in Patients With Stage 2 Systolic [NCT00927394]	Phase 4	1,143 participants (Actual)	Interventional	2009-05-31	Completed
Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor (ARNI) With Amlodipine on Ventricular Remodeling in Hypertension and Left Ventricular Hypertrophy. [NCT04929600]	Phase 4	120 participants (Anticipated)	Interventional	2021-11-28	Recruiting
Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker [NCT01805804]	Phase 4	88 participants (Anticipated)	Interventional	2017-01-31	Terminated(stopped due to Recall of some valsartan preparations. 88 patients enrolled and completed the observation. All patients are in continuous observation and are well.)
A Multi-center, Randomized, Placebo- and Active-controlled, Parallel-group, 24-week Proof of Concept and Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Heart Failure [NCT06142383]	Phase 2	720 participants (Anticipated)	Interventional	2023-12-14	Not yet recruiting
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Dose-finding Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SPH3127 Tablets in the Treatment of Diabetic Kidney Disease [NCT05593575]	Phase 2	320 participants (Anticipated)	Interventional	2023-03-22	Recruiting
Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics? [NCT00732966]		30 participants (Anticipated)	Interventional	2008-09-30	Not yet recruiting
A 16 Week Multi-center, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide (HCTZ) Monotherapy in Very [NCT00698646]	Phase 4	384 participants (Actual)	Interventional	2008-04-30	Completed
A Multicenter, Double-blind, Randomized, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 mg as Compared to Amlodipine/Valsartan 5/40 mg or to Amlodipine 5 mg Once Daily in Elderly Patients Wi [NCT00699192]	Phase 3	965 participants (Actual)	Interventional	2008-05-31	Completed
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension [NCT00921570]	Phase 4	105 participants (Actual)	Interventional	2008-02-29	Completed
Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial [NCT01030458]	Phase 4	183 participants (Actual)	Interventional	2010-09-30	Completed
Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia. [NCT02662894]	Phase 3	0 participants (Actual)	Interventional	2019-10-31	Withdrawn(stopped due to Sponsor decision)
Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients. [NCT00738972]	Phase 3	12 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Study terminated early due to sample size, not possible to perform further statistical analysis.)
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]	Phase 4	2,400 participants (Anticipated)	Interventional	2016-02-29	Recruiting
The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Affects on Cerebral Blood Flow [NCT01400256]	Phase 4	0 participants (Actual)	Interventional	2007-08-31	Withdrawn(stopped due to lack of recruitment/patient population)
Prospective Observational Study of the Sacubitril-Valsartan Treatment Effectiveness. [NCT04133428]		100 participants (Anticipated)	Observational	2019-04-04	Recruiting
A 12-week Multicenter, Randomized, Double-blind, Parallel-group, Active-control Study to Evaluate the Antihypertensive Efficacy and Safety of Valsartan/Amlodipine-based Regimen Versus a Losartan-based Regimen in Patients With Stage 2 Systolic Hypertension [NCT00931710]	Phase 4	488 participants (Actual)	Interventional	2009-07-31	Completed
The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction: The RSVP-AMI Trial [NCT03893435]		192 participants (Actual)	Interventional	2018-12-01	Completed
"An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease" [NCT05580510]	Phase 2/Phase 3	160 participants (Anticipated)	Interventional	2023-02-06	Not yet recruiting
Safety and Efficacy of Angiotensin Receptor-neprilysin Inhibitor After Left Ventricular Assist Device ImplanT (SEAL-IT) Study [NCT04191681]	Phase 4	50 participants (Anticipated)	Interventional	2019-11-08	Recruiting
Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients [NCT04218435]		200 participants (Actual)	Observational	2019-01-01	Completed
An 8-week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patie [NCT00809926]	Phase 4	451 participants (Actual)	Interventional	2009-01-31	Completed
Sacubitril/Valsartan for Dialysis Patients With CKD5 Stage Complicated With Hypertension- A Prospective, Randomized, Controlled Multicenter Study [NCT05243199]	Phase 4	330 participants (Actual)	Interventional	2020-08-01	Completed
PRevention of cArdiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, Multicenter Trial [NCT03760588]	Phase 2	214 participants (Anticipated)	Interventional	2019-01-14	Active, not recruiting
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Amlodipine 10 mg Plus Valsartan 160 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free C [NCT00523744]	Phase 3	257 participants (Actual)	Interventional	2007-07-31	Completed
Role of ARNi in Ventricular Remodeling in Hypertensive LVH [NCT03553810]	Phase 2	80 participants (Anticipated)	Interventional	2019-04-12	Recruiting
Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension [NCT00790946]	Phase 4	250 participants (Anticipated)	Interventional	2006-06-30	Recruiting
A Multicenter, Randomized, Double Blind, Parallel Design Trial to Evaluate the Blood Pressure Lowering Efficacy Comparing Moderate Versus Aggressive Treatment Regimen of Valsartan + Amlodipine in Patients Uncontrolled on ARB Monotherapy [NCT00666536]	Phase 4	728 participants (Actual)	Interventional	2008-03-31	Completed
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan and Hydrochlorothiazide Combined and Alone, in Patients With Metabolic Syndrome [NCT00170937]	Phase 4	507 participants	Interventional	2004-11-30	Completed
Evaluation in Real Life Conditions of Sacubitril-valsartan Combination in Patients With Chronic Heart Failure and Sleep Apnea Syndrome [NCT02916160]	Phase 4	124 participants (Actual)	Interventional	2016-09-22	Completed
A 54 Week, Extension to the Double-blind, Multicenter, Multifactorial, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients [NCT00170976]	Phase 3	403 participants (Actual)	Interventional	2004-04-30	Completed
A 10-12 Week Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of the Combination of Valsartan (320 mg) and Simvastatin (80 mg) Compared to Valsartan (320 mg) and Simvastatin (80 mg) Monotherapies in Essential Hypertension and Hyperchole [NCT00171093]	Phase 3	369 participants	Interventional	2004-09-30	Completed
A 26-week Double-blind, Randomized, Multicenter Parallel-group Trial to Compare the Effects of Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women With Impaired Exercise Tolerance [NCT00171132]	Phase 4	64 participants (Actual)	Interventional	2004-08-31	Completed
Efficacy and Safety of Fluvastatin 80 mg or Valsartan 160 mg and Their Combination in Dyslipidemic Patients With Arterial Hypertension and Endothelial Dysfunction [NCT00171327]	Phase 4	213 participants (Actual)	Interventional	2004-07-31	Completed
Comparative, Open Multicenter Trial Assessing the Effect on Albumin Excretion Rate of 320mg Valsartan (With or Without HCTZ) vs 40mg Lisinopril (With or Without HCTZ) on Hypertensive Patients With Diabetic and Non-diabetic Nephropathy and Albuminuria [NCT00171600]	Phase 4	54 participants (Actual)	Interventional	2005-07-31	Terminated
A Double-blind, Double-dummy, Multi-centre, Randomized, Active Controlled, Parallel Group Pilot Trial to Compare the Effects of Valsartan and Atenolol on the Pro-thrombotic State in Patients With Mild to Moderate Hypertension. [NCT00171756]	Phase 4	92 participants (Actual)	Interventional	2004-06-30	Completed
A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nep [NCT00153023]	Phase 4	885 participants	Interventional	2003-04-30	Completed
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP) [NCT00154271]	Phase 4	1,677 participants (Actual)	Interventional	2004-01-31	Completed
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS [NCT04686643]	Phase 3	306 participants (Anticipated)	Interventional	2021-02-01	Not yet recruiting
Comparative Open-label,Randomized, Fasting/Fed, Single Dose, Three-way Crossover Bioequivalence Study of Valsartan and Amlodipine Tablets (Hua Yuan Pharmaceutical LLC, China) and Valsartan and Amlodipine Tablets (Ⅰ) (Novartis Pharma Schweiz AG, Switzerlan [NCT04085627]	Phase 1	84 participants (Actual)	Interventional	2018-10-08	Active, not recruiting
Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction - PRESENT HF Study [NCT05487261]	Phase 4	260 participants (Anticipated)	Interventional	2022-12-13	Recruiting
[NCT01004237]	Phase 4	52 participants (Actual)	Interventional	2009-11-30	Completed
A Randomized, Multicenter, Double-blind, 6 Week Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 6 Months - 5 Years Old With Hypertension, Followed by a 2 Week Placebo Withdrawal Period. [NCT00435162]	Phase 3	74 participants (Actual)	Interventional	2007-03-31	Completed
A Multicenter, Randomized, Double-blind, Parallel-group, Evaluation of 12 Weeks of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children 6 to 17 Years of Age With Hypertension [NCT00433836]	Phase 3	300 participants (Actual)	Interventional	2007-01-31	Completed
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational Clinical Trial to Evaluate the Efficacy of Aliskiren and Valsartan Versus Placebo in Lowering Levels on NT-proBNP in Stabilized Patients Post Acute Coronary Syndromes [NCT00409578]	Phase 2	1,101 participants (Actual)	Interventional	2007-02-28	Completed
A Randomized, Open-label, Multicenter, Cross-over Trial to Evaluate the Efficacy of a 20 Week Treatment of Valsartan 320 mg Versus Atenolol 100 mg in Combination With Hydrochlorothiazide on Microcirculation in Hypertensive Patients [NCT00396656]	Phase 3	30 participants (Actual)	Interventional	2005-12-31	Completed
Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography [NCT03990480]	Phase 4	230 participants (Actual)	Interventional	2018-12-01	Completed
Effect of Valsartan on Endothelial Function, Oxidative Stress, Carotid Atherosclerosis, and Endothelial Progenitor Cells (EFFERVESCENT) [NCT00208767]	Phase 2	120 participants (Actual)	Interventional	2005-02-28	Completed
A Randomized, Double-blind, Valsartan 80 Mg-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension [NCT01878201]	Phase 2	75 participants (Actual)	Interventional	2013-05-31	Completed
[NCT01904981]	Phase 4	19 participants (Actual)	Interventional	2014-01-31	Completed
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM [NCT01912534]	Phase 2	211 participants (Actual)	Interventional	2014-03-31	Completed
Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy [NCT01917149]	Phase 4	480 participants (Actual)	Interventional	2005-03-31	Completed
A Randomized, Open Label, Multiple Dose, Cross-over, Phase I Trial to Evaluate a Pharmacokinetic Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers [NCT01918709]	Phase 1	30 participants (Actual)	Interventional	2011-09-30	Completed
Prospective, Randomized, Open-label, Blinded Endpoint, Forced Titration Study to Compare Telmisartan Combined With HCTZ (80mg/12.5mg), to Valsartan Combined With HCTZ (160mg/12.5mg), for the Control of Mild-to-moderate Hypertension in Obese Patients With [NCT00239538]	Phase 4	840 participants (Actual)	Interventional	2003-01-31	Completed
A Study to Compare Treating Hypertension With Valsartan 160 MG to Valsartan 320 Mg [NCT00241137]	Phase 3	3,790 participants (Actual)	Interventional	2003-09-30	Completed
A Study to Evaluate the Efficacy of the Valsartan/Simvastatin Combinations 160/20mg up Titrated to 320/20mg Versus 160/40mg up Titrated to 320/40mg in Patients With Both Essential Hypertension and Hypercholesterolemia [NCT00254475]	Phase 3	871 participants (Actual)	Interventional	2005-11-30	Completed
Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data. [NCT04736433]		6,066 participants (Actual)	Observational	2020-09-22	Completed
A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of Valsartan/Amlodipine and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment [NCT01167153]	Phase 4	564 participants (Actual)	Interventional	2010-05-31	Completed
Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up [NCT00171574]	Phase 4	124 participants (Actual)	Interventional	2004-11-30	Completed
A Multi-center, Factorial Study to Evaluate Efficacy & Safety of 8 Wks Treatment With VAH631 [Valsartan (40 & 80 mg) and Hydrochlorothiazide (6.25 & 12.5 mg) Combined & Alone in Essential Hypertensive Patients] - Double-blind Study of VAH631 in Patients W [NCT00311740]	Phase 3	582 participants (Actual)	Interventional	2006-03-31	Completed
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? [NCT04606563]	Phase 3	341 participants (Actual)	Interventional	2020-10-09	Terminated(stopped due to DSMC recommendation due to futility)
A Single Center Randomized Controlled Clinical Study on the Treatment of Children With Purpura Nephritis With Huaiqihuang Granules [NCT04623866]	Early Phase 1	10 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
Effects of Dapagliflozin on Hypotensive Patients With Depressed Left Ventricular Ejection Fraction After Sacubitril/Valsartan Therapy [NCT04575675]	Phase 4	78 participants (Actual)	Interventional	2020-05-29	Completed
A Randomized, Double-blind, Parallel Group, Active-controlled, 38-week Study to Evaluate the Efficacy of Valsartan Versus Amlodipine on the Arterial Properties of Postmenopausal Women With Mild to Moderate Hypertension [NCT00171054]	Phase 4	125 participants (Actual)	Interventional	2003-09-30	Completed
Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease [NCT01129557]	Phase 4	46 participants (Actual)	Interventional	2009-09-30	Terminated
The Drug Interaction Study of SP2086 and Valsartan in Healthy Subjects [NCT02817217]	Phase 1	24 participants (Anticipated)	Interventional	2016-03-31	Recruiting
A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan in Healthy Male Volunteer [NCT01609907]	Phase 1	30 participants (Actual)	Interventional	2011-11-30	Completed
An Open-Label, Randomized, Two-Treatment, Two Period Crossover, Single-Dose Study to Determine the Relative Bioavailability of Fixed Combination of Final Market Image (FMI) Aliskiren/Valsartan 75/160 mg Tablets and the Free Combination of Aliskiren 75 mg [NCT00416468]	Phase 1	32 participants	Interventional	2006-11-30	Completed
Regression of Fatty Heart by Valsartan Therapy [NCT00745953]	Phase 4	0 participants (Actual)	Interventional	2007-08-31	Withdrawn
A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Modera [NCT00413413]	Phase 3	1,134 participants (Actual)	Interventional	2007-01-31	Completed
Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study [NCT03315832]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2023-01-02	Withdrawn(stopped due to problem of faisability)
Randomized,Open-label,Parallel Design Comparator Study of Effect of Nifedipine GITS/OROS (Adalat) 30 mg in Combination With Valsartan (Diovan) 80 mg Compared to Valsartan (Diovan) 160 mg Monotherapy in Patients Whose Blood Pressure is Not Well Controlled [NCT00993109]	Phase 4	360 participants (Actual)	Interventional	2010-02-28	Completed
A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + [NCT00523549]	Phase 4	229 participants (Actual)	Interventional	2006-11-30	Completed
A Comparative Pharmacokinetic and Pharmacodynamic Study of Morning Versus Evening Administration of Valsartan in Healthy Adults [NCT02631031]	Phase 1	24 participants (Actual)	Interventional	2015-11-30	Completed
Prospective Comparison of ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure [NCT05117736]		48 participants (Anticipated)	Interventional	2022-03-15	Active, not recruiting
Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage [NCT02687932]	Phase 4	118 participants (Actual)	Interventional	2016-03-31	Completed
Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance [NCT01252238]		24 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Study sponsor terminated study due to AE's reported with valsartan and aliskiren)
A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy [NCT00655330]		170 participants (Anticipated)	Interventional	2008-05-31	Active, not recruiting
A Single Center, Randomized, Double-blind, Active Controlled, Parallel Group Study to Demonstrate Non-inferiority of a Fixed Dose Combination of 5 mg Amlodipine and 80 mg Valsartan to 160 mg Valsartan in the Treatment of Hypertension [NCT01070043]	Phase 4	60 participants (Actual)	Interventional	2009-06-30	Completed
A Single Randomized, Open,Cross-over, Phase I Study to Access the Drug-drug Interaction of SP2086 and Valsartan [NCT02815657]	Phase 1	16 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized, Double Blind, Double Dummy, Placebo Controlled Phase III Trial to Evaluate the Efficacy, Safety of Coadministered Pitavastatin and Valsartan in Patients With Hypertension and Dyslipidemia(COCTAIL Study) [NCT01402843]	Phase 3	150 participants (Anticipated)	Interventional	2011-06-30	Completed
A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatin and Valsartan Co-administration and Livalo® Fixed Combination Drug in Healthy Male Subjects [NCT01406431]	Phase 1	48 participants (Actual)	Interventional	2011-08-31	Completed
A Multicenter, Open-Label, Single-Arm, Free Tablet Combination, Long-Term Study to Evaluate the Safety of Nebivolol in Combination With Valsartan in Patients With Stage 1 or Stage 2 Essential Hypertension [NCT01415505]	Phase 3	812 participants (Actual)	Interventional	2011-08-31	Completed
The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects [NCT00185055]	Phase 4	20 participants	Interventional	2004-11-30	Completed
A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome [NCT01432106]	Phase 1	0 participants (Actual)	Interventional	2011-02-28	Withdrawn(stopped due to Novartis terminated all projects involving aliskiren. Findings of the DMC overseeing the ALTITUDE clinical trial found a higher incidence of adverse events.)
A Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of an Angiotensin Receptor Blocker (Valsartan) and Highly Active Antiretroviral Therapy (HAART) Versus HAART Alone for the Treatment of HIV-Associated Nephropathy [NCT00089518]	Phase 3	0 participants (Actual)	Interventional		Withdrawn
A Randomized, Double-blind, Placebo-controlled, Forced-titration, Phase IV Study Comparing Telmisartan 80 mg + Hydrochlorothiazide 25 mg Versus Valsartan 160 mg + Hydrochlorothiazide 25 mg Taken Orally for Eight Weeks in Patients With Stage 1 or Stage 2 H [NCT00168779]	Phase 4	1,185 participants	Interventional	2005-09-30	Completed
Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy [NCT00170963]	Phase 3	1,018 participants (Actual)	Interventional	2004-10-31	Completed
A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertensive Patients [NCT00171041]	Phase 3	265 participants (Actual)	Interventional	2002-12-31	Completed
A 2 x 5-week Multicenter, Cross-over Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan 80 mg Compared to Irbesartan 150 mg in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis [NCT00171080]	Phase 3	86 participants (Actual)	Interventional	2004-04-30	Completed
A 24-Week Study to Assess Blood Pressure Independent Effects of Valsartan Treatment, Benazepril Treatment and Combination of Both Valsartan and Benazepril Treatment on Urinary Albumin Excretion Rate With Type II Diabetes Mellitus and Microalbuminuria [NCT00171119]	Phase 4	81 participants (Actual)	Interventional	2004-01-31	Terminated
A Study to Describe Vascular and Renal Effects and Safety of Valsartan 80 and 160 mg in Arterial Hypertension Patients [NCT00171353]	Phase 4	109 participants (Actual)	Interventional	2004-07-31	Completed
Valsartan Plus Hydrochlorothiazide in Patients With Hypertension and Cardiovascular Risk Factors [NCT00171782]	Phase 4	76 participants (Actual)	Interventional	2004-02-29	Completed
A Phase IV Clinical Trial of Intensified Blood Pressure Management in Primary Care Using Valsartan Alone and as Combination Anti-Hypertensive Therapy [NCT00902304]	Phase 4	2,337 participants (Actual)	Interventional	2009-07-31	Completed
[NCT00200694]	Phase 4	18 participants	Interventional	2005-03-31	Terminated(stopped due to difficulty in patients's inclusion)
Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial [NCT01850160]	Phase 3	124 participants (Actual)	Interventional	2013-04-30	Completed
A Multi-center, Multiple Dose, Open-label, Four-cohort, Parallel Study to Assess the Pharmacokinetic Drug Interaction Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension. [NCT00548067]	Phase 3	111 participants (Actual)	Interventional	2007-09-30	Completed
Prospective Comparison of ARNI to Alternate Oral Vasodilator Therapies to Determine the Hemodynamic Profile and Relative Tolerability of (ARNIs) in Patients With Decompensated Heart Failure and Low Cardiac Output [NCT04206865]	Phase 4	0 participants (Actual)	Interventional	2019-11-25	Withdrawn(stopped due to New study initiated)
Controlled Trial on the Short-term Effects of Sacubitril/Valsartan Therapy on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Patients With NYHA II-III Heart Failure and Reduced Systolic Function Using 11C-acetate Positron Emission Tomography [NCT03300427]	Phase 4	55 participants (Actual)	Interventional	2018-07-05	Completed
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation [NCT05498181]	Phase 2	100 participants (Anticipated)	Interventional	2022-10-11	Recruiting
Randomized, Prospective, Parallel Group, Placebo-Controlled, Multi-Center Study on the Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence [NCT00376272]	Phase 3	1,442 participants (Actual)	Interventional	2004-11-30	Completed
A 12-month Open-label, Multicenter Observation Study on the Occurrence of Major Adverse Cardiac Events (MACE) in Patients With Acute Myocardial Infarction (AMI) Receiving Pitavastatin/Valsartan Treatment [NCT04270344]		905 participants (Anticipated)	Observational	2018-07-01	Recruiting
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volu [NCT01494727]	Phase 1	48 participants (Anticipated)	Interventional	2012-02-29	Completed
A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extensi [NCT00338936]	Phase 3	362 participants (Actual)	Interventional	2006-05-31	Completed
A 8-week, Multi Center(10),Single Arm, Open-labeled Prospective Study of Valsartan 160 mg in 200 Mild to Moderate Chinese Hypertension Patients Forced Titrated From 2-week Therapy of Valsartan 80 mg. [NCT01541189]	Phase 4	200 participants (Actual)	Interventional	2012-02-29	Completed
An 8 Weeks Open Label National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy [NCT01241487]	Phase 4	150 participants (Anticipated)	Interventional	2009-02-28	Completed
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 [NCT04883528]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2021-08-06	Completed
Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis [NCT02754518]	Phase 4	40 participants (Actual)	Interventional	2016-04-30	Completed
A 24 Week, Multi-centre, Open Label, Non Controlled Study to Assess the Efficacy of Valsartan in Reducing Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus [NCT00550095]	Phase 4	509 participants (Actual)	Interventional	2007-06-30	Completed
A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction [NCT02884206]	Phase 3	592 participants (Actual)	Interventional	2016-11-23	Completed
Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback [NCT02966665]	Phase 1	420 participants (Anticipated)	Interventional	2008-09-30	Recruiting
Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder [NCT01699490]	Phase 4	200 participants (Anticipated)	Interventional	2012-08-31	Recruiting
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in Patients With Heart Failure With Preserved Ejection Fraction Monitored With the CardioMEMS Device (ARNIMEMS-HFpEF) [NCT04753112]	Phase 3	14 participants (Actual)	Interventional	2020-10-29	Completed
A Randomised, Double-blind, Double-dummy, Placebo-controlled, Forced-titration, Comparison of MICARDIS® HCT (Telmisartan 80 mg / Hydrochlorothiazide 25 mg) Versus DIOVAN® HCT (Valsartan 160 mg / Hydrochlorothiazide 25 mg) Using Seated Trough Cuff Blood Pr [NCT00240448]	Phase 4	1,109 participants (Actual)	Interventional	2003-09-30	Completed
A Single Center, Open Label, Single Arm Trial To Evaluate The Effect Of Twenty Four Weeks Of Treatment With 80 Mg To 320 Mg Valsartan On Insulin Sensitivity In Subjects With Impaired Glucose Tolerance (Igt) [NCT00241072]	Phase 4	27 participants (Actual)	Interventional	2002-09-30	Completed
A Multicenter, Double Blind, Randomized Study With Two Parallel Groups Comparing The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic Syndrome [NCT00241150]	Phase 4	80 participants (Actual)	Interventional	2002-11-30	Completed
Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris [NCT00424801]		10 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis)
An Open-Label, Randomized, Two-Treatment, Two Period Crossover, Single-Dose Study to Determine the Relative Bioavailability of Fixed Combination of Final Market Image (FMI) Aliskiren/Valsartan 150/80 mg Tablets and the Free Combination of Aliskiren 150 mg [NCT00416728]	Phase 1	32 participants	Interventional	2006-11-30	Completed
A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With [NCT00280540]	Phase 4	648 participants	Interventional	2005-12-31	Completed
Effect of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Valsartan as Part of Intensified Multi-factorial Intervention Compared to EC-MPS Plus Standard Practice of Care on Development of Transplant Nephropathy in Cadaver Donor Kidney Recipients Given B [NCT00308425]	Phase 3	119 participants (Actual)	Interventional	2002-10-31	Completed
A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy [NCT00327145]	Phase 3	894 participants (Actual)	Interventional	2006-03-31	Completed
The Comparison of the Antihypertensive Efficacy and Tolerability Between Valsartan Plus Hydrochlorothiazide 80mg/12.5mg and Amlodipine 5mg in the Essential Hypertensive Patients [NCT00426478]	Phase 4	80 participants (Anticipated)	Interventional	2006-11-30	Completed
A Cross-over Trial to Identify Patient Characteristics That Predict Blood Pressure Response to Antihypertensive Therapy in General Practice [NCT00457483]	Phase 4	120 participants (Actual)	Interventional	2007-08-31	Completed
An 8 Week Extension to a Randomized, Double-blind, Parallel Group, Active-controlled, Multi-center, 14 Week Study to Evaluate the Effectiveness of a Valsartan Versus and Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With St [NCT00351130]	Phase 4	79 participants (Actual)	Interventional	2006-06-30	Completed
A 54-week Extension to the Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of VAA489 (Valsartan and Amlodipine Combined) and Alone in Essential Hypertensive Patients - Long Te [NCT00446524]	Phase 3	403 participants (Actual)	Interventional	2007-02-28	Completed
Study on Optimal Anti-hypertensive Therapy With Valsartan by Using Home Blood Pressure Measurement [NCT00460213]	Phase 4	103 participants (Actual)	Interventional	2006-07-31	Completed
A Multi-Center, Randomized, Proof-of-Concept, Parallel Control Study With Remind Cap® in Patients With Essential Hypertension and Newly Treated With Valsartan+/-Hydrochlorothiazide (HCTZ) [NCT00487123]	Phase 4	0 participants	Interventional		Completed
A Prospective, Randomized, Probe Trial to Evaluate Whether, at Comparable Blood Pressure Control, Combined Therapy With the ACEI Benazepril and the ARB Valsartan, Reduces the Incidence of Microalbuminuria More Effectively Than BEN or VAL Alone in Hyperten [NCT00503152]	Phase 3	612 participants (Actual)	Interventional	2007-05-31	Completed
Effects of Valsartan on Cardiovascular Events in Patients With Renal Dysfunction [NCT00140790]	Phase 4	1,000 participants (Actual)	Interventional	2006-08-31	Terminated(stopped due to The number of actual events was extremely low. We extended the study period, but it was still not enough. Also, many patients were loss of follow up.)
A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease [NCT00133328]	Phase 4	3,000 participants	Interventional	2002-01-31	Active, not recruiting
PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease [NCT04335786]	Phase 4	23 participants (Actual)	Interventional	2020-04-17	Terminated(stopped due to Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of the REMAP-CAP trial.)
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 [NCT03005184]	Phase 2	0 participants (Actual)	Interventional	2017-09-30	Withdrawn(stopped due to Study is being redesigned and submitted as a new study.)
Renin Angiotensin System Blockade in Renal Transplant Patients With Presence of PECs in Urine [NCT04769778]	Phase 4	180 participants (Anticipated)	Interventional	2020-02-19	Recruiting
Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression [NCT00518479]		42 participants (Actual)	Interventional	2003-09-30	Completed
A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. (Previously NCT02682719) [NCT04687111]	Phase 2	250 participants (Actual)	Interventional	2015-12-16	Active, not recruiting
A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active Controlled Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Valsartan on Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (H [NCT03988634]	Phase 3	465 participants (Actual)	Interventional	2019-06-27	Completed
A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients. [NCT00409851]	Phase 3	1,293 participants (Actual)	Interventional	2003-04-30	Completed
A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction [NCT00170924]	Phase 4	317 participants (Actual)	Interventional	2004-08-31	Completed
Anti-Hypertensive Effect of Sacubitril/Valsartan in Resistant Hypertension: Randomized Clinical Trial - The HEVA Study [NCT04637152]	Phase 2	100 participants (Anticipated)	Interventional	2020-11-11	Recruiting
Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT) [NCT00190580]	Phase 4	312 participants (Actual)	Interventional	2003-02-28	Completed
A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan (160 mg and 320 mg) and Amlodipine (10 mg) Combined and Alone in Hypertensive Patients [NCT00409643]	Phase 3	1,259 participants (Actual)	Interventional	2004-01-31	Completed
A Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients. [NCT00409760]	Phase 3	1,930 participants (Actual)	Interventional	2003-01-31	Completed
A Randomized, Double-blind, Valsartan-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan(BR-A-657•K) During 24hours by Dose in Patients With Mild to Moderate Essential Hypertension [NCT00922441]	Phase 2	92 participants (Actual)	Interventional	2008-12-31	Completed
A Single Center, Randomized Trial to Evaluate the Effects of Diovan to Maintain Sinus Rhythm in Patients With Persistent Atrial Fibrillation [NCT00343499]	Phase 4	200 participants (Anticipated)	Interventional	2004-11-30	Terminated(stopped due to Inability to recruit)
A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension [NCT00353912]	Phase 3	571 participants (Actual)	Interventional	2006-06-30	Completed
Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study [NCT04397302]		652 participants (Actual)	Observational [Patient Registry]	2019-01-13	Completed
A Comparative Study of the Efficacy of Irbesartan/Hydrochlorothiazide 300/25 mg Versus Valsartan/Hydrochlorothiazide 160/25 mg Using Home Blood Pressure Monitoring in the Treatment of Mild to Moderate Hypertension [NCT00500604]	Phase 4	1,617 participants (Actual)	Interventional	2007-07-31	Completed
A Prospective, Randomized, Probe Trial to Evaluate Whether,at Comparable Blood Pressure Control,Combined Therapy With ACEI BEN and ARB VAL Reduces Progression to ESRD More Effectively Than BEN or VAL Alone in High Risk Patients With Type 2 Diabetes and Ov [NCT00494715]	Phase 3	102 participants (Actual)	Interventional	2007-05-31	Completed
[NCT00530595]		0 participants	Interventional		Completed
Repurposing Valsartan May Protect Against Pulmonary Hypertension [NCT06053580]	Phase 2	60 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
An Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy of the Combination of Valsartan and Hydrochlorothiazide and Amlodipine in Hypertensive Patients Not Controlled With Valsartan and Hydrochlorothiazide [NCT00400777]	Phase 4	460 participants (Anticipated)	Interventional	2006-08-31	Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
A Prospective, Randomized, Double-Blind, Forced Titration Trial to Compare the Efficacy of MICARDIS® (Telmisartan 80 mg p.o. Once Daily) and Diovan® (Valsartan 160 mg p.o. Once Daily) Using Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild [NCT00034840]	Phase 4	490 participants	Interventional	2001-10-31	Completed
The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism Among African Americans: Pilot Study [NCT03938389]	Phase 4	90 participants (Anticipated)	Interventional	2020-02-25	Active, not recruiting
An Multicenter Study to Evaluate the Efficacy and Tolerability of a 4-week Therapy With the Combination of Valsartan 160mg + Amlodipine 5mg in Hypertensive Patients Not Adequately Responding to 4-week Treatment With Amlo 5mg or Felodipine 5mg in Monothera [NCT00392262]	Phase 3	224 participants (Actual)	Interventional	2006-08-31	Completed
The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study [NCT00129233]	Phase 4	1,150 participants (Actual)	Interventional	2004-10-31	Completed
A 12 Week Treatment, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Valsartan 160-320 mg With Regard to Effects on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome [NCT00394745]	Phase 3	45 participants (Actual)	Interventional	2005-11-30	Completed
The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) [NCT00202618]	Phase 4	160 participants	Interventional	2003-12-31	Recruiting
Effect of Sacubitril/Valsartan on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension [NCT04800081]		264 participants (Anticipated)	Interventional	2020-07-09	Recruiting
The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP [NCT00162955]	Phase 4	150 participants (Actual)	Interventional	2004-05-31	Completed
Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension [NCT00407680]	Phase 4	80 participants (Anticipated)	Interventional	2006-10-31	Recruiting
Comparison of the Combination of Valsartan 320 mg Plus Hydrochlorothiazide 12.5 mg and Valsartan 320 mg Plus Hydrochlorothiazide 25 mg to Valsartan 320 mg in Mild to Moderate Hypertensive Patients Not Adequately Controlled With Valsartan 320 mg [NCT00170989]	Phase 3	2,714 participants (Actual)	Interventional	2004-09-30	Completed
A Double-Blind, Randomized, Multi-Center Study Followed By 12 Months Open-Label Treatment To Evaluate The Dose Response And Safety Of Valsartan In Pediatric Hypertension Patients 1 - 5 Years Of Age [NCT00171028]	Phase 3	90 participants (Actual)	Interventional	2003-12-31	Completed
A Study to Evaluate the Effectiveness of Valsartan 320 mg in Combination With Lisinopril 20 mg Versus Monotherapy With Lisinopril 40 mg or Valsartan 320 mg in Hypertensive Patients With Microalbuminuria on the Reduction of Urinary Albumin Creatinine Ratio [NCT00171067]	Phase 3	134 participants (Actual)	Interventional	2004-07-31	Completed
A Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Determine the Effects of Valsartan on Exercise Time in Subjects With Symptomatic Diastolic Heart Failure [NCT00171106]	Phase 4	150 participants	Interventional	2002-12-31	Completed
A Study to Evaluate the Safety and Efficacy of Valsartan/Amlodipine Compared to Lisinopril/Hydrochlorothiazide Given Once Daily for 6 Weeks is Patients With Severe Hypertension [NCT00171535]	Phase 3	130 participants (Actual)	Interventional	2004-10-31	Completed
Black Education and Treatment of Hypertension (BEAT HTN) [NCT00661895]	Phase 4	99 participants (Actual)	Interventional	2005-08-31	Completed
The Effect of Sacubitril/Valsartan on Cardiovascular Events Outcome in Maintenance Dialysis Patients With Heart Failure and Efficacy Prediction of Baseline LVEF Value：A Prospective Cohort Study [NCT04572724]	Phase 4	120 participants (Anticipated)	Interventional	2020-07-06	Recruiting
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension [NCT00241007]	Phase 3	836 participants (Actual)	Interventional	2003-12-31	Completed
A Multi-center, Double Blind, Randomized, Parallel Group Study to Evaluate the Effects of Valsartan on Proteinuria in Hypertensive Subjects With Type 2 Diabetes Mellitus [NCT00241085]	Phase 4	392 participants (Actual)	Interventional	2002-11-30	Completed
A Randomized, Double Blind, Double Dummy, Parallel Group, Active-Controlled Study To Evaluate The Effectiveness Of Morning Versus Evening Doses Of 320 Mg Valsartan Versus 40 Mg Lisinopril On The 24 Hour Blood Pressure Profile In Patients With Hypertension [NCT00241124]	Phase 4	1,099 participants (Actual)	Interventional	2004-04-30	Completed
Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy [NCT01425411]	Phase 4	38 participants (Actual)	Interventional	2006-11-30	Completed
A Multicenter, Double-blind, Randomized, Active Controlled, Parallel Group Trial Comparing the Combinations of Valsartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Valsartan 80 mg in Patients With Mild to Moderate Essential Hypertension Not Adequately Cont [NCT00250562]	Phase 3	1,171 participants (Actual)	Interventional	2005-10-31	Completed
An Open-Label, Randomized, Single Dose, Two Period, Crossover Study to Determine the Relative Bioavailability of Valsartan 160 mg Japanese Formulation and Valsartan 160 mg Global Formulation in Healthy Adult Volunteers [NCT00415883]	Phase 1	40 participants	Interventional	2006-07-31	Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study). [NCT00295542]	Phase 4	3,344 participants (Actual)	Interventional	2000-03-31	Completed
A 6-Week Study to Evaluate the Combination of Valsartan/HCTZ (160/12.5mg With Forced Titration to Maximum Dose of 320/25mg) Compared to Valsartan Monotherapy (160mg With Forced Titration to 320mg) as Initial Therapy in Patients With Severe Hypertension [NCT00273299]	Phase 3	607 participants (Actual)	Interventional	2005-11-30	Completed
A 28-week, Multicenter Study to Evaluate the Effects of Valsartan/Hydrochlorothiazide (160/12.5 mg) in Comparison With Hydrochlorothiazide (25 mg) Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide (12.5 mg) [NCT00277472]	Phase 4	300 participants (Actual)	Interventional	2005-11-30	Completed
Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care [NCT05155137]	Phase 3	12,268 participants (Anticipated)	Interventional	2021-12-20	Recruiting
A Multicenter, Single-arm, Prospective, Observational Study to Evaluate the Safety and Effectiveness of a Fixed-dose Combination Containing Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patient With Hypertension and Hypercholesterolemia [NCT04398771]		1,000 participants (Anticipated)	Observational	2020-09-01	Not yet recruiting
A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of [NCT02554890]	Phase 4	887 participants (Actual)	Interventional	2016-04-29	Completed
A 12-Week Multicenter, 2-Arm Regimen, Exploratory Study to Evaluate the Tolerability and Safety of Valsartan Administered Once Daily vs Daily, in Patients With Stable, Chronic Heart Failure (NYHA Class Ll-lll) [NCT00294086]	Phase 2	160 participants	Interventional	2005-12-31	Completed
Prospective, Randomized, Open-Label Study in Patients With Mild-to-Moderate Essential Hypertension to Compare the Antihypertensive Efficacy Determined by Ambulatory Blood Pressure Monitoring of Valsartan and Enalapril After Missing One Dose [NCT00302705]	Phase 4	150 participants (Actual)	Interventional	2005-01-31	Completed
A 14 Week Study to Evaluate Effectiveness of a Valsartan Versus an Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy [NCT00304226]	Phase 4	1,288 participants (Actual)	Interventional	2006-02-28	Completed
A National, Multicentric and Comparative Study to Evaluate Efficacy and Tolerability of the Association of Valsartan and Amlodipine Versus Amlodipine Alone in the Treatment of Essential Arterial Hypertension - Stages I and II (Mild to Moderate). [NCT00333489]	Phase 4	551 participants (Actual)	Interventional	2004-03-31	Completed
Effects of Sodium Intake on Pharmacokinetic/Pharmacodynamic Relationship of a Single Dose of a Renin Angiotensin System-Blocker, or a Beta-Blocker in Normotensive Sodium-Depleted or Replated Volunteers in a Cross-Over Study [NCT00310778]	Phase 1	64 participants (Actual)	Interventional	2006-03-31	Completed
A Multi-centre Study to Evaluate the Effects of Valsartan and the Combination of Valsartan and Simvastatin on Blood Pressure (Ambulatory and Std Cuff) and on Biochemical Markers of Endothelial Function (hsCRP, MCP-1, Serum F2 Isoprostanes, PAI-1, tPA, PIC [NCT00385931]	Phase 3	412 participants (Actual)	Interventional	2002-01-31	Completed
[NCT01652339]	Phase 1	40 participants (Actual)	Interventional	2012-07-31	Completed
A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase Ⅲ Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hyper [NCT01918332]	Phase 3	168 participants (Actual)	Interventional	2012-04-30	Completed
A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction (AMI) [NCT02924727]	Phase 3	5,669 participants (Actual)	Interventional	2016-12-09	Completed
A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volu [NCT01735890]	Phase 1	48 participants (Actual)	Interventional	2012-09-30	Completed
A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension [NCT01692301]	Phase 2	454 participants (Actual)	Interventional	2012-12-31	Completed
A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatn and Valsartan Co-administration and Livalo Complex Product in Healthy Male Subjects [NCT01764178]	Phase 1	52 participants (Actual)	Interventional	2013-01-22	Completed
Clinical and Genetic Determinants of Disease Progression and Response to Lifestyle and Pharmacological Interventions in Patients With Hypertrophic Cardiomyopathy [NCT05366101]	Phase 2/Phase 3	168 participants (Actual)	Interventional	2019-04-01	Completed
Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, Four-Period Crossover Study in Healthy Egyptian Male Volunteers [NCT01767259]		24 participants (Actual)	Interventional	2012-10-31	Completed
Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, Four-Period Crossover Study in Healthy Egyptian Male Volunteers (PART II) [NCT01767298]		24 participants (Actual)	Interventional	2012-10-31	Completed
A Prospective, Randomised, Double-blind, Double-dummy Trial to Compare the Efficacy of Micardis® (Telmisartan) (80 mg p.o. Once Daily) and Valsartan (160 mg p.o. Once Daily) in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambul [NCT02242318]	Phase 4	440 participants (Actual)	Interventional	2001-09-30	Completed
[NCT01819220]	Phase 4	16 participants (Actual)	Interventional	2009-04-30	Completed
Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects [NCT01819779]	Phase 1	53 participants (Actual)	Interventional	2013-03-31	Completed
Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty [NCT04743063]		40,000 participants (Anticipated)	Observational	2021-01-14	Active, not recruiting
Contribution of Neuropeptide Y (NPY) to Vasoconstriction and Sympathetic Activation in the Setting of Dipeptidyl Peptidase IV (DPP4) Inhibition [NCT02639637]	Phase 4	18 participants (Actual)	Interventional	2015-12-31	Completed
A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients [NCT03686657]	Phase 1/Phase 2	115 participants (Anticipated)	Interventional	2023-10-10	Not yet recruiting
Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease [NCT05638880]	Phase 2	60 participants (Anticipated)	Interventional	2022-12-20	Recruiting
A Multicenter Study to Evaluate the Long-term Safety and Tolerability of Open-label LCZ696 in Patients With Acute Myocardial Infarction Who Previously Participated in CLCZ696G2301 (PARADISE-MI) [NCT04637555]	Phase 3	0 participants (Actual)	Interventional	2021-05-26	Withdrawn(stopped due to CLCZ696G2301E1 extension study did not start as the core study (CLCZ696G2301) did not meet the primary endpoint.)
A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age [NCT01447485]	Phase 1	12 participants (Actual)	Interventional	2011-08-31	Completed
Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation [NCT05528419]	Phase 4	300 participants (Anticipated)	Interventional	2023-02-06	Recruiting
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy [NCT00367562]	Phase 4	20 participants	Interventional	1996-01-31	Completed
Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril [NCT00657241]	Phase 3	30 participants (Actual)	Interventional	2008-04-30	Completed
Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan After Oral Administration Using 240 ml Non-caloric Water, a Carbohydrate Enriched Drink and Grapefruit Juice in Correlation to the Intestinal Availability of Water as Quantified by [NCT03012763]	Phase 1	9 participants (Actual)	Interventional	2016-04-30	Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF) [NCT05194111]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2022-03-09	Recruiting
Clinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic Cardiomyopathy [NCT03832660]	Phase 2	168 participants (Actual)	Interventional	2019-05-03	Completed
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combina [NCT00360178]	Phase 3	198 participants (Actual)	Interventional	2006-07-31	Completed
Add-on Effects of Valsartan on Morbi- Mortality in High Risk Hypertension [NCT00149227]	Phase 4	3,031 participants (Actual)	Interventional	2004-01-31	Completed
Prospective Comparison of Sacubitril/Valsartan Versus Valsartan on the Outcome of Heart Failure With Improved Ejection Fraction: a Pilot Study [NCT04803175]		100 participants (Anticipated)	Observational [Patient Registry]	2021-03-16	Recruiting
The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction [NCT05508035]	Phase 3	666 participants (Anticipated)	Interventional	2022-09-15	Not yet recruiting
A Multicenter, Prospective Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Patient With Essential Hypertension [NCT02415192]		2,001 participants (Anticipated)	Observational	2014-07-31	Recruiting
The Effects of Sacubitril/Valsartan Compared to Valsartan on Left Ventricular Remodelling in Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction: a Randomised, Double-blinded, Active-comparator, Cardiac-MR Based Trial [NCT03552575]	Phase 3	93 participants (Actual)	Interventional	2018-07-01	Completed
A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy. [NCT01928628]	Phase 3	449 participants (Actual)	Interventional	2012-05-31	Completed
Effect of Fully Blocking Type 1 Angiotensin Receptor on Blood Pressure, Cardiac Structure, Cardiac Function and Cognitive Function in Postmenopausal Hypertensive Women [NCT03432468]		102 participants (Anticipated)	Interventional	2018-04-01	Not yet recruiting
A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy [NCT00426348]	Phase 4	75 participants (Actual)	Interventional	2007-05-31	Completed
A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hype [NCT00425997]	Phase 4	480 participants (Anticipated)	Interventional	2006-12-31	Completed
An 8-week, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine in Patients With Moderate to Severe Hypertension. [NCT00327587]	Phase 3	2,279 participants (Actual)	Interventional	2006-05-31	Completed
Investigating the Effect of Renin-Angiotensin System Inhibitors in Addition to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Prospective Open-label Study [NCT04707508]	Phase 4	203 participants (Actual)	Interventional	2017-12-01	Completed
A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension [NCT01870739]	Phase 2	115 participants (Actual)	Interventional	2013-10-31	Completed
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction [NCT01920711]	Phase 3	4,822 participants (Actual)	Interventional	2014-07-18	Completed
Effect of Add-on of Amlodipine Versus Valsartan on Diastolic Dysfunction Associated With Hypertension [NCT02973035]	Phase 4	104 participants (Actual)	Interventional	2016-12-31	Completed
Real World Experience in HFrEF Patients Treated With sAc/vaL in ITaly [NCT05448872]		924 participants (Actual)	Observational	2020-11-23	Completed
Early Treatment of ARNI on Myocardial Remodeling and Progress in Patients With Post-AMI (EARLYmyo-CRPⅠ) [NCT04342351]	Phase 4	280 participants (Anticipated)	Interventional	2020-05-01	Not yet recruiting
An Multicenter Study to Evaluate the Efficacy and Safety of a 5 Week Therapy With the Combination of Valsartan 160 mg Plus Amlodipine 10 mg in Hypertensive Patients Not Adequately Responding to a 5 Week Therapy With Ramipril 5 mg and Felodipine 5 mg [NCT00367939]	Phase 3	132 participants (Actual)	Interventional	2005-12-31	Completed
Prospective Comparison of an ARNI With an ACE Inhibitor on enDOthelial Function by Brachial Artery Reactivity (PARADOR) [NCT03119623]	Phase 4	0 participants (Actual)	Interventional	2017-06-01	Withdrawn(stopped due to Lost funding prior to study commencing)
A Multi-center, Prospective Randomized Controlled Trial on the Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction [NCT04912167]	Phase 3	376 participants (Anticipated)	Interventional	2021-11-30	Not yet recruiting
Efficacy of a Combination of Amlodipine / Valsartan on Blood Pressure Control, With One Nocturnal or Diurnal Intake a Day, in Ambulatory Blood Pressure Monitoring Setting, in Essential Uncontrolled Hypertensive Patients With Amlodipine 5mg ; The ExPERT St [NCT00700271]	Phase 4	478 participants (Actual)	Interventional	2007-10-31	Completed
Effects and Safety of Sacubitril/Valsartan Versus Valsartan on Refractory Hypertension: The EOSORH Trial [NCT05545059]	Phase 3	138 participants (Anticipated)	Interventional	2022-09-24	Recruiting
A Prospective, Randomized, Open-Label, 13 to 14-week Study of the Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Subjects With Left Ventricular Hypertrophy (LVH) [NCT03180593]	Phase 4	30 participants (Actual)	Interventional	2017-02-07	Completed
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol [NCT02403349]	Phase 4	105 participants (Actual)	Interventional	2012-05-31	Active, not recruiting
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation [NCT05991284]	Phase 4	110 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI [NCT04149990]	Phase 2	100 participants (Anticipated)	Interventional	2018-10-12	Recruiting
A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension [NCT01681576]	Phase 2	72 participants (Actual)	Interventional	2012-08-31	Completed
Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients [NCT02606279]		1 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Change in study design and inability to recruit participants)
An Investigator-initiated, Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint Study to Assess the Effect of In-hospital Initiation of Sacubitril Valsartan on the NT-proBNP Concentrations in Patients Admitted Due to Acute Exacerbation of He [NCT05164653]	Phase 4	400 participants (Anticipated)	Interventional	2021-12-27	Active, not recruiting
Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA) [NCT02519010]	Phase 1	36 participants (Actual)	Interventional	2011-03-31	Completed
Improving Arterial Wall Characteristics in Patients After Myocardial Infarction With a Very Low Dose of Fluvastatin and Valsartan: Proof-of-concept Study [NCT03309618]		36 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension [NCT01672476]	Phase 3	293 participants (Actual)	Interventional	2012-04-30	Completed
The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF: A Randomized Controlled Trial [NCT05089539]	Phase 2	60 participants (Anticipated)	Interventional	2021-11-01	Not yet recruiting
A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data [NCT05096143]		42,269 participants (Actual)	Observational	2020-06-03	Completed
Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models [NCT05096039]		1,614,719 participants (Actual)	Observational	2020-04-10	Completed
Ambulatory 24-Hour Cardiac Oxygen Consumption and Blood Pressure-Heart Rate Variability: Effects of Nebivolol and Valsartan Alone and in Combination [NCT05170061]	Phase 3	26 participants (Actual)	Interventional	2013-02-28	Completed
Preventive Arterial Wall Phenotype in Subjects at Moderate Cardiovascular Risk Induced by Very Low-dose Fluvastatin/Valsartan Combination: a Pilot Study [NCT03393377]		20 participants (Actual)	Interventional	2014-09-30	Completed
PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure [NCT03387163]		402 participants (Actual)	Observational	2018-02-09	Completed
Efficacy and Safety of Single Pill Combination (Amlodipine/Valsartan) in Hypertensive Patients Not Controlled on Previous Monotherapy: An Observational Real Life Study [NCT03371797]		800 participants (Actual)	Observational	2018-02-20	Completed
A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in [NCT00097786]	Phase 3	9,306 participants (Actual)	Interventional	2002-01-31	Completed
A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge® (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients [NCT02062645]	Phase 4	115 participants (Actual)	Interventional	2014-02-28	Completed
Effect of Heart-Protecting Musk Pill on Diabetic Microangiopaemia in Type 2 Diabetes Patients [NCT05095922]	Phase 4	60 participants (Anticipated)	Interventional	2023-03-28	Recruiting
Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II [NCT05269615]	Phase 4	80 participants (Anticipated)	Interventional	2023-03-20	Recruiting
Bioequivalence Study of 160 mg Valsartan Film-coated Caplets Produced by PT Dexa Medica in Comparison With the Innovator Film-coated Tablets (Diovan® 160, Novartis Pharma AG) [NCT02518451]		48 participants (Actual)	Interventional	2013-06-30	Completed
A Randomized, Parallel Controlled Trial of Roxadustat Combined withSacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome [NCT05053893]		40 participants (Anticipated)	Interventional	2021-09-22	Recruiting
A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Without Chronic Kidney Disease, Followed by a 20 Week Open-labe [NCT01617681]	Phase 3	127 participants (Actual)	Interventional	2012-11-08	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00000620 (6) [back to overview]	Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]	First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]	Stroke in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]	First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]	First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00097786 (6) [back to overview]	Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide
NCT00097786 (6) [back to overview]	Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan
NCT00097786 (6) [back to overview]	Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide
NCT00097786 (6) [back to overview]	Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan
NCT00097786 (6) [back to overview]	Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan
NCT00097786 (6) [back to overview]	Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinide
NCT00149227 (10) [back to overview]	New Onset or Worsening of Diabetes Mellitus or IGT
NCT00149227 (10) [back to overview]	New Onset, Recurrence or Worsening of Arteriosclerosis Obliterans
NCT00149227 (10) [back to overview]	Transition to Dialysis, Doubling of Plasma Cr Levels
NCT00149227 (10) [back to overview]	New Onset or Recurrence of Transient Ischemic Attack
NCT00149227 (10) [back to overview]	New Onset or Recurrence of Acute Myocardial Infarction
NCT00149227 (10) [back to overview]	New Onset or Recurrence of Stroke
NCT00149227 (10) [back to overview]	Hospitalization Due to the New Onset, Occurrence or Worsening of Angina Pectoris and Additional Concomitant Use of Other Anti-anginal Agents or Increase of Dosage
NCT00149227 (10) [back to overview]	Hospitalization Due to the New Onset, Recurrence or Worsening of Heart Failure and Additional Concomitant Use of Other Anti-heart Failure Agents or Increase of Dosage
NCT00149227 (10) [back to overview]	All Cause Mortality
NCT00149227 (10) [back to overview]	New Onset of Acute Dissecting Aneurysm of the Aorta
NCT00171054 (13) [back to overview]	Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38
NCT00171054 (13) [back to overview]	Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)
NCT00171054 (13) [back to overview]	Changes in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38
NCT00171054 (13) [back to overview]	Changes in Mean Left Carotid Distensibility at Week 38
NCT00171054 (13) [back to overview]	Changes in Mean Right Carotid Distensibility at Week 12
NCT00171054 (13) [back to overview]	Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12
NCT00171054 (13) [back to overview]	Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12
NCT00171054 (13) [back to overview]	Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)
NCT00171054 (13) [back to overview]	Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12
NCT00171054 (13) [back to overview]	Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)
NCT00171054 (13) [back to overview]	Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38
NCT00171054 (13) [back to overview]	Changes in Mean Right Carotid Distensibility at Week 38
NCT00171054 (13) [back to overview]	Changes in Mean Left Carotid Distensibility at Week 12
NCT00208767 (1) [back to overview]	Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years
NCT00386607 (8) [back to overview]	Overall Percentage of Patients With Adverse Events
NCT00386607 (8) [back to overview]	Overall Percentage of Patients With Adverse Events
NCT00386607 (8) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure
NCT00386607 (8) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure
NCT00386607 (8) [back to overview]	Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg in Extension Treatment
NCT00386607 (8) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure.
NCT00386607 (8) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure.
NCT00386607 (8) [back to overview]	Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg
NCT00391846 (8) [back to overview]	Total Number of Titration Steps in Prescribed Heart Failure Treatment
NCT00391846 (8) [back to overview]	Number of Days in Hospital for CV Reason
NCT00391846 (8) [back to overview]	Number of CV Deaths
NCT00391846 (8) [back to overview]	Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)
NCT00391846 (8) [back to overview]	Changes in NT-proBNP Values Over Time in All Patients
NCT00391846 (8) [back to overview]	Changes in Heart Failure Symptoms
NCT00391846 (8) [back to overview]	Changes in Health-related Quality of Life
NCT00391846 (8) [back to overview]	Discontinuations
NCT00396656 (6) [back to overview]	Arterial Pressure Waveform Augmentation Index at the End of Treatment
NCT00396656 (6) [back to overview]	Difference in Mean Post-treatment Microcirculation at a Sodium Nitroprusside Injected Site Compared to NaCl Injected Sites
NCT00396656 (6) [back to overview]	Arterial Pressure Waveform Pulse Wave Velocity at the End of Treatment
NCT00396656 (6) [back to overview]	Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Injected Sites Compared to NaCl Injected Sites
NCT00396656 (6) [back to overview]	Difference in Mean Post-treatment Microcirculation at Acetylcholine (ACH) Plus L-NMMA Injected Sites Compared to NaCl Injected Sites
NCT00396656 (6) [back to overview]	Mean Post-treatment Microcirculation at NaCl Injected Sites
NCT00409578 (4) [back to overview]	Percentage of Patients With a Cardiac Event
NCT00409578 (4) [back to overview]	Percentage of Patients With a Composite Clinical-biochemical Event
NCT00409578 (4) [back to overview]	Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8
NCT00409578 (4) [back to overview]	Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 8
NCT00413049 (6) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
NCT00413049 (6) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
NCT00413049 (6) [back to overview]	Percentage of Patients Achieving a Diastolic Response at the End of the Study (Week 8)
NCT00413049 (6) [back to overview]	Percentage of Patients Achieving Diastolic Control at the End of the Study (Week 8)
NCT00413049 (6) [back to overview]	Percentage of Patients Achieving Overall Control at the End of the Study (Week 8)
NCT00413049 (6) [back to overview]	Change in 24-hour Mean Ambulatory Diastolic and Systolic BP From Baseline at the End of the Study (Week 8)
NCT00413413 (5) [back to overview]	Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)
NCT00413413 (5) [back to overview]	Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)
NCT00413413 (5) [back to overview]	Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)
NCT00413413 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
NCT00413413 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
NCT00425373 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)
NCT00425373 (5) [back to overview]	Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)
NCT00425373 (5) [back to overview]	Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)
NCT00425373 (5) [back to overview]	Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)
NCT00425373 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)
NCT00433836 (4) [back to overview]	Change From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients
NCT00433836 (4) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00433836 (4) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00433836 (4) [back to overview]	Decrease in MSSBP to < 95th Percentile for Age, Gender and Height
NCT00435162 (4) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)
NCT00435162 (4) [back to overview]	Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)
NCT00435162 (4) [back to overview]	Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)
NCT00435162 (4) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)
NCT00437645 (5) [back to overview]	Percentage of Patients Achieving a Systolic Response at Weeks 4, 8, and 12
NCT00437645 (5) [back to overview]	Change in Mean Sitting Systolic and Diastolic Blood Pressure (msSBP, msDBP) From Baseline to Weeks 4, 8, and 12
NCT00437645 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 8
NCT00437645 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 8
NCT00437645 (5) [back to overview]	Percentage of Patients With Peripheral Edema From Baseline to Week 8
NCT00439738 (7) [back to overview]	Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg)
NCT00439738 (7) [back to overview]	Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg)
NCT00439738 (7) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00439738 (7) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00439738 (7) [back to overview]	Change From Baseline in Postprandial Glucose
NCT00439738 (7) [back to overview]	Change From Baseline in Postprandial Insulin
NCT00439738 (7) [back to overview]	Change From Baseline in Postprandial Non-esterified Fatty Acids
NCT00446511 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26
NCT00446511 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26
NCT00446511 (5) [back to overview]	Number of Patients With Adverse Events
NCT00446511 (5) [back to overview]	Change From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20
NCT00446511 (5) [back to overview]	Percentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26
NCT00446563 (15) [back to overview]	Percentage of Participants Who Experienced Adverse Events (AEs)
NCT00446563 (15) [back to overview]	Percentage of Participants Achieving Target Blood Pressure at Week 52
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI
NCT00446563 (15) [back to overview]	Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)
NCT00446563 (15) [back to overview]	Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)
NCT00446563 (15) [back to overview]	Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)
NCT00446563 (15) [back to overview]	Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI
NCT00457626 (3) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00457626 (3) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00457626 (3) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00523549 (7) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00523549 (7) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00523549 (7) [back to overview]	Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity
NCT00523549 (7) [back to overview]	Change in Lateral Mitral Annular Myocardial Relaxation Velocity
NCT00523549 (7) [back to overview]	Change in Left Atrial Size
NCT00523549 (7) [back to overview]	Change in Estimated Central Aortic Pressure
NCT00523549 (7) [back to overview]	Percent Change From Baseline in Vascular Stiffness
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Rate During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Rate During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Pressure During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Pressure During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
NCT00546754 (13) [back to overview]	Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 12
NCT00546754 (13) [back to overview]	Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Systolic Blood Pressure From Baseline to Week 12
NCT00546754 (13) [back to overview]	Change in Uric Acid From Baseline to Week 12
NCT00546754 (13) [back to overview]	Change in Systolic Blood Pressure From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 12
NCT00546754 (13) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Week 12
NCT00546754 (13) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 6
NCT00546754 (13) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 12
NCT00546754 (13) [back to overview]	Time to Achieve Target Blood Pressure
NCT00546754 (13) [back to overview]	Change in Uric Acid From Baseline to Week 6
NCT00546754 (13) [back to overview]	Change in Diastolic Blood Pressure From Baseline to Week 6
NCT00549770 (9) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT00549770 (9) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT00549770 (9) [back to overview]	Change From Baseline in Nighttime maDBP and maSBP
NCT00549770 (9) [back to overview]	Change From Baseline in Daytime maDBP and maSBP
NCT00549770 (9) [back to overview]	Change From Baseline in 24-hour Mean Ambulatory DBP (maDBP) and maSBP
NCT00549770 (9) [back to overview]	Percentage of Participants Who Achieved Successful Control in msSBP
NCT00549770 (9) [back to overview]	Percentage of Participants Who Achieved Successful Control in msDBP
NCT00549770 (9) [back to overview]	Percentage of Participants Who Achieved a Successful Response in msSBP
NCT00549770 (9) [back to overview]	Percentage of Participants Who Achieved a Successful Response in msDBP
NCT00591578 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg.
NCT00591578 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg.
NCT00591578 (15) [back to overview]	Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.
NCT00591578 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
NCT00591578 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
NCT00591578 (15) [back to overview]	Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00591578 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00657241 (6) [back to overview]	Central Systolic Blood Pressure
NCT00657241 (6) [back to overview]	Difference in Resting CTTI Between Carvedilol CR (Beta-blocker) and Valsartan (ARB) in Combination With Lisinopril.
NCT00657241 (6) [back to overview]	Heart Rate (Beats/Min)
NCT00657241 (6) [back to overview]	Stroke Volume (SV)
NCT00657241 (6) [back to overview]	Systemic Vascular Resistance
NCT00657241 (6) [back to overview]	Cardiac Output
NCT00661895 (1) [back to overview]	Percentage of Subjects Achieving Blood Pressure Goals
NCT00666536 (6) [back to overview]	Percentage of Patients Achieving BP Goal of MSSBP < 140mmHg at Weeks 2, 4, 8 and 12
NCT00666536 (6) [back to overview]	Percentage of Patients Achieving the Blood Pressure (BP) Goal of < 140/90 mmHg at Weeks 2,4,8 and 12
NCT00666536 (6) [back to overview]	Change From Baseline to Week 4 in Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00666536 (6) [back to overview]	Change From Baseline to Week 4 in Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00666536 (6) [back to overview]	Change From Baseline to Weeks 2, 8 and 12 in MSDBP
NCT00666536 (6) [back to overview]	Change From Baseline to Weeks 2, 8 and 12 in MSSBP
NCT00687973 (11) [back to overview]	Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)
NCT00687973 (11) [back to overview]	Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)
NCT00687973 (11) [back to overview]	Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)
NCT00687973 (11) [back to overview]	Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)
NCT00687973 (11) [back to overview]	Change From Baseline of Pulse Pressure at Week 24 (Office BP)
NCT00687973 (11) [back to overview]	Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)
NCT00687973 (11) [back to overview]	Change From Baseline of SBP/DBP at Week 24 (Office BP)
NCT00687973 (11) [back to overview]	Change From Baseline of Aix at Week 24
NCT00687973 (11) [back to overview]	Change From Baseline of Aix Corrected to Heart Rate at Week 24
NCT00687973 (11) [back to overview]	Change From Baseline of Augmentation Index (Aix) at Week 8
NCT00687973 (11) [back to overview]	Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)
NCT00696436 (15) [back to overview]	Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
NCT00696436 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
NCT00696436 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
NCT00696436 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.
NCT00696436 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
NCT00696436 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696436 (15) [back to overview]	Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00698646 (6) [back to overview]	Time in Weeks to Achieving the First Treatment Success (Defined as the Time of the First Achievement of the Target Blood Pressure Goal [MSSBP/MSDBP <140/90 mmHg])
NCT00698646 (6) [back to overview]	Change From Baseline to Week 4 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00698646 (6) [back to overview]	Change From Baseline to Week 4, 8, 12 and 16 in Office Cuff Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00698646 (6) [back to overview]	Change From Baseline to Weeks 8, 12 and 16 in Office Cuff Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00698646 (6) [back to overview]	Cumulative Percentage of Patients Achieving Blood Pressure Goal (MSSBP < 140 mmHg)
NCT00698646 (6) [back to overview]	Cumulative Percentage of Patients Achieving the Blood Pressure Control of < 140/90 mmHg
NCT00699192 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
NCT00699192 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
NCT00699192 (5) [back to overview]	Percentage of Patients Achieving a Systolic Blood Pressure Response at Week 8
NCT00699192 (5) [back to overview]	Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)
NCT00699192 (5) [back to overview]	Percentage of Patients Achieving Systolic Blood Pressure Control at the End of the Study (Week 8)
NCT00700271 (11) [back to overview]	Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) Variation Between Week 0 and Week 8 in Office Blood Pressure
NCT00700271 (11) [back to overview]	Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) Variation Between Week -4 to Week 8 in Office Blood Pressure
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in Nocturnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in Diurnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in 6-hour Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Percentage of Participants With Nocturnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 120/70 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Percentage of Participants With Diurnal Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 135/85 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Percentage of Participants With 24-hour Mean Systolic Blood Pressure (SBP)/Diastolic Blood Pressure (DBP) < 125/80 mmHg at Endpoint With Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in 24-hour Mean Systolic Blood Pressure (SBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Absolute Reduction From Baseline in 24-hour Mean Diastolic Blood Pressure (DBP) on Ambulatory Blood Pressure Monitoring
NCT00700271 (11) [back to overview]	Percentage of Participants With Controlled Office Mean Seated Systolic Blood Pressure (msSBP)/Mean Seated Diastolic Blood Pressure (msDBP) at Endpoint
NCT00732069 (2) [back to overview]	Interleukin 1 Beta
NCT00732069 (2) [back to overview]	F2-Isoprostanes
NCT00809926 (10) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8
NCT00809926 (10) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
NCT00809926 (10) [back to overview]	Completers Analysis for Change From Baseline in MSSBP at Week 8
NCT00809926 (10) [back to overview]	Mean Change From Baseline in Plasma Renin Activity (PRA) at Week 8
NCT00809926 (10) [back to overview]	Longitudinal Repeated Measure Analysis for Change in MSSBP From Baseline Through Week 8
NCT00809926 (10) [back to overview]	Mean Change From Baseline in Plasma Renin Concentration (PRC) at Week 8
NCT00809926 (10) [back to overview]	Percentage of Patients Achieving Blood Pressure Control (Defined as Patients Achieving a MSSBP <140 mmHg and MSDBP <90 mmHg) at Week 8
NCT00809926 (10) [back to overview]	Percentage of Responders (Defined as Patients With MSSBP <140 mmHg or a Decrease From Baseline ≥20 mmHg) at Week 8
NCT00809926 (10) [back to overview]	Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (MADBP)
NCT00809926 (10) [back to overview]	Change From Baseline in Mean Ambulatory Systolic Blood Pressure (MASBP).
NCT00819767 (3) [back to overview]	Change in Resting vs. Peak Heart Rate Systolic Blood Pressure (SBP) From Week 8 (End of Active Treatment) to 24-hours After a Missed Dose
NCT00819767 (3) [back to overview]	Change in Resting vs. Peak Heart Rate Systolic Blood Pressure (SBP) From Baseline to Week 8 After a Missed Dose
NCT00819767 (3) [back to overview]	Change in Resting vs. Peak Heart Rate Systolic Blood Pressure (SBP) From Baseline to Week 8
NCT00887588 (24) [back to overview]	Change From Baseline in Arterial Stiffness Parameters: Brachial Systolic Blood Pressure (SBP), Brachial Diastolic Blood Pressure (DBP), Central Augmentation Pressure, Central Pressure at T1-DP, Central SBP, Central DBP, Central Mean Pressure
NCT00887588 (24) [back to overview]	Change From Baseline in Albumin/Creatinine Ratio
NCT00887588 (24) [back to overview]	Change From Baseline in Arterial Stiffness Parameters: Heart Rate
NCT00887588 (24) [back to overview]	Change From Baseline in Arterial Stiffness Parameters: Heart Rate Correct Cen Aug/Pulse Ht
NCT00887588 (24) [back to overview]	Change From Baseline in Arterial Stiffness Parameters: Pulse Wave Velocity
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography Parameters: Left Atrial Volume Index
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography Parameters: Left Ventricular Ejection Fraction
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography Parameters: Left Ventricular Mass
NCT00887588 (24) [back to overview]	Percentage of Participants With New York Heart Association (NYHA) Class I, II, II or IV
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography Parameters: LVE Diastolic Volume, LVE Systolic Volume, Left Ventricular Stroke Volume, Left Atrial Volume
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography Parameters: Ratio of E to A Velocity, E/e' Ratio
NCT00887588 (24) [back to overview]	Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score and Individual Domain Summary Scores
NCT00887588 (24) [back to overview]	Change From Baseline in NT-proBNP and Brain Natriuretic Peptide (BNP)
NCT00887588 (24) [back to overview]	Change From Baseline in Sitting SBP, Sitting DBP and Sitting Pulse Pressure (PP)
NCT00887588 (24) [back to overview]	Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography Parameters: Left Ventricular Mass Index
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography Parameters: Tricuspid Regurgitation Velocity
NCT00887588 (24) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
NCT00887588 (24) [back to overview]	Percentage of Participants With Clinical Composite Assessment of Improved, Unchanged or Worsened
NCT00887588 (24) [back to overview]	Change From Baseline in Plasma Cyclic Guanine Monophosphate (cGMP)
NCT00887588 (24) [back to overview]	Change From Baseline in Serum Creatinine
NCT00887588 (24) [back to overview]	Change in Echocardiography Parameters: Isovolumic Relaxation Time
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography (ECHO) Parameters: Left Ventricular End (LVE) Diastolic Diameter, LVE Systolic Diameter, Septal End Diastolic Thickness, Posterior LV Wall End Diastolic Thickness, Relative Wall Thickness, Left Atrial Dimension
NCT00887588 (24) [back to overview]	Change From Baseline in Echocardiography Parameters: Ewave Velocity, A Wave Velocity, e' at Septal Mitral Annulus, e' at Lateral Mitral Annulus
NCT00902304 (12) [back to overview]	Number of Patients With Major Clinical Endpoints
NCT00902304 (12) [back to overview]	Number of Patients With Depression
NCT00902304 (12) [back to overview]	Participants With End Organ Disease at Baseline and Week 26
NCT00902304 (12) [back to overview]	Number of 'Early Responder' Patients Who Achieve Individualized Blood Pressure Control After 1 or 2 Adjustments
NCT00902304 (12) [back to overview]	Change in Self-care Behavior Score From Baseline to Week 26
NCT00902304 (12) [back to overview]	Percentage of Patients Who Have Achieved Their Pre-specified (Individualized National Heart Foundation of Australia Criteria) Blood Pressure (BP) Target
NCT00902304 (12) [back to overview]	Change in the EQ-5D Score
NCT00902304 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure
NCT00902304 (12) [back to overview]	Change in Absolute Cardiovascular Risk Score
NCT00902304 (12) [back to overview]	Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline to Week 26
NCT00902304 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure
NCT00902304 (12) [back to overview]	Number of Patients With at Least One Adverse Events Attributable to Anti-hypertensive Therapy
NCT00922441 (1) [back to overview]	Mean Change of Diastolic Blood Pressure
NCT00927394 (12) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (MADBP) at Week 8
NCT00927394 (12) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure (MASBP) at Week 8
NCT00927394 (12) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00927394 (12) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (MAPP) at Week 8
NCT00927394 (12) [back to overview]	Change From Baseline in Mean Sitting Pulse Pressure (MSPP) at Week 8
NCT00927394 (12) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00927394 (12) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events and Death
NCT00927394 (12) [back to overview]	Percentage of Responders
NCT00927394 (12) [back to overview]	Change From Baseline in Plasma Aldosterone at Week 8
NCT00927394 (12) [back to overview]	Percentage of Patients Achieving Blood Pressure Control
NCT00927394 (12) [back to overview]	Change From Baseline in Plasma Renin Concentration (PRC) at Week 8
NCT00927394 (12) [back to overview]	Change From Baseline in Plasma Renin Activity (PRA) at Week 8
NCT00931710 (6) [back to overview]	Change in Mean Sitting Systolic Blood Pressure After 6 Weeks
NCT00931710 (6) [back to overview]	Cumulative Percentage of Patients Achieving Blood Pressure Control
NCT00931710 (6) [back to overview]	Cumulative Percentage of Treatment Responders
NCT00931710 (6) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure After 6 Weeks
NCT00931710 (6) [back to overview]	Change in Mean Sitting Systolic and Diastolic Blood Pressure After 12 Weeks
NCT00931710 (6) [back to overview]	Cumulative Percentage of Patients With Incidence of Peripheral Edema Before or at the Corresponding Visit
NCT01001572 (5) [back to overview]	Percentage of Participants With Overall Blood Pressure Control at 8 Week Endpoint
NCT01001572 (5) [back to overview]	Percentage of Participants With Diastolic Blood Pressure Control at 8 Week Endpoint
NCT01001572 (5) [back to overview]	Percentage of Participants With a Diastolic Blood Pressure Response at 8 Week Endpoint
NCT01001572 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to Week 8 Endpoint
NCT01001572 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to Week 8 Endpoint
NCT01030458 (4) [back to overview]	Proportion of Patients Reaching Blood Pressure Control at the End of Follow-up
NCT01030458 (4) [back to overview]	Side-effects to Study Medications
NCT01030458 (4) [back to overview]	Sitting Systolic Blood Pressure on Automated Measurement
NCT01030458 (4) [back to overview]	Time to Blood Pressure Control
NCT01070043 (5) [back to overview]	Change From Baseline in Mean Systolic Blood Pressure (mSBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours
NCT01070043 (5) [back to overview]	Change From Baseline in Mean Diastolic Blood Pressure (mDBP) From Ambulatory Blood Pressure Measurement (ABPM) Over 24 Hours After 8 Weeks of Treatment During the Double-blind Phase
NCT01070043 (5) [back to overview]	Number of Participants With Adverse Events During Double-blind Phase
NCT01070043 (5) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) From Office Blood Pressure Measurement
NCT01070043 (5) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) From Office Blood Pressure Measurement
NCT01129557 (12) [back to overview]	Cumulative Incidence of Aldosterone Breakthrough in Subjects Who Completed the 9-month Study Protocol.
NCT01129557 (12) [back to overview]	Mean 24-hour Urine Sodium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Pre- and Post-treatment 24-hour Urine Protein in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Pre- and Post-treatment 24-hour Urine Sodium in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Pre- and Post-treatment 24-urine Aldosterone in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Pre- and Post-treatment Serum Aldosterone in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Pre- and Post-treatment Serum Creatinine in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Pre- and Post-treatment Serum Potassium in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Serum Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Serum Potassium Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Urine Aldosterone Over Time During 9-month Treatment Course in Subjects With and Without Aldosterone Breakthrough.
NCT01129557 (12) [back to overview]	Pre- and Post-treatment Blood Pressure in Subjects With and Without Aldosterone Breakthrough.
NCT01167153 (7) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks)
NCT01167153 (7) [back to overview]	Change From Baseline in Orthostatic Pulse at 12 Weeks
NCT01167153 (7) [back to overview]	Percentage of Patients in Whom Blood Pressure Target Was Achieved at the Study End Point at 12 Weeks
NCT01167153 (7) [back to overview]	Change From Baseline in Orthostatic SBP and DBP at 12 Weeks
NCT01167153 (7) [back to overview]	Percentage of Patients With Effective Systolic Blood Pressure (SBP) Control Rate and Effective Diastolic Blood Pressure (DBP) Control Rate at the Study End Point (12 Weeks)
NCT01167153 (7) [back to overview]	Change From Baseline in Sitting Pulse at 12 Weeks
NCT01167153 (7) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at the Study End Point (12 Weeks)
NCT01252238 (3) [back to overview]	Pulse Wave Velocity
NCT01252238 (3) [back to overview]	Aortic Compliance
NCT01252238 (3) [back to overview]	Change in Insulin Sensitivity by HOMA at 12 Weeks
NCT01281306 (15) [back to overview]	Change From Baseline in Nighttime maSBP and maDBP
NCT01281306 (15) [back to overview]	Change From Baseline in Mean Ambulatory Pulse Pressure
NCT01281306 (15) [back to overview]	Change From Baseline in Mean Diastolic Blood Pressure (msDBP)
NCT01281306 (15) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events and Death
NCT01281306 (15) [back to overview]	Number of Participants Who Achieved Blood Pressure Control and Blood Pressure Response
NCT01281306 (15) [back to overview]	Change From Baseline in msSBP and msDBP in Participants >= 65 Years of Age
NCT01281306 (15) [back to overview]	Change From Baseline in msSBP and msDBP in Participants < 65 Years of Age
NCT01281306 (15) [back to overview]	Change From Baseline in Mean 24 Hour Ambulatory SBP (maSBP) and Mean 24 Hour Ambulatory DBP (maDBP)
NCT01281306 (15) [back to overview]	Change From Baseline in maSBP and maDBP in Participants >= 65 Years of Age
NCT01281306 (15) [back to overview]	Change From Baseline in maSBP and maDBP in Participants < 65 Years of Age
NCT01281306 (15) [back to overview]	Change From Baseline in maSBP and maDBP in Non-dippers
NCT01281306 (15) [back to overview]	Change From Baseline in maSBP and maDBP in Dippers
NCT01281306 (15) [back to overview]	Change From Baseline in Daytime maSBP and maDBP
NCT01281306 (15) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01281306 (15) [back to overview]	Change From Baseline in Mean Sitting Pulse Pressure
NCT01353508 (19) [back to overview]	Percent Change From Baseline in Aldosterone Biomarker
NCT01353508 (19) [back to overview]	Glomerular Filtration Rate (GFR) Over Time
NCT01353508 (19) [back to overview]	Cumulative 7-day Urinary Sodium Excretion
NCT01353508 (19) [back to overview]	7-day Cumulative Diuresis
NCT01353508 (19) [back to overview]	24-hour Urinary Sodium Excretion
NCT01353508 (19) [back to overview]	Supine Pulse Rate
NCT01353508 (19) [back to overview]	24-hour Diuresis
NCT01353508 (19) [back to overview]	Supine Systolic Blood Pressure
NCT01353508 (19) [back to overview]	Urinary Cyclic Guanosine Monophosphate (cGMP) Excretion Over 24 Hours
NCT01353508 (19) [back to overview]	Percent Change From Baseline in Brain Natriuretic Peptide (BNP) Biomarker
NCT01353508 (19) [back to overview]	Percent Change From Baseline in C-terminal-proendothelin-1 (CT-proET-1) Biomarker
NCT01353508 (19) [back to overview]	Renal Blood Flow (RBF) Over Time
NCT01353508 (19) [back to overview]	Percent Change From Baseline in C-type Natriuretic Peptide (proCNP) Biomarker
NCT01353508 (19) [back to overview]	Percent Change From Baseline in Mid-regional Pro-adrenomedullin (MR-proADM) Biomarker
NCT01353508 (19) [back to overview]	Percent Change From Baseline in N-terminal-proBNP (NT-proBNP) Biomarker
NCT01353508 (19) [back to overview]	Percent Change From Baseline in Plasma Mid-regional Pro-atrial Natriuretic Peptide (MR-proANP) Biomarker
NCT01353508 (19) [back to overview]	Percent Change From Baseline in Urinary Electrolyte Excretion (Sodium, Potassium, Chloride and Calcium)
NCT01353508 (19) [back to overview]	Supine Diastolic Blood Pressure
NCT01353508 (19) [back to overview]	Percent Change From Baseline in Blood Plasma Creatinine
NCT01365481 (5) [back to overview]	Percentage of Chronic Kidney Disease (CKD) Patients Who Had >=50% Reduction in Urine Albumin/Creatinine Ratio (UACR) From Baseline to End Point
NCT01365481 (5) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)
NCT01365481 (5) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MsDBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF)
NCT01365481 (5) [back to overview]	Number of Participants With MSSBP, MSDBP and (MSSBP and MSDBP Combined) < 95th Percentile for Gender, Age, and Height
NCT01365481 (5) [back to overview]	Percentage of Chronic Kidney Disease (CKD) Patients Who Had Estimated Glomerular Filtration Rate (eGFR) Decrease > 25 % From Baselinefrom Baseline to End Point
NCT01617681 (4) [back to overview]	Patients Achieving <90th Percentile for Age, Gender and Height at Week 6 Endpoint in Both MSBP and MDBP
NCT01617681 (4) [back to overview]	CKD Patients Achieving Urine Albumin Creatinine Ratio Percentage Reduction (UACR) >=25% at Week 6
NCT01617681 (4) [back to overview]	Change From Baseline in Mean Diastolic Blood Pressure (MDBP) at Week 6
NCT01617681 (4) [back to overview]	Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint
NCT01681576 (5) [back to overview]	Cumulative Sodium Excretion (Natriuresis) at Day 1
NCT01681576 (5) [back to overview]	Cumulative Sodium Excretion (Natriuresis) at Day 28
NCT01681576 (5) [back to overview]	Seated Office Blood Pressure (BP) (Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)) Over Time
NCT01681576 (5) [back to overview]	Urine Volume (Diuresis) Over Time
NCT01681576 (5) [back to overview]	Mean Sitting Pulse Pressure (PP) Over Time
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Pulse Wave Velocity (PWV)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Pulse (CPP) Pressure
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Arterial Pressure (MAP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Pulse Pressure (msPP)
NCT01870739 (10) [back to overview]	Change From Baseline in Local Aortic Strain at 52 Weeks
NCT01870739 (10) [back to overview]	Number of Patients With Reported Adverse Events, Serious Adverse Events and Death
NCT01870739 (10) [back to overview]	Change From Baseline in Augmentation Pressure at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Ascending Aorta Distensibility at 52 Week
NCT01870739 (10) [back to overview]	Change From Baseline in Augmentation Index at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Carotid-femoral Pulse Wave Velocity at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Distal Descending Aorta Distensibility at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Proximal Descending Aorta Distensibility at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Regional Aortic Pulse Wave Velocity at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Central Blood Pressure at 52 Weeks
NCT01918332 (2) [back to overview]	sitDBP Changes at Week 8 From Baseline
NCT01918332 (2) [back to overview]	LDL-C Percentage Changes at Week 8 From Baseline
NCT01920711 (5) [back to overview]	Participants With First Occurrence of a Composite Renal Endpoint
NCT01920711 (5) [back to overview]	Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations.
NCT01920711 (5) [back to overview]	All-cause Mortality
NCT01920711 (5) [back to overview]	Change From Baseline to Month 8 in New York Heart Association (NYHA) Functional Class
NCT01920711 (5) [back to overview]	Change in the Clinical Summary Score From Baseline to Month 8 by Kansas City Cardiomyopathy Questionnaire (KCCQ)
NCT02062645 (5) [back to overview]	Diastolic Blood Pressure (DBP) at Baseline, Week 4 and 8
NCT02062645 (5) [back to overview]	Systolic Blood Pressure (SBP) at Baseline, Week 4 and 8
NCT02062645 (5) [back to overview]	Percentage of Participants With Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
NCT02062645 (5) [back to overview]	Percentage of Participants With High Sodium Intake and Blood Pressure (BP) <140/90 mmHg at Week 4 and 8
NCT02062645 (5) [back to overview]	SBP and DBP in Patients With High Sodium Intake at Week 4 and 8
NCT02480764 (7) [back to overview]	Percentage of Participants Who Achieved Target Clinic SBP <130 mm Hg, Target Clinic DBP <80 mm Hg or Both at Week 8
NCT02480764 (7) [back to overview]	Percentage of Participants Who Achieved a Clinic SBP Response at Week 8
NCT02480764 (7) [back to overview]	Percentage of Participants Who Achieved a Clinic DBP Response at Week 8
NCT02480764 (7) [back to overview]	Percentage of Participants Who Achieved Target Clinic SBP <140 mm Hg, Clinic DBP <90 mm Hg or Both at Week 8
NCT02480764 (7) [back to overview]	Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure (DBP)
NCT02480764 (7) [back to overview]	Percentage of Participants Who Achieved Both Clinic SBP and DBP Response at Week 8
NCT02480764 (7) [back to overview]	Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure (SBP)
NCT02554890 (9) [back to overview]	Change From Baseline in High Sensitivity Troponin (Hs-Troponin)
NCT02554890 (9) [back to overview]	Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio
NCT02554890 (9) [back to overview]	N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8
NCT02554890 (9) [back to overview]	N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline
NCT02554890 (9) [back to overview]	Number of Patients With Incidences of Angioedema
NCT02554890 (9) [back to overview]	Number of Patients With Incidences of Hyperkalemia
NCT02554890 (9) [back to overview]	Change From Baseline in Urinary cGMP
NCT02554890 (9) [back to overview]	Number of Patients With Incidences of Symptomatic Hypotension
NCT02554890 (9) [back to overview]	Change From Baseline in BNP to NTproBNP Ratio
NCT02639637 (13) [back to overview]	Mean Arterial Pressure
NCT02639637 (13) [back to overview]	NPY Metabolites
NCT02639637 (13) [back to overview]	Insulin
NCT02639637 (13) [back to overview]	Venous Norepinephrine
NCT02639637 (13) [back to overview]	Venous tPA
NCT02639637 (13) [back to overview]	Glucose
NCT02639637 (13) [back to overview]	Forearm Blood Flow
NCT02639637 (13) [back to overview]	Arterial Norepinephrine
NCT02639637 (13) [back to overview]	DPP4 Activity
NCT02639637 (13) [back to overview]	Arterial tPA
NCT02639637 (13) [back to overview]	Heart Rate
NCT02639637 (13) [back to overview]	ACE Activity
NCT02639637 (13) [back to overview]	Low Frequency Variability of Blood Pressure Activity
NCT02690974 (8) [back to overview]	Percentage of Participants on LCZ696 200 mg Bid at Month 12
NCT02690974 (8) [back to overview]	Median Time to Reach LCZ696 200 mg
NCT02690974 (8) [back to overview]	Time to Each Up-titration to LCZ696 100 mg and LCZ696 200 mg
NCT02690974 (8) [back to overview]	Percentage of Participants With Down-titration Changes From LCZ696 200 mg During 12 Months of Treatment
NCT02690974 (8) [back to overview]	Percentage of Participants on Guideline Recommended Dose of Beta-blockers and MRAs Over Time
NCT02690974 (8) [back to overview]	Change From Baseline in the Six Minute Walk Test (6MWT) at Month 6 and Month 12
NCT02690974 (8) [back to overview]	Percentage of Participants Requiring Down-titration From LCZ696 200 mg
NCT02690974 (8) [back to overview]	Percentage of Participants on LCZ696 200 mg Bid at Month 6
NCT02754518 (35) [back to overview]	Change From Baseline in RV Remodeling Free-Wall Curvature (%)
NCT02754518 (35) [back to overview]	Change From Baseline in RV Remodeling Septal Curvature (%)
NCT02754518 (35) [back to overview]	Change From Baseline in RV Remodeling Tricuspid Regurgitation
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling 2D End-Diastolic Diameter (cm)
NCT02754518 (35) [back to overview]	Change From Baseline in (MIBG) Early hm Ratio
NCT02754518 (35) [back to overview]	Change From Baseline in (MIBG) Late hm Ratio
NCT02754518 (35) [back to overview]	Change From Baseline in Blood Pressure - Diastolic (mmHg)
NCT02754518 (35) [back to overview]	Change From Baseline in Blood Pressure - Systolic (mmHg)
NCT02754518 (35) [back to overview]	Change From Baseline in Exercise Performance - 6 Minute Walk
NCT02754518 (35) [back to overview]	Change From Baseline in Exercise Performance - CPX - Peak RER
NCT02754518 (35) [back to overview]	Change From Baseline in Exercise Performance - CPX - Peak VO2 (mL/kg/Min)
NCT02754518 (35) [back to overview]	Change From Baseline in Exercise Performance - CPX - VE/VC02
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Clinical Summary
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Overall Summary
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Physical Limitation
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Quality of Life Score
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Social Limitation
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Symptom Burden
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Symptom Frequency
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Symptom Stability
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Total Symptom
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling 2D End-Systolic Diameter (cm)
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling 3D End-Diastolic Volume (mL)
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling 3D End-Systolic Volume (mL)
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling Conicity (%)
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling Global Longitudinal Strain (%)
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling Left Atrial Volume (mL)
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling LV Ejection Fraction (%)
NCT02754518 (35) [back to overview]	Change From Baseline in LV Remodeling Sphericity (%)
NCT02754518 (35) [back to overview]	Change From Baseline in NT-proBNP Levels
NCT02754518 (35) [back to overview]	Change From Baseline in Rho-associated Protein Kinase (ROCK)
NCT02754518 (35) [back to overview]	Change From Baseline in RV Remodeling Ejection Fraction (%)
NCT02754518 (35) [back to overview]	Change From Baseline in RV Remodeling End Systolic Volume (mL)
NCT02754518 (35) [back to overview]	Change From Baseline in RV Remodeling End-Diastolic Volume (mL)
NCT02754518 (35) [back to overview]	Change From Baseline in KCCQ - Self Efficacy
NCT02788656 (6) [back to overview]	Change in NT-proBNP
NCT02788656 (6) [back to overview]	The Difference Between Mean Change in PAPm From Baseline on Sacubitril/Valsartan Compared to ACEI/ARB
NCT02788656 (6) [back to overview]	The Acute Change in PAPm After the First Administration of Sacubitril/Valsartan
NCT02788656 (6) [back to overview]	Mean Change in PAPm in Both Groups on Sacubitril/Valsartan
NCT02788656 (6) [back to overview]	Difference Between Mean Change in Mean Pulmonary Artery Pressure (PAPm) With Sacubitril/Valsartan Compared to the Mean Change in PAPm With Continued ACEi/ARB
NCT02788656 (6) [back to overview]	Determine the Change in Distance Walked During a Standard 6 Minute Walk Test From Baseline
NCT02816736 (2) [back to overview]	Composite Endpoint of the Effects of LCZ696 (Number of Days)
NCT02816736 (2) [back to overview]	Change in NT-proBNP
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Left Ventricular Ejection Fraction (LVEF)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Left Ventricular End Diastolic Volume Index (LVEDVi)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Left Ventricular End Systolic Volume Index (LVESVi)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Mitral Annular E' Velocity (Doppler Tissue Imaging)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Ventricular-vascular Coupling (Ea/Ees)
NCT02874794 (12) [back to overview]	Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
NCT02874794 (12) [back to overview]	Pearson Correlation Coefficient Between Change From Baseline in Aortic Characteristic Impedance and Biomarker Levels: B-type Natriuretic Peptide (BNP) During Both Trough and 4 Hours Post-dose at Week 4
NCT02874794 (12) [back to overview]	Pearson Correlation Coefficient Between Change From Baseline in Aortic Characteristic Impedance and Biomarker Levels: cGMP/U-creatinine During Both Trough and 4 Hours Post-dose at Week 4
NCT02874794 (12) [back to overview]	Change From Basekine in Echocardiographic Measure: Mitral E/E'
NCT02874794 (12) [back to overview]	Change From Baseline in Aortic Characteristic Impedance at Week 12
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Global Longitudinal Strain
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Left Atrial Volume Index (LAVi)
NCT02887183 (10) [back to overview]	Change in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to One Year
NCT02887183 (10) [back to overview]	Change in Log-transformed NT-proBNP Concentration and Change in Echocardiographic Measurements LVESVi, LVEDVi, LAVi, and LVEF From Baseline to Month 6
NCT02887183 (10) [back to overview]	Change in Log-transformed NT-proBNP and Change in Structural Cardiac Measurements LVESVi, LVEDVi, LAVi, and LVEF From Baseline to One Year
NCT02887183 (10) [back to overview]	Change From Baseline in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) and Change in Left Ventricular Ejection Fraction (LVEF) by Selected Groups of Interest at Month 6
NCT02887183 (10) [back to overview]	Change From Baseline in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) and Change in Change in Left Atrial Volume Index (LAVi) by Selected Groups of Interest at Month 6
NCT02887183 (10) [back to overview]	Mean Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ-23) Clinical Summary Score From Baseline to Month 12
NCT02887183 (10) [back to overview]	Change in Left Atrial Volume Index (LAVi), Left Ventricular End Diastolic Volume Index (LVEDVi), Left Ventricular End Systolic Volume Index (LVESVi), and From Baseline to One Year
NCT02887183 (10) [back to overview]	Change From Baseline in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) and Change in Left Ventricular End Systolic Volume Index (LVESVi) by Selected Groups of Interest at Month 6
NCT02887183 (10) [back to overview]	Change From Baseline in Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) and Change in Left Ventricular End Diastolic Volume Index (LVEDVi) by Selected Groups of Interest at Month 6
NCT02887183 (10) [back to overview]	Change in Left Ventricular Ejection Fraction (LVEF) From Baseline to One Year
NCT02900378 (13) [back to overview]	Number and Percentage of Participants With Improved Symptoms of Heart Failure as Assessed by Patient Global Assessment (PGA)
NCT02900378 (13) [back to overview]	Total Weekly Time Spent in Moderate-to-Vigorous Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Total Weekly Time Spent in Light Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Change From Baseline in Peak Six Minutes of Daytime Physical Activity
NCT02900378 (13) [back to overview]	Change From Baseline (Week 0) in Mean Daily Non-sedentary Daytime Activity at End of Study (Week 12)
NCT02900378 (13) [back to overview]	Change From Baseline (Week 0) in the Six Minute Walk Test (6MWT) at End of Study (Week 12)
NCT02900378 (13) [back to overview]	Change From Baseline (Week 0) in the Six Minute Walk Test (6MWT) at Weeks 4 and 8
NCT02900378 (13) [back to overview]	Change From Baseline in Mean Daily Light Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Change From Baseline in Mean Daily Moderate-to-Vigorous Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Change From Baseline in Mean Daily Non-sedentary Daytime Activity in Two-weekly Intervals
NCT02900378 (13) [back to overview]	Change From Baseline in Mean Daily Non-sedentary Daytime Activity in Weekly Intervals
NCT02900378 (13) [back to overview]	Number and Percentage of Participants Achieving PGA Score at Weeks 4, 8 and 12
NCT02900378 (13) [back to overview]	Total Weekly Time Spent in Non-sedentary Daytime Physical Activity
NCT02924727 (7) [back to overview]	Number of Participants With a Confirmed Composite of CV Death or HF Hospitalization
NCT02924727 (7) [back to overview]	All-cause Mortality for Full Analysis Set (FAS)
NCT02924727 (7) [back to overview]	Total Number of Confirmed Composite Endpoints
NCT02924727 (7) [back to overview]	Number of Participants With First CEC (Clinical Endpoint Committee) Confirmed Primary Composite Endpoint
NCT02924727 (7) [back to overview]	All Collected Deaths
NCT02924727 (7) [back to overview]	Number of Participants With a Confirmed Composite of HF Hospitalization or Outpatient HF
NCT02924727 (7) [back to overview]	Number of Participants With a Confirmed Composite of CV Death, Non-fatal Spontaneous Myocardial Infarction or Non-fatal Stroke
NCT02970669 (6) [back to overview]	Change in Mean Activity Counts During Most Active 30 Minutes of Day From Baseline to Week 9 and 16
NCT02970669 (6) [back to overview]	Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 9 and 16
NCT02970669 (6) [back to overview]	Ratio of Mean Activity Counts Collected During the Most Active 30 Minutes of the Subject's Day Between Week 8 and Baseline
NCT02970669 (6) [back to overview]	Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 1
NCT02970669 (6) [back to overview]	Change in Mean Activity Counts During Most Active 30 Minutes of Day From Baseline to Week 1
NCT02970669 (6) [back to overview]	Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 8
NCT03066804 (7) [back to overview]	Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24
NCT03066804 (7) [back to overview]	Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24
NCT03066804 (7) [back to overview]	Change From Baseline in NYHA Functional Class at Week 24
NCT03066804 (7) [back to overview]	Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24
NCT03066804 (7) [back to overview]	Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12
NCT03066804 (7) [back to overview]	Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
NCT03066804 (7) [back to overview]	Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24
NCT03552575 (8) [back to overview]	Change in High Sensitivity Troponin I Levels
NCT03552575 (8) [back to overview]	Change in Left Ventricular Ejection Fraction
NCT03552575 (8) [back to overview]	Change in Left Ventricular End Systolic Volume Index
NCT03552575 (8) [back to overview]	Change in Left Ventricular End-Diastolic Volume Index
NCT03552575 (8) [back to overview]	Change in Left Ventricular Mass Index
NCT03552575 (8) [back to overview]	Change in Left Atrial Volume Index
NCT03552575 (8) [back to overview]	Change in Patient Well Being as Assessed by Patient Global Assessment Questionnaire
NCT03552575 (8) [back to overview]	Change in N-terminal Prohormone of B-type Natriuretic Peptide Levels
NCT03909295 (1) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Intervention	participants (Number)
Glycemia Trial: Intensive Control	391
Glycemia Trial: Standard Control	327

Intervention	mm Hg (Least Squares Mean)
	Week 12	Week 36
Amlodipine 10 mg	-14.2	-13.9
Valsartan 320 mg	-9.1	-11.1

Intervention	mmHg (Mean)
	Week 2 (Visit 5)	Week 4 (Visit 6)	Week 6 (Visit 7)	Week 10 (Visit 8)	Week 14 (Visit 9)	Week 18 (Visit 10)	Week 28 (Visit 11)	Week 41 (Visit 12)	Week 54 (Visit 13)	Endpoint (value at week 54 or LOCF)
Core Treatment	-7.9	-10.8	-11.8	-12.5	-13.7	-15.0	-15.2	-15.2	-14.2	-13.4

Intervention	Percentage of patients (Number)
Placebo	2.9
Aliskiren 300 mg	4.9
Valsartan 320 mg	4.9
Aliskiren/Valsartan 300/320 mg	4.0

Intervention	Percentage of patients (Number)
Placebo	79.5
Aliskiren 300 mg	73.5
Valsartan 320 mg	77.2
Aliskiren/Valsartan 300/320 mg	75.2

Intervention	pg/mL (Geometric Mean)
Placebo	0.582
Aliskiren 300 mg	0.563
Valsartan 320 mg	0.614
Aliskiren/Valsartan 300/320 mg	0.635

Intervention	pg/mL (Geometric Mean)
Placebo	0.642
Aliskiren 300 mg	0.597
Valsartan 320 mg	0.670
Aliskiren/Valsartan 300/320 mg	0.682

Intervention	mmHg (Mean)
	Diastolic BP	Systolic BP
Amlodipine 5 mg	0.3	-0.2
Valsartan/Amlodipine 80/5 mg	-6.3	-7.3

Intervention	Percentage of patients (Number)
Valsartan/Amlodipine 80/5 mg	70.5
Valsartan 80 mg	44.1
Valsartan 160 mg	58.6

Intervention	Percentage of patients (Number)
Valsartan/Amlodipine 80/5 mg	74.4
Valsartan 80 mg	53.6
Valsartan 160 mg	64.2

Intervention	Percentage of patients (Number)
Valsartan/Amlodipine 80/5 mg	77.9
Valsartan 80 mg	57.8
Valsartan 160 mg	66.6

Intervention	mm Hg (Least Squares Mean)
Valsartan + Amlodipine 40/2.5 mg	-16.7
Valsartan + Amlodipine 40/5 mg	-22.0
Valsartan + Amlodipine 80/2.5 mg	-16.9
Valsartan + Amlodipine 80/5 mg	-22.9
Valsartan 40 mg	-9.3
Valsartan 80 mg	-9.5
Amlodipine 2.5 mg	-13.6
Amlodipine 5 mg	-16.6
Placebo	-4.4

Intervention	Percentage of patients (Number)
Valsartan + Amlodipine 40/2.5 mg	55.3
Valsartan + Amlodipine 40/5 mg	75.4
Valsartan + Amlodipine 80/2.5 mg	59.4
Valsartan + Amlodipine 80/5 mg	72.2
Valsartan 40 mg	33.1
Valsartan 80 mg	30.1
Amlodipine 2.5 mg	41.0
Amlodipine 5 mg	57.1
Placebo	18.7

Intervention	Percentage of patients (Number)
Valsartan + Amlodipine 40/2.5 mg	77.4
Valsartan + Amlodipine 40/5 mg	88.0
Valsartan + Amlodipine 80/2.5 mg	80.6
Valsartan + Amlodipine 80/5 mg	86.4
Valsartan 40 mg	52.1
Valsartan 80 mg	47.9
Amlodipine 2.5 mg	62.1
Amlodipine 5 mg	74.5
Placebo	36.1

Intervention	Percentage of patients (Number)
Valsartan + Amlodipine 40/2.5 mg	67.3
Valsartan + Amlodipine 40/5 mg	82.6
Valsartan + Amlodipine 80/2.5 mg	72.5
Valsartan + Amlodipine 80/5 mg	80.9
Valsartan 40 mg	46.2
Valsartan 80 mg	41.1
Amlodipine 2.5 mg	55.3
Amlodipine 5 mg	67.1
Placebo	31.9

Intervention	mm Hg (Least Squares Mean)
Valsartan + Amlodipine 40/2.5 mg	-13.5
Valsartan + Amlodipine 40/5 mg	-16.5
Valsartan + Amlodipine 80/2.5 mg	-12.6
Valsartan + Amlodipine 80/5 mg	-17.0
Valsartan 40 mg	-8.5
Valsartan 80 mg	-8.8
Amlodipine 2.5 mg	-10.3
Amlodipine 5 mg	-13.4
Placebo	-4.8

Intervention	Percentage of patients (Number)
	Week 4 (n=576, 535)	Week 8 (n=567, 510)	Week 12 (n=569, 531)
Amlodipine 10 mg	25.42	25.49	31.26
Valsartan/Amlodipine 160/5 mg	35.07	34.22	37.96

Intervention	mmHg (Least Squares Mean)
	msSBP: Week 4 (n=576, 535)	msSBP: Week 8 (n=567, 510)	msSBP: Week 12 (n=569, 531)	msDBP: Week 4 (n=576, 535)	msDBP: Week 8 (n=576, 510)	msDBP: Week 12 (n=569, 531)
Amlodipine 10 mg	-6.48	-6.11	-7.82	-4.23	-3.97	-4.90
Valsartan/Amlodipine 160/5 mg	-8.40	-8.15	-9.08	-5.05	-4.68	-5.50

Intervention	participants (Number)
	Week 4	Week 8	Week 12	Week 16	End of Study
HCTZ +Amlodipine	18	23	46	65	68
Valsartan/HCTZ (Hydrochlorothiazide)	33	59	57	62	68

Intervention	mm Hg (Mean)
	Baseline	Week 8	Change from baseline
HCTZ +Amlodipine	159.0	137.5	-21.5
Valsartan/HCTZ (Hydrochlorothiazide)	159.7	131.2	-28.6

Intervention	mg/dL (Mean)
	Baseline visit (0 minutes)	Week 16 (0 minutes)	Change from baseline to week 16 (0 minutes)	Baseline visit (120 minutes)	Week 16 (120 minutes)	Change from baseline to week 16 (120 minutes)
HCTZ +Amlodipine	99.4	102.8	3.4	127.7	146.5	18.9
Valsartan/HCTZ (Hydrochlorothiazide)	98.0	98.1	-0.5	123.9	126.3	2.1

valsartan

Description

Cross-References

Synonyms (205)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (3)

Pathways (1)

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (116)

Molecular Functions (39)

Ceullar Components (23)

Bioassays (255)

Research

Studies (3,419)

Market Indicators

Research Demand Index: 127.37

Study Types

Clinical Trials (393)

Trial Overview

Trial Outcomes

Death From Any Cause in the Glycemia Trial.

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

Stroke in the Blood Pressure Trial.

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide

Percentage of Patients Reaching the Endpoint: Core Cardiovascular Morbidity and Mortality Event - Valsartan Versus Non-valsartan

Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Nateglinide Versus Non-nateglinide

Percentage of Patients Reaching the Endpoint: Extended Morbidity and Mortality Event - Valsartan Versus Non-valsartan

Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan

Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Nateglinide Versus Non-nateglinide

New Onset or Worsening of Diabetes Mellitus or IGT

New Onset, Recurrence or Worsening of Arteriosclerosis Obliterans

Transition to Dialysis, Doubling of Plasma Cr Levels

New Onset or Recurrence of Transient Ischemic Attack

New Onset or Recurrence of Acute Myocardial Infarction

New Onset or Recurrence of Stroke

Hospitalization Due to the New Onset, Occurrence or Worsening of Angina Pectoris and Additional Concomitant Use of Other Anti-anginal Agents or Increase of Dosage

Hospitalization Due to the New Onset, Recurrence or Worsening of Heart Failure and Additional Concomitant Use of Other Anti-heart Failure Agents or Increase of Dosage

All Cause Mortality

New Onset of Acute Dissecting Aneurysm of the Aorta

Change in Left Ventricular Mass Index (LVMI) and Diastolic Function Using Echocardiography From Baseline to Week 38

Change From Baseline to Week 38 in the Carotid-femoral Pulse Wave Velocity (PWV)

Changes in Central Blood Pressure, Evaluated by Applanation Tonometry From Baseline at Weeks 12 and 38

Changes in Mean Left Carotid Distensibility at Week 38

Changes in Mean Right Carotid Distensibility at Week 12

Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Week 12

Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 12

Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at End-point (Week 38)

Change From Baseline for Endothelial Function Measured by Brachial Artery Flow-mediated Vasodilatation (FMD) Using the Brachial Artery Reactivity Test (BART) at Week 12

Change From Baseline in Post-ischemic Forearm Skin Reactive Hyperemia at Endpoint (Week 38)

Changes in Baroreflex Sensitivity as it Relates to Changes in Carotid Distensibility From Baseline to Week 38

Changes in Mean Right Carotid Distensibility at Week 38

Changes in Mean Left Carotid Distensibility at Week 12

Change in the Mean Vessel Wall Area (VMA) of the Carotid Bulb From Baseline to 2 Years

Overall Percentage of Patients With Adverse Events

Overall Percentage of Patients With Adverse Events

Change From Baseline in Mean Sitting Systolic Blood Pressure

Change From Baseline in Mean Sitting Diastolic Blood Pressure

Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg in Extension Treatment

Change From Baseline in Mean Sitting Diastolic Blood Pressure.

Change From Baseline in Mean Sitting Systolic Blood Pressure.

Percentage of Patients Achieving Blood Pressure Control Target of < 140/90 mmHg

Total Number of Titration Steps in Prescribed Heart Failure Treatment

Number of Days in Hospital for CV Reason

Intervention	mmHg (Mean)
CKD Patients: Valsartan+Enalapril	-20.4
CKD Patients: Enalapril	-11.7
Non-CKD Patients: Valsartan	-7.5
Non-CKD Patients: Enalapril	-7.2

Intervention	mmHg (Mean)
CKD Patients: Valsartan+Enalapril	-23.6
CKD Patients: Enalapril	-18.2
Non-CKD Patients: Valsartan	-11.6
Non-CKD Patients: Enalapril	-10.2

Intervention	Percentage of patients (Number)
	Systolic BP control	Diastolic BP control
Non-CKD Patients: Enalapril	63.0	91.7
Non-CKD Patients: Valsartan	66.0	95.1

Intervention	mmHg (Mean)
	Baseline	Change from Baseline at Week 26
Valsartan Open Label	70.7	-6.6

Intervention	mm Hg (Mean)
	Week 8	Week 24
Intensive Treatment Regimen	-25.74	-30.37
Standard Treatment Regimen	-22.31	-25.06

Intervention	ratio (Mean)
Intensive Treatment Regimen	-0.951
Standard Treatment Regimen	-0.680

Intervention	cm/s (Mean)
Intensive Treatment Regimen	1.544
Standard Treatment Regimen	1.476

Intervention	cm (Mean)
Intensive Treatment Regimen	-0.127
Standard Treatment Regimen	-0.104

Intervention	Percentage of participants (Number)
	msSBP < 140 mmHg	msDBP < 90 mmHg
Amlodipine+Valsartan+HCTZ - Phase 3	59.3	83.5

Intervention	Percentage of participants (Number)
	msSBP < 140 mmHg	msDBP < 90 mmHg
Amlodipine+Valsartan - Phase 2	44.6	72.6